Document:

Exhibit
                                        10.16

 

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL.

 

EXCLUSIVE LICENSE AND COMMERCIALIZATION AGREEMENT

 

This Exclusive License and Commercialization Agreement (this “Agreement”), dated as of 16 December 2020 (“Effective Date”), is made by and between POINT Biopharma Inc., having an address 4850 West 78th Street, Indianapolis, Indiana 46268, United States (“POINT”); Canadian Molecular Probe Consortium having a business office at C/O CPDC, Nuclear Research Building - A316, 1280 Main Street West, Hamilton, Ontario, Canada, L8S 4K1 (“CanProbe”); the Centre for Probe Development and Commercialization having a business office at Nuclear Research Building - A316, 1280 Main Street West, Hamilton, Ontario, Canada, L8S 4K1 (“CPDC”); and the University Health Network having a business office at 101 College Street, Suite 150, Heritage Building, MaRS Centre, Toronto, Ontario M5G 1L7 Canada (“UHN”). CanProbe, CPDC and UHN are collectively referred to herein as “Licensor”. Each of POINT, CanProbe, CPDC and UHN may be referred to herein as a “Party” or together as “Parties”.

 

WHEREAS POINT is a clinical phase company specializing in development, commercialization and marketing of radiotherapeutics.

 

WHEREAS CanProbe is a joint venture between UHN and CPDC, and is a leader in developing, manufacturing and supplying of radiopharmaceuticals.

 

WHEREAS UHN, with funds from [***] and [***], is sponsoring a Phase 3 clinical trial named “A Prospective Single-Arm, Multi-Centre Study of the Efficacy and Safety of Lutetium – 177 Octreotate (Lu-DOTATATE) Treatment with individualized dosimetry in patients with 68Ga-DOTATE identified Somatostatin Receptor Positive Neuroendocrine Tumors” (the “Study”).

 

WHEREAS UHN is the owner of the rights and title to the data and results arising from the Study (“Study Data”) and CPDC is a manufacturer of Lutetium – 177 Octreotate (Lu-DOTATATE) (the “Product”) and owns intellectual property relating to a process for production of the Product for the Study, including documentation relating to quality control, quality assurance and any other relevant procedures, and the relevant analytical data relating to a validated process for production of the Product for the Study (collectively, the “CPDC IP”) and together, the Study Data and CPDC IP constitute the “Study IP”.

 

WHEREAS UHN and CPDC collectively have exclusive rights for global commercialization of the Study IP, and the rights to license such rights.

 

WHEREAS CanProbe has been designated by CPDC and UHN to seek global regulatory approval of the Product and to further seek third parties for the global commercialization of the Study IP.

 

WHEREAS POINT desires to exclusively license the Study IP subject to the terms and conditions below.

 

[***] = Indicates confidential information omitted from the exhibit.

 

 

NOW, THEREFORE, in consideration of the premises and mutual covenants set out in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

 

1.         Definitions.

 

The following terms and their correlatives have the following meanings:

 

1.1        “Affiliate” means any corporation or other entity which directly or indirectly controls, is controlled by, or is under common control with, a Party, for so long as such control exists. For the purposes of this Section 1.1, “control” shall mean: (i) in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) (or such lesser percentage that is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of the stock or shares entitled to vote for the election of directors, or the power to direct the management and policies of such corporate entities, and (ii) in the case of non- corporate entities, direct or indirect ownership of at least fifty percent (50%) of the equity interest, in such non-corporate entities or the power to direct the management and policies of such non-corporate entities.

 

1.2        “Approved Indication“ means, with respect to the Product, a disease or condition for which the treatment or prevention has received Regulatory Approval.

 

1.3        “Business Day” means any day that is not a Saturday, Sunday, or statutory holiday in Canada.

 

1.4        “Calendar Half Year” means each six (6) month period commencing January 1 and July 1 of each Calendar Year.

 

1.5        “Calendar Year” means each successive period of twelve (12) months commencing on January 1 and ending on December 31.

 

1.6        “Ceased Sales” means failure for POINT, its Affiliate(s) and/or Sublicensee(s) (as appropriate), to achieve sales to the equivalent of at least [***]% of the eligible population within [***] months of obtaining Regulatory Approval in the respective Sub-Territory or having sales dropping below [***]% of the average sales occurring within the previous Calendar Year in the respective Sub-Territory.

 

1.7        “Commercialization Data” means a summary of the results and data generated by POINT under the Commercialization Plan.

 

1.8        “Commercialization Plan” means the written model for commercialization of the Product set forth in Schedule C, attached hereto, and which may be amended from time to time in accordance with the terms of this Agreement. The Commercialization Plan will contain a marketing plan, which shall be designed to attain optimal sales for the Product in the Territory.

 

1.9        “Commercially Reasonable Efforts” means, with respect to any obligations or activities of POINT to accomplish an objective under this Agreement, the efforts and resources comparable to those undertaken by a radiopharmaceutical company of comparable size and resources as POINT relating to the research, development or commercialization of a similar product owned by such company, or to which such company has exclusive rights, with comparable market potential and which is at a similar stage in its lifecycle. For this purpose, all relevant factors, as measured by the facts and circumstances at the time such efforts are due, shall be taken into account, including, as applicable and without limitation, stage of development; efficacy and safety relative to competitive products in the marketplace; actual or anticipated Regulatory Approval; labeling; the nature and extent of market exclusivity (including patent coverage, proprietary position and regulatory exclusivity); and the cost and time required for and likelihood of obtaining Regulatory Approval.

 

1.10      “Commercial Purposes” means commercial development, including the sale or the offering for sale of commercial products for legitimate business and/or regulatory purposes including, but not limited to, for use to obtain approval of investigational drug applications, multi-centered clinical trial applications for approved indications, abbreviated or new drug applications, abbreviated or new drug submission, biologics license applications, marketing authorizations and the like, subject to applicable Law.

 

[***] = Indicates confidential information omitted from the exhibit.

 

 

1.11      “Development” or “Develop” means non-clinical and clinical drug development activities pertaining to a pharmaceutical product, including toxicology, pharmacology, test method development and stability testing, process and manufacturing development, formulation development, delivery system development, quality assurance and quality control development, statistical analysis, clinical studies (including pre- and post-approval studies), regulatory affairs, pharmacovigilance and Regulatory Approval and clinical study regulatory activities (including regulatory activities directed to obtaining pricing and reimbursement approvals).

 

1.12      “Dollars” means Canadian Dollars, and “$” shall be interpreted accordingly.

 

1.13      “Field” means all Approved Indications and indications for which a Regulatory Approval is being sought.

 

1.14      “GST/HST” means the goods and services tax and the harmonized sales tax imposed under Part IX of the Excise Tax Act (Canada).

 

1.15      “Improvement” means any Intellectual Property that:

 

(a)        results from an improvement or enhancement of the Licensed Technology by a Party other than POINT; or

 

(b)        is discovered, developed, or derived using or practicing the Licensed Technology by a Party other than POINT; or

 

(c)        but for the license granted in this Agreement, would infringe, or contribute to, or induce the infringement of, or read on, any Patent Right and is discovered, developed, or derived by a Party other than POINT.

 

1.16      “Indication” means an application for a label indicating the applicable drug for an initial patient population in each case that requires a clinical trial for Regulatory Approval.

 

1.17      “Intellectual Property” means any inventions, innovations, developments, discoveries, processes, methods, protocols, specifications, compounds, biological and chemical materials, copyrights, trademarks, and trade secrets, in whatever mode of expression, and any copies of the foregoing in any medium, and all Patent Rights. 

 

1.18      “Joint Commercialization Committee” or “JCC” means the committee described in Section 7.1.

 

1.19      “Know-How” means any ideas, techniques, expertise and procedures directly and solely related to the Product that are owned and controlled by the Licensor and which are not in the public domain.

 

1.20      “Law” means, individually and collectively, any and all laws, ordinances, rules, rulings, directives, administrative circulars and regulations of any kind whatsoever of any governmental authority or Regulatory Authority within the applicable jurisdiction.

 

1.21      “Licensed Technology” means the Patent Right and Study IP and Know-How and Improvements thereto.

 

[***] = Indicates confidential information omitted from the exhibit.

 

 

1.22      “Patent Right” means any of the following which pertain to the Licensed Technology and are owned by any of CPDC, UHN and/or CanProbe:

 

(a)       patents;

 

(b)       pending patent applications, including, all provisional applications, continuations, continuations-in-part, divisions , renewals, Patent Cooperation Treaty (PCT) applications and all patents granted thereon;

 

(c)       all patents-of-addition, reissues, re-examinations and extensions or restorations by existing or future extension or restoration mechanisms, including, supplementary protection certificates or the equivalent thereof;

 

(d)      inventor’s certificates;

 

(e)      all Canadian, United States, and foreign counterparts of any of the foregoing.

 

1.23      “Person” means an individual, a corporation, a partnership, a trust, any unincorporated organization or any other entity, and “Persons” has a similar corresponding meaning.

 

1.24      “POINT Technology” means any Intellectual Property owned or licensed by POINT as of the Effective Date or thereafter including during the Term (other than as a result of the licenses granted to POINT under this Agreement) which pertains to the Product or Licensed Technology. For clarity, POINT Technology includes Intellectual Property that pertains to the Product and/or Licensed Technology, and is solely or jointly invented, developed or derived as of the Effective Date or during the Term by one or more persons who assign that Intellectual Property and/or other proprietary rights to POINT.

 

1.25     “Prosecution and Maintenance” means, with respect to a Patent Right, the preparing, filing, and prosecuting of patent applications and maintenance of patents, as well as re-examinations, and reissues, with respect to such patents; and “Prosecute and Maintain” have the correlative meaning. The defense of an opposition “Opposition Defense” (which includes the defense of an Inter Parties Review (IPR) at the U.S. Patent and Trademark Office) with respect to any Patent Right is separate from and not included within the Prosecution and Maintenance of a Patent Right.

 

1.26      “Regulatory Approval” means all approvals (including any applicable governmental price and reimbursement approvals), licenses, registrations, and authorizations of any federal, national, multinational, state, provincial or local Regulatory Authority, department, bureau or other governmental entity that are necessary and sufficient for the marketing and sale of a product in a country or group of countries. Regulatory Approval includes any required pricing and reimbursement approval for the Product.

 

1.27      “Regulatory Authority” means, with respect to a country, the regulatory authority or regulatory authorities of such country with authority over the testing, manufacture, use, storage, importation, promotion, marketing, pricing or sale of a pharmaceutical product in such country.

 

1.28       “Regulatory Materials” means regulatory applications, submissions, notifications, communications, correspondence, registrations, drug approvals and/or other filings made to, received from or otherwise conducted with a Regulatory Authority in order to Develop, manufacture, market, sell or otherwise Commercialize the Product in a particular country or jurisdiction.

 

1.29      “Sublicensee” means any Person granted a sublicense by the Licensee pursuant to Section 2.1.

 

[***] = Indicates confidential information omitted from the exhibit.

 

 

1.30      “Sub-Territory” means any one of the following jurisdictions: Canada, United States of America, European Union and each individual country in the Rest of the World (“ROW”); collectively, the “Sub-Territories”. For clarity, a country in the ROW is considered a Sub-Territory once POINT has applied for a Regulatory Approval therein.

 

1.31      “Taxes” means any present or future taxes, levies, imposts, duties, charges, assessments or fees of any nature (including any interest thereon).

 

1.32      “Territory” means the world.

 

1.33      “Third Party” means any entity other than a Party or an Affiliate of a Party.

 

All other defined terms are as otherwise defined in the text of the Agreement.

 

Schedules. The following schedules are attached to and form part of this Agreement:

 

Schedule A – CPDC Intellectual Property

 

Schedule B – UHN Study Data

 

Schedule C – Commercialization Plan

 

Schedule D – Compliance Schedule

 

2.         License and Sublicenses.

 

2.1        From and after the Effective Date until the end of the Term:

 

(a)        Exclusive License Grant. Subject to the terms and conditions herein, the Licensor hereby grants to POINT an exclusive (including as against the Licensor subject to below Reservation of Rights), sublicensable (pursuant to Section 2.2), terminable, amendable license to the Patent Right, Know-How, Study IP and Improvements thereto, to develop, make, have made, sell, have sold, and supply (subject to Section 2.3 and Section 6.1) Product for use in the Field in the Territory and to apply to Regulatory Authorities using the Licensed Technology in order to obtain approval for the manufacture, distribution, and sale of Product for use in the Field in the Territory during the Term (the “Exclusive License”).

 

(b)        Obligation to Market. POINT shall use Commercially Reasonable Efforts to market, distribute sell and/or have sold the Product in the Territory, and specifically in Canada, USA, EU and at least one country in ROW. A timetable will be negotiated in good faith by the Parties for the marketing approval and launch of Product in each of the Sub-Territories.

 

(c)        Amendment. The Licensor, in its sole discretion, shall have the right to amend the Exclusive License if POINT does not meet its obligations under Section 2.1(b) as determined by the Licensor in its reasonable discretion (for example by removal of Sub-Territories, or loss of exclusivity of the Exclusive License and/or Field within a particular Sub-Territory).

 

(d)        Non-Compete. The Licensor and its Affiliates shall not, directly or indirectly, develop, manufacture any form of the Product for Commercial Purposes either on its own behalf or in conjunction with a Third Party during the Term.

 

[***] = Indicates confidential information omitted from the exhibit.

 

 

Reservation of Rights. Notwithstanding the foregoing and for clarity, the Licensor shall retain its rights to use the Licensed Technology for any non-commercial, internal research purposes, (and with respect to UHN, academic or educational purposes), including in scientific cooperation with non-commercial third parties, without restriction, including the ability to distribute any material(s) disclosed and/or claimed in the Licensed Technology for non-profit academic research use to non-commercial entities as is customary in the scientific community, with the further retention of its rights to grant non-commercial licences for the same purposes, subject to POINT’s prior review and written response regarding any such non-commercial licence, and where POINT’s written response will not be unreasonably delayed.

 

Product used in clinical trials outside of the Approved Indications or indications for which Regulatory Approval has been sought can be manufactured by the Licensor or acquired through POINT. POINT will be kept informed of any such clinical trial. Product used in clinical trials in the Approved Indications or indications for which Regulatory Approval has been sought by the Licensor and its permitted licensees for non-commercial, internal research purposes (and with respect to UHN, academic or educational purposes), including in scientific cooperation with non-commercial third parties, will be provided by POINT (or as appropriate, its Sublicensee(s) or Affiliate(s)). In cases where the Product is provided by POINT (or as appropriate, its Sublicensee(s) or Affiliate(s)), the Product will be provided on terms to be negotiated by the Parties, but in no event [***] and further shall in no event [***].

 

Except in association with or otherwise further to the agreement of POINT, the foregoing purposes described in this section exclude Commercial Purposes.

 

Notwithstanding the foregoing and for clarity, if POINT cannot (i) provide the Product for non-commercial research use or (ii) supply the Product for sale, and after a period of [***] days, then Licensor reserves the right to manufacture or have manufactured the Product to (i) provide the Product for non-commercial clinical research under a Health Canada approved clinical trial application and/or (ii) sell the Product in accordance with Health Canada regulations for approved drugs to patients at the following sites during the remediation period by POINT: [***].

 

2.2        Sublicenses. POINT shall have the right to grant sublicenses under the rights licensed to POINT under Sections 2.1(a) solely in accordance with this Section 2.2 as follows:

 

(a)          subject to the Licensor’s prior review and written response, not to be unreasonably delayed, for use and distribution of the Product in the Field within the Territory;

 

(b)          such sublicense shall refer to this Agreement and shall be subordinate to and consistent with the terms and conditions of this Agreement, and shall not limit the ability of POINT (individually or through the activities of its Affiliates and Sublicensees) to fully perform all of its obligations under this Agreement or the Licensor’s rights under this Agreement;

 

(c)           in such sublicense, the Sublicensee shall agree to be subject to, and bound by any relevant terms and conditions of this Agreement mutatis mutandis, including:

 

(i)          confidentiality obligations substantially equivalent to those imposed on POINT hereunder;

 

(ii)         termination rights in favour of Licensor substantially similar to those in Section 15.3 and 15.4;

 

(iii)        a right-to-audit clause to permit POINT to audit the facilities and records of each Sublicensee, and Licensor shall have a right to review such audits performed by POINT as they pertain to use and distribution of the Product in the Field in the Territory;

 

(iv)        reporting obligations requiring the Sublicensee to make reports to POINT, to keep and maintain records of sales made pursuant to such sublicense and to grant access to such records by the Licensor’s independent accountant to the same extent required from POINT pursuant to Section 9;

 

[***] = Indicates confidential information omitted from the exhibit.

 

 

(v)        obligations requiring its employees, contractors and agents to grant Licensor all rights in and to any Improvements and any other obligations that might be required to protect the Licensed Technology or the Licensor’s rights under this Agreement; and

 

(vi)        POINT shall include a third party beneficiary clause for Licensor’s benefit in Sublicensee agreements;

 

(d)        POINT shall inform the Licensor in writing within thirty (30) days after the execution and delivery by POINT of any sublicense and shall provide a copy to the Licensor. POINT reserves the right to redact such agreement if other assets than the Product are included, without removing any provisions relevant to the sublicensing of the Product.

 

(e)        POINT shall be responsible for performing all of its obligations set forth in this Agreement, without regard to whether it has granted any sublicense under this Section 2.2; and

 

(f)         such sublicenses shall expressly prohibit the granting of further right of a sub-sub-license.

 

2.3        Permitted Subcontracting.

 

(a)        POINT may subcontract its proprietary manufacturing activities to a Third Party subject to the Licensor’s prior written review and response, not to be unreasonably delayed and provided that any such Third Party shall have entered into a written agreement with POINT that includes terms and conditions (i) protecting and limiting use and disclosure of the Licensed Technology, Confidential Information and (ii) requiring such Third Party, as applicable, and its employees, contractors and agents to grant Licensor all rights in and to any Improvements, Patent Rights, and Know-How created, conceived or reduced to practice in connection with the performance of any such subcontracted activities.

 

3.         POINT’s Obligations.

 

3.1        Commercially Reasonable Efforts. POINT shall use Commercially Reasonable Efforts to:

 

(a)          seek regulatory approvals and obtain and maintain Regulatory Approvals(s) for all Indications covered
by the Study in each Sub-Territory. POINT shall be responsible for all costs in relation to Regulatory Approval(s), set up of
manufacturing sites, supply, marketing and drug distribution and reimbursement in the Territory;

 

(b)          make all necessary arrangements for commercial sale of the Product in each Sub- Territory, including but not limited
to, process scale-up, technology transfer to its Affiliates and/or Third Parties, commercial manufacturing and global distribution
of the Product;

 

(c)           manufacture, have manufactured, market, distribute, sell and have sold the Product in the Field in the Territory and to otherwise perform (itself or through its Affiliates or by permitted sublicensing) its obligations under the Commercialization Plan;

 

(d)          promote the Product for Approved Indications;

 

(e)          conduct all post-marketing studies as required by the regulatory agencies of each country in the Sub-Territory where the Product is authorized, subject to Section 6.11.

 

Provided that POINT uses Commercially Reasonable Efforts, POINT shall not be responsible to Licensor for any inability or failure to successfully achieve what is described in (a)-(e) above.

 

[***] = Indicates confidential information omitted from the exhibit.

 

 

The Product shall be branded and marketed throughout the Territory under or using such trade marks, trade names, trade dress, logos and designs and labelling content (“Branding Elements”) as POINT may in its sole discretion determine (subject to applicable laws in each Sub-Territory). All Branding Elements shall, as between POINT and the Licensor, be owned exclusively by POINT and upon termination or amendment of the license to a Terminated Product, will be transferred and assigned to the Licensor.

 

4.         Licensor’s Obligations.

 

4.1        Licensor’s Obligations. The Licensor shall use reasonable efforts to:

 

(a)        provide access to the Licensed Technology as it is or as made;

 

(b)        keep POINT informed of all developments and approval discussions, and shall permit POINT’s authorized representative(s) to fully participate in and direct any pre-marketing meetings with Regulatory Authorities (to the extent that the Licensor is so permitted) in respect of the Product;

 

(c)        keep POINT informed of all inspections by Regulatory Authorities at clinical sites in respect of the Study, to make available the audit results to POINT, and to permit POINT to guide preparation for an inspection and draft responses to Regulatory Authority observations; 

 

(d)        conduct any remediation activities in accordance with GCP and as required by Regulatory Authorities in respect of the Study, including documentation development and data collection requirements as defined by the approved protocol or any amendments thereto;

 

(e)        to complete the Study and maintain Sponsor responsibilities on the Study, including supply of the clinical trial materials, clinical monitoring, database hosting and data collection activities including data entry and query resolution as per the approved protocol and any amendments thereto;

 

(f)          support POINT in the following tasks associated with the technology transfer and validation of the manufacturing process as used for the Product during the Study by providing, to a mutually agreed work-plan, the following supporting documentation and technical support, at POINT’s cost: (i) technology transfer of manufacturing process and analytical methods; (ii) supply development and process validation reports; (iii) manufacturing & quality control documentation; and (iv) quality control method validation/verification;

 

(g)          support, at POINT’s cost, a mutually agreed work-plan in respect of POINT’s efforts to gain adoption
of the Product in the Territory, subject to mutually agreed upon conditions; and

 

(h)          support, at POINT’s cost, a mutually agreed work-plan, in respect of POINT’s effort in obtaining and
maintaining Regulatory Approval(s) (via filings with Regulatory Authorities) for use in the Field in the Territory in respect
of the Product.

 

(i)            Support, at POINT’s cost, data mining, programming and statistical analysis, in preparation for, or
as requested by, Regulatory Authorities.

 

5.         Commercialization Activities

 

5.1        Commercialization Plan. The Parties will work together to develop a Commercialization Plan based on an independent assessment, which assessment was completed and paid for by CanProbe.

 

[***] = Indicates confidential information omitted from the exhibit.

 

 

5.2        Amendments. The Commercialization Plan may be amended from time to time. The Commercialization Plan will be reviewed as necessary at each meeting of the JCC and at any other time upon the reasonable request of any Party.

 

5.3        Records. POINT shall maintain, or cause to be maintained, records of its activities under the Commercialization Plan in sufficient detail and for patent and regulatory purposes, which shall properly reflect all work included in the Commercialization Plan consistent with its internal procedures and policies.

 

6.         Commercial Supply; Clinical Trials.

 

6.1        Commercial Supply. Notwithstanding any other provision of this Agreement, the Parties shall use Commercially Reasonable Efforts to offer a first right of refusal to [***] as the back-up to POINT’s facility for the commercial supply of the Product on terms mutually agreed by the Parties.

 

6.2        Clinical Trials.

 

(a)         UHN shall have a right of first negotiation to [***]. Such right of first negotiation shall be deemed satisfied if POINT notifies UHN (as per Section 17.9) of [***] and UHN is provided a period of at least [***] days to notify POINT of its intention to enter into negotiations. Thereafter, POINT shall make itself available to negotiate in good faith for a period of up to [***] days with respect to the aforementioned. 

 

(b)         POINT shall have the right to audit UHN to ensure [***] as directed by Regulatory Authority and GCP requirements, at POINT’s cost. Any audit shall be conducted in alignment with [***], and shall be mutually agreed upon by the Parties.

 

7.         Joint Commercialization Committee.

 

7.1        Establishment and Composition of the JCC. 

 

(a)        Within [***] days of the Effective Date, the Parties shall assemble the JCC. The JCC will meet [***] a year in whichever way that is possible or convenient for the representatives.

 

(b)        Initially, the JCC shall be composed of two (2) representatives from POINT and two (2) from the Licensor.

 

(c)        The Licensor’s representatives will initially be CanProbe’s President and CanProbe’s Secretary, and the Secretary shall be the chairperson of the JCC. POINT will provide a list of their representatives to the Licensor within [***] days after the Effective Date. Each Party will promptly notify the other Parties in writing of any change in its appointed representatives.

 

(d)        Each Party may invite employees and consultants to attend meetings of the JCC, subject to their agreement, who are bound to obligations of confidentiality, non-use, and assignment of inventions similar to those of that Party’s members of the JCC.

 

7.2        Role and Mandate of the JCC. The JCC is a committee through which the Licensor is kept informed of POINT’s commercial activities. The JCC shall discuss and exchange all relevant information regarding the activities of the Parties under this Agreement. In particular, the JCC shall:

 

(a)        review and discuss the Commercialization Plan objectives and progress under the Commercialization Plan and review and discuss the performance and results of the Commercialization Plan, discuss and approve proposed amendments to the Commercialization Plan;

 

[***] = Indicates confidential information omitted from the exhibit.

 

 

(b)        perform such other functions as appropriate to further the purposes of this Agreement, as expressly set forth in this Agreement or as mutually agreed upon by the Parties in writing.

 

(c)        keep Licensor informed of regulatory developments relating to the Product in the Field in the Territory

 

(d)        review and unanimously approve any remedial action with respect to the Product in the Field in the Territory. 

 

(e)        Each Party will bear its own costs relating to any JCC meeting. 

 

Meetings of the JCC are effective only if at least one representative of each of POINT and of Licensor is present at the meeting or participating by teleconference. The Parties will endeavor to schedule meetings of the JCC at least [***] months in advance.

 

7.3        Reports.

 

(a)    POINT shall furnish to the JCC a written report (each, a “Progress Report”), at the end of each [***], that: (i) describes in reasonable detail, POINT’s progress under the Commercialization Plan during the relevant [***]; and (ii) includes a summary of the results and data generated by POINT under the Commercialization Plan during the relevant [***], in each case to the extent reasonably necessary to support and advance the Commercialization Plan.

 

(b)        For clarity, the Progress Reports required in this subsection are in addition to any other reporting requirements under this Agreement.

 

7.4      Dissolution of the JCC. The JCC shall automatically dissolve and have no further responsibilities or authority after such time as the activities to be conducted under the Commercialization Plan have been completed (or such other time as agreed by the Parties).

 

8.         Regulatory Matters.

 

8.1        Regulatory Correspondence. Commencing on the Effective Date with respect to all countries in the Territory, POINT shall use Commercially Reasonable Efforts in respect of the Product as the primary interface with and shall otherwise handle all correspondence, meetings and other interactions with the relevant Regulatory Authorities concerning regulatory activities related to the Product in the Field in the Territory, and POINT shall be responsible for preparing and filing any and all Regulatory Materials for the Product in the Field in the Territory at its sole expense.

 

8.2        Obligation to Inform. POINT shall promptly notify Licensor in writing of any action or decision by POINT with regard to, as well as any action or decision by, any Regulatory Authority in the Territory regarding the Product in the Field. Progress and status of the actions and decisions shall be reviewed and discussed by the JCC. POINT shall provide Licensor with reasonable advance notice of all meetings, conferences and discussions scheduled with any Regulatory Authority in the Territory concerning the Product, and shall consider in good faith any input from Licensor in preparing for such meetings, conferences or discussions. To the extent permitted by applicable Laws, Licensor shall have the right to participate in any such meetings, conferences or discussions and POINT shall facilitate such participation. If Licensor elects not to participate in such meetings, conferences or discussions, POINT shall provide Licensor with written summaries of such meetings, conferences or discussions with any Regulatory Authority in the Territory in English as soon as practicable after the conclusion thereof.

 

8.3         Regulatory Costs. POINT shall be solely responsible for all of its costs and expenses related to the preparation, filing and maintenance of all Regulatory Materials and Regulatory Approvals for Products in the Field in the Territory.

 

[***] = Indicates confidential information omitted from the exhibit.

 

 

8.4        Notification of Threatened Action. Each Party shall immediately notify the other Party in writing of any information it receives regarding any threatened or pending action, inspection or communication by or from any Third Party, including a Regulatory Authority, which may affect the Development, commercialization or regulatory status of the Product. Upon receipt of such information, the Parties shall consult with each other in an effort to arrive at a mutually acceptable procedure for taking appropriate action.

 

8.5         Adverse Event Reporting and Safety Data Exchange. Within [***] days after the Effective Date, the Parties shall define and finalize the actions that the Parties shall employ with respect to Products to protect patients and promote their well-being in written pharmacovigilance agreement(s), if applicable. Each Party hereby agrees to comply with its respective obligations under such pharmacovigilance agreement(s), as amended, and to cause its Affiliates and Sublicensees (as the case may be) to comply with such obligations. POINT shall have sole responsibility for establishing and maintaining the post-marketing global safety database of adverse events and relevant safety information for the Product.

 

8.6        Remedial Actions. Each Party will notify the other Party immediately, and promptly confirm such notice in writing, if it obtains information indicating that the Product may be subject to any recall, corrective or other regulatory action taken by virtue of applicable Laws. The Parties will assist each other in gathering and evaluating such information as is necessary to determine the necessity of conducting any remedial action. POINT shall, and shall ensure that its Affiliates and Sublicensees will, maintain adequate records to permit the Parties to trace the manufacture, distribution and use of the Product. In the event POINT determines that any remedial action with respect to the Product in the Field in the Territory should be commenced or is required by the applicable Regulatory Authority, POINT shall have the right to control and coordinate all efforts necessary to conduct such remedial action; provided that, with respect to any such remedial action that is not imposed upon POINT by applicable Law or a Regulatory Authority, such remedial action shall have been reviewed and approved by the JCC. If the JCC fails to unanimously approve a remedial action that is not imposed upon POINT by applicable Law or Regulatory Authority within [***] days after such remedial action is presented to the JCC for review and approval, then the Parties’ Executive Officers (one Executive Officer from each Party) shall, within [***] thereafter, review and approve by majority such remedial action or, in the event that the Executive Officers fail to approve such remedial action within such time period, POINT has the right to control and coordinate the efforts necessary to conduct such remedial action as provided above.

 

8.7        Pricing. All Product pricing and labelling shall, subject to applicable regulatory requirements, be at POINT’s sole discretion. Notwithstanding POINT’s pricing discretion, pricing for public payors and hospitals in [***] shall be matched to the lowest pricing granted in [***], which POINT shall accomplish using [***] or [***].

 

9.         Payments.

 

9.1        One Time Payment. POINT shall make a one-time payment to the Licensor of five hundred thousand Dollars ($500,000) in immediately available funds, payable upon execution of this Agreement. The grant of License will not be effective until such time as the Licensor has received such payment.

 

9.2        Milestone Payments.

 

(a)        POINT shall promptly notify the Licensor in writing following the first achievement of each of the milestone events set forth below with respect to the Product. Upon receipt of such notice, the Licensor shall issue an invoice to POINT and POINT shall promptly pay to the Licensor, in accordance with this Article 9, the applicable non-refundable, non-creditable milestone payment set forth below (“Milestone Payment”). Each such Milestone Payment will be due one time only upon the first achievement of the specified milestone with respect to the Product.

 

[***] = Indicates confidential information omitted from the exhibit.

 

 

	
Milestone Payments

	
 

	
Payment Due

	
Amount (CAD)

	
Within [***] days of receiving a first market approval in Canada in any Indication

	
$[***]

	
Within [***] days of receiving a first market approval in the USA for GEP-NETs

	
$[***]

	
Within [***] days of receiving market approval in the USA for first NET Indication other than GI/pancreas (GEP)-NETs

	
$[***]

	
Within [***] days of receiving a first market approval in the EU in any Indication

	
$[***]

	
Within [***] days of receiving a first market approval in the rest of the world (“ROW”) in any Indication

	
$[***]

 

At execution of the Memorandum of Understanding On February 7, 2020, POINT has paid a non-reimbursable payment of CAD $250,000 for a [***] day exclusivity period. This amount will be credited against the first Milestone Payment.

 

9.3        Net Sales. “Net Sales” means the total invoiced sales revenue and associated amounts received, for Products sold (as appropriate) by POINT, an Affiliate and Sublicensee(s), less the following deductions:

 

(a)        sales taxes or other taxes separately stated in the invoice;

 

(b)        shipping and insurance charges actually paid and separately stated on the invoice;

 

(c)        actual allowances, rebates, credits and refunds for returned or defective goods;

 

(d)       chargeback payments and rebates (or the equivalent thereof) granted to managed health care organizations or to federal, state/provincial, local and other governments, including their agencies, purchasers, and/or reimbursers, or to trade customers;

 

(e)        normal and customary trade and quantity discounts, retroactive price reductions, or other allowances actually allowed or granted from the billed amount and taken; and

 

(f)         any import or export duties, tariffs, or similar charges incurred with respect to the import or export of Product into or out of a country in the Territory.

 

Notwithstanding the foregoing, Net Sales will not include, and will be deemed zero with respect to, (a) the distribution of reasonable quantities of promotional samples of Products, (b) amounts received by POINT, its Affiliate(s) or Sublicensee(s) for the internal resale of Products among and to POINT, its Affiliates or Sublicensees; and (c) amounts received by POINT, its Affiliates or Sublicensees for Products provided for clinical trials, research or educational purposes, or charitable or compassionate use purposes.

 

All of the aforementioned deductions shall be determined as incurred in the ordinary course of business in type and amount consistent with POINT’s, or its applicable Affiliate’s or Sublicensee’s (as the case may be), business practices consistently applied across its product lines and accounting standards and verifiable based on the POINT sales reporting system. Where the Product is distributed, sold or bundled with other products, all such deductions shall be fairly and equitably allocated to such Product, such that the Product does not bear a disproportionate portion of such deductions.

 

[***] = Indicates confidential information omitted from the exhibit.

 

 

Accruals will be made in accordance with Canadian generally accepted accounting principles (“Canadian GAAP”). Net Sales shall be determined from POINT’s or its Affiliates’ or its Sublicensees’ books (as the case may be) and records shall be kept in accordance with Canadian GAAP.

 

9.4        Royalty Payments.

 

(a)        Royalty Fee. POINT shall pay royalties to the Licensor of [***] percent ([***]%) of the aggregate annual Net Sales of the Product in the Territory by POINT, directly and through its Affiliates and Sublicensees, in each Calendar Year, subject to any applicable adjustments or reductions provided for in this Agreement (“Royalty Fees”).

 

(b)        Royalty Reporting. POINT shall provide to the Licensor written reports within [***] days following the end of Calendar Half Year in the Calendar Year for which royalties are due, setting out (i) the Net Sales of Product in the Territory sold by POINT, its Affiliates and Sublicensees during that Calendar Half Year; (ii) a calculation of the amount of royalties due on Net Sales during such Calendar Half Year; (iii) the exchange rates used, if any, in determining the amount due or performing any necessary currency conversion; and (iv) any withholding Taxes required to be paid from such royalties (combined within each Calendar Year, such Calendar Half Year written reports constitute the “Annual Royalty Report”). The information in the Annual Royalty Report will be deemed POINT’s Confidential Information.

 

9.5        Sublicensing Fee. 

 

(a)        Sublicensing Fee. POINT shall pay to the Licensor a [***] percent ([***]%) sublicensing fee (“Sublicensing Fee”) on all payments and revenues (in addition to [***]% of Net Sales) received by POINT in the nature of compensation for the sublicensing of the Product (and/or any associated Licensed Technology), provided that where POINT has made a Sublicensee responsible for all or part of a Milestone Payment, such Milestone Payment will not be considered to form part of POINT’s compensation as aforesaid except to the extent where milestone payments received by POINT from Sublicensee are in excess of the Milestone Payment owed to Licensor, wherein POINT shall pay to Licensor [***] percent ([***]%) of such excess plus such Milestone Payment. POINT shall however be liable for any failure of any of its Sublicensees to make all or part of a Milestone Payment. Notwithstanding the foregoing, this Section 9.5(a) and Sublicensing Fee shall not apply to POINT for sublicenses granted to any POINT Affiliate.

 

(b)        Sublicensing Reporting. POINT shall provide to the Licensor written reports within [***] days following the end of each Calendar Half Year in the Calendar Year for which Sublicensing Fees are payable.

 

9.6           Stacking Royalties. In the event that it is necessary in order for POINT or its Sublicensee(s) to sell the Product in a Sub-Territory or to obtain a license and to pay royalties to one or more Third Parties on Net Sales of any Product(s), and if the aggregate royalty burden payable on any Product(s) for those Third Party licenses is greater than [***]% of Net Sales, then POINT may reduce the Royalty Fees or Sublicensing Fees due to the Parties for sales of such Product in such Sub-Territory by [***] percent ([***]%) of such necessary royalties actually paid to the Third Party(ies) on Net Sales of Product in such Sub-Territory within the same royalty period.

 

9.6          
Currency.

 

(a)           All currency amounts in this Agreement are expressed in Dollars and all payments to be made by POINT to the Licensor under this Agreement shall be made in Dollars by wire transfer in immediately available funds to a bank and account designated the Licensor herein. When conversion of amounts received by POINT in any currency other than Dollars is required, such conversion shall be calculated using the rate of exchange using the following methodology:

 

(i)          The calculation of Milestone Payments, Royalty Fees, and Sublicensing Fees will be made in Dollars regardless of the countries in which sales are made. Net Sales made in currencies other than Dollars will be converted into Dollars using a fixed exchange rate (subject to monthly adjustments as described below). The fixed exchange rate will apply to all payments related to the Net Sales during the month for which that fixed exchange rate applies independent of the actual invoice date.

 

[***] = Indicates confidential information omitted from the exhibit.

 

 

(ii)         Exchange rates will reset at the end of each month based on the applicable close price exchange rates on the final Business Day of such month as published in the Wall Street Journal. The exchange rates as so reset at the end of a month shall apply to all payments based on Net Sales received during the immediately following month and in no event shall such reset exchange rates be applicable to payments based on Net Sales in prior periods.

 

9.7        Taxes.

 

(a)        POINT will make all payments to the Licensor under this Agreement without deduction or withholding for Taxes except to the extent that any such deduction or withholding is required by Law in effect at the time of payment. The Parties agree to use commercially reasonable efforts to minimize any withholding or similar Tax imposed upon payments payable under this Agreement and to consult in good faith before taking any action that is reasonably expected to result in the application of a withholding or similar Tax imposed upon payments payable under this Agreement.

 

(b)        Any Tax required to be withheld on amounts payable under this Agreement will promptly be paid by POINT on behalf of the Licensor to the appropriate governmental authority, and POINT will furnish the Licensor with proof of payment of such Tax. Any such Tax required to be withheld will be an expense of and borne by the Licensor.

 

(c)         POINT and the Licensor will cooperate with respect to all documentation required by any taxing authority or reasonably requested by POINT to secure a reduction in the rate of applicable withholding Taxes.

 

(d)        All payments due to the Licensor from POINT pursuant to this Agreement shall be paid exclusive of GST/HST and similar commodity Taxes (including VAT).

 

9.8        Audits.

 

(a)        Audit Rights. During the Term and for a period of the longer of: (a) the length of time required to retain such records in accordance with applicable Law and (b) [***] years thereafter, POINT shall keep (and shall cause its Affiliates and Sublicensees to keep) complete and accurate records pertaining to the sale or other disposition of Product in sufficient detail to permit the Licensor to confirm the accuracy of all royalties and Sublicensing Fees due hereunder, kept in accordance with Canadian GAAP. The Licensor shall have the right to cause an independent, certified public accountant reasonably acceptable to POINT to audit such records to confirm Net Sales, Milestone Payments, Royalty Fees, Sublicensing Fees, and other payments. Such audits may be exercised during normal business hours upon reasonable prior written notice to POINT. Prompt adjustments will be made by the Parties to reflect the results of such audit. The Licensor shall bear the full cost of such audit unless such audit discloses an underpayment by POINT of more than [***] percent ([***]%) of the aggregate amount of Royalty Fees or other payments due for such audited period, in which case, POINT shall bear the full cost of such audit and shall remit to the Licensor the amount of any underpayment within [***] days after receipt of an invoice from the Licensor. All information in such records will be deemed POINT’s Confidential Information.

 

[***] = Indicates confidential information omitted from the exhibit.

 

 

9.9        Invoicing; Manner of Payment

 

(a)        With respect to any Calendar Year for which the Licensor is entitled to payment, POINT shall provide the Annual Royalty Report to the Licensor within [***] days of the end of each Calendar Year. The Licensor shall provide an invoice to POINT within [***] days of the receipt of the Annual Royalty Report. Within the later of [***] days of the date such invoice is provided by the Licensor to POINT, or (b) [***] days after the end of the Calendar Year, POINT shall pay the Licensor the aggregate amounts set forth in such invoice (or any other invoice that may be submitted pursuant to this Agreement) unless POINT disputes a portion thereof of in good faith (in which event POINT shall the pay the undisputed portion thereof).

 

Any payments or portions thereof due by POINT to the Licensor hereunder which are not paid when due shall bear interest at the prime rate of interest quoted by the Bank of Canada as at the due date, plus [***]% ([***] percent) per annum compounded monthly until the date paid to Licensor. This Section 8 shall in no way limit any other remedies available to the Licensor.

 

Invoices to POINT should be sent to:

 

Bill Demers

CFO

POINT Biopharma Inc.

22 St. Clair Avenue East, Suite 1201

Toronto, Ontario, Canada,

M4T 2S3

 

(b)        Manner of Payment. All payments to be made by POINT to Licensor hereunder shall be by wire transfer to the relevant bank account detailed below or such other bank account as Licensor (as applicable) may designate in writing from time to time during the Term.

 

Unless otherwise indicated, payments should be made to the following account:

 

Beneficiary Bank Name: [***]

 

Account Name: [***]
Account Number: [***]
Swift Code: [***]
Clearing Code: [***]
Bank Address: [***]

 

With a notice of payment sent to:
[***] (email: [***])

 

10.        Intellectual Property.

 

10.1         Ownership.

 

(a)          CPDC confirms that CPDC has full and exclusive ownership to all CPDC Intellectual Property set forth in Schedule A. CPDC will remain the sole owner of all other rights and title to the CPDC IP.

 

(b)         UHN confirms that UHN has full and exclusive ownership of all Study Data.

 

(c)          Except as expressly granted herein, POINT shall have no rights to the CPDC IP owned by CPDC or UHN Study Data owned by UHN.

 

[***] = Indicates confidential information omitted from the exhibit.

 

 

(d)          POINT shall and will own all POINT Technology.

 

(e)          POINT shall be responsible for the filing, registration, prosecution and maintenance of all trademarks and tradenames and for the registration and maintenance of all domain names necessary to achieve the purposes hereunder.

 

(f)           POINT will assign the Regulatory Approvals, Regulatory Materials, trademarks, tradenames and
domain names as the Licensor directs upon termination of this Agreement.

 

10.2       Prosecution of Patents.

 

(a)        Licensed Patents Rights. POINT shall be responsible for the handling and directing of the preparation, filing, prosecution, maintenance and any opposition defense of the licensed Patent Right. POINT shall keep any other Party that has ownership interest (particularly, assignment by an inventor) informed of all material steps with regard to the preparation, filing, prosecution, and maintenance of any licensed Patent Right, including but not limited to for example, by providing a copy of material communications to and from any patent authority in the Territory regarding such Patent Right, and by providing drafts of any material filings or responses to be made to such patent authorities in the Territory. POINT shall consider in good faith the requests and suggestions of other Party or Parties with respect to such drafts and with respect to strategies for filing and prosecuting the licensed Patent Right in the Territory. No later than [***] days following the end of each Calendar Year, POINT shall provide the other Party or Parties a written report summarizing all actions taken during the preceding year with respect to the licensed Patent Right. If POINT elects not to file any patent application of the Patent Right or otherwise abandon the prosecution or maintenance of any licensed Patent Right, then (a) POINT shall provide the other Party or Parties with reasonable notice of such decision so as to permit the other Party of Parties to decide whether to assume such responsibilities (such notice shall, to the extent reasonably feasible for POINT, be given no later than [***] days prior to the next deadline to take any necessary action with the relevant patent office); and (b) the other Party or Parties shall have the right, but not the obligation, to control the filing, prosecution and maintenance of such Patent Right (or patent application). Licensor may file, prosecute, or maintain such application and/or Patent Rights at its own expense and any license granted under this Agreement shall exclude such Patent Right.

 

(b)        POINT shall be directly responsible for all reasonable costs (Prosecution and Maintenance Expenses) incurred in the Prosecution and Maintenance of such licensed Patent Right that comprise the Licensed Technology.

 

10.3        Enforcement.

 

(i)         Each Party shall notify the others promptly of any apparent, threatened, or actual infringement by a Third Party of any Patent Right licensed under this Agreement, or misappropriation of any trade secret of Know-How licensed under this Agreement or of any Opposition Defense, of which the Party becomes aware. 

 

(ii)         The notifying Party shall promptly furnish the other with all known details or evidence of such infringement or misappropriation or opposition.

 

(iii)        Each Party shall notify the other within [***] days of any Third Party communications pertaining to any such Patent Right that the Party receives as patent owner or as the marketing authorization holder pursuant to the Canadian Patented Medicines (Notice of Compliance) Regulations or the United States Drug Price Competition and Patent Term Restoration Act of 1984 or equivalent regime in any other country.

 

[***] = Indicates confidential information omitted from the exhibit.

 

 

(iv)       POINT shall have the first right, but not the obligation, to enforce or defend an opposition to the licensed Patent Right with respect to such Third Party infringement or opposition or otherwise abate such infringement or opposition of the licensed Patent Right, at its sole cost and expense. In such event, POINT shall have the right to control any litigation or other enforcement action and to enter into, or permit, the settlement of any such litigation or other enforcement action with respect to the licensed Patent Right and such Third Party infringement or opposition. The Parties each agree to cooperate reasonably with POINT in any action to enforce the licensed Patent Right at POINT’s expense, including by executing reasonably appropriate documents, cooperating in discovery and joining as a party in any such suit if deemed a necessary party. All monies recovered upon the final judgment of an opposition or settlement of any such suit to enforce the licensed Patent Right pursuant to this Section shall be first used to reimburse POINT for the costs and expenses incurred in connection with such opposition or suit. Any remainder that represents lost profits or lost sales of Product shall be treated as Net Sales and shall allocated to POINT, and shall be subject to the royalty payment to pursuant to Section 9.4. Any remainder that does not represent lost profits or lost sales of Product shall be retained by POINT.

 

(v)        If POINT does not, within [***] days of receipt of notice of a Third Party infringement from another party abate the infringement or file suit in at least one Sub-Territory to enforce the licensed Patent Right against at least one infringing party, the other Parties hereunder shall, at their sole cost, have the right to enforce the licensed Patent Right. POINT agrees to cooperate reasonably with the enforcing parties in any action to enforce the licensed Patent Right with respect to Third Party infringement including by executing reasonably appropriate documents, cooperating in discovery and joining as a party in any such suit if deemed a necessary party. All monies recovered upon the final judgment or settlement of any such suit to enforce the licensed Patent Right shall be retained by the enforcing parties.

 

(vi)       A settlement or consent judgment or other voluntary final disposition of an action brought by a Party under this section may be entered into without the consent of the other Parties, provided that such settlement, consent judgment, or other disposition does not admit the invalidity or unenforceability of any Intellectual Property owned or licensed by the other Parties, and provided further that any rights granted to a Third Party to continue any activity upon which such action was based in such settlement, consent judgment, or other disposition shall be limited to the product or activity that was the subject of the action.

 

(vii)      Any
damages or recovery obtained as a result of such action, whether by judgment, award, decree or settlement, shall be
allocated, firstly, to reimbursement of the Party who brought the action for its out-of-pocket expenses incurred in bringing
such suit or proceeding (including any advisory counsel) (provided that it has reimbursed each of the other Parties for its
out-of-pocket expenses incurred in providing assistance as provided for above), and secondly, the balance to the Party who
brought such suit or proceeding, except that in the event a court awards POINT any recovery of lost profits for any lost Net
Sales of Product on account of any such Third Party infringement of licensed Patent Right, POINT shall owe the Licensor
royalties based on such award of lost Net Sales as determined in accordance with the License, as the case may be, but only
after POINT has been reimbursed for any out-of-pocket costs including counsel’s fees.

 

10.4          Infringement of Third-Party Patent Rights. POINT shall use reasonable efforts to avoid infringing or misappropriating any Third Party’s Intellectual Property in conducting any activities under this Agreement. Each Party shall promptly notify the others in the event it becomes aware of any patent rights controlled by a Third Party that may pertain to any such activities of the Parties.

 

10.5           Patent Term Restoration. POINT shall cooperate in obtaining patent term restoration or supplemental protection certificates or their equivalents in any country where applicable to the Patent Rights. If elections with respect to obtaining such patent term restoration for any Patent Right exclusively licensed to POINT are to be made, POINT shall have the right to make the election to seek patent term restoration or supplemental protection and the Licensor shall abide by such election

 

[***] = Indicates confidential information omitted from the exhibit.

 

 

10.6          Employee Agreements. Prior to beginning work relating to any aspect of the subject matter of this Agreement and/or being given access to Confidential Information of the other Parties, each appropriate employee, consultant, contractors and/or agent of the Licensor and POINT shall have signed or shall be bound to a commercially reasonable non-disclosure and/or Intellectual Property assignment agreement, including the provision that POINT shall promptly notify the Licensor of any Intellectual Property in connection with or related to the CPDC Intellectual Property or UHN Intellectual Property and each appropriate employee, consultant, contractor and/or agent of POINT agrees to assign its rights and interest in and to any such Intellectual Property to POINT as applicable. Each Party will be responsible for any compensation or payment to its employees, consultants, contractors or agents in connection with the invention of any Patent Right.

 

10.7          Cooperation. Each Party shall reasonably cooperate with the other Parties in the Prosecution and Maintenance of the Patent Rights pursuant to this Agreement. Such cooperation includes promptly executing all documents, or requiring inventors, subcontractors, employees, former employees (to the extent reasonably available) and consultants and agents to execute all documents, as reasonable and appropriate so as to enable the Prosecution and Maintenance or enforcement of any such Patent Rights in any country.

 

11.        Confidentiality.

 

11.1      Confidentiality; Exceptions. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing or required as a condition of a sublicense, the Parties agree that, during the Term and for [***] years thereafter (except for Know-How, which shall be perpetual), the receiving Party will keep confidential and will not publish or otherwise disclose or use for any purpose other than as provided for in this Agreement any information furnished to it by the other Parties pursuant to this Agreement (collectively, “Confidential Information”). Notwithstanding the foregoing, Confidential Information will not include any information to the extent that it can be established by written documentation by the receiving Party that such information:

 

(a)        is obtained or was already known by the receiving Party or its Affiliates as a result of disclosure from a Third Party that the receiving Party neither knew nor should have known was under an obligation of confidentiality to the disclosing Party with respect to such information;

 

(b)        was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party through no act or omission of the receiving Party or its Affiliates in breach of this Agreement;

 

(c)         became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party or its Affiliates in breach of this Agreement; or

 

(d)        is independently discovered or developed by the receiving Party or its Affiliates (without reference to or use of Confidential Information of the disclosing Party) as demonstrated by the receiving Party’s documented evidence prepared contemporaneously with such independent Development or other equally competent evidence.

 

11.2      Authorized Disclosure. Except as expressly provided otherwise in this Agreement, each Party may use and disclose Confidential Information of the other Parties solely as follows:

 

(a)          POINT or its Affiliates and the Licensor or its Affiliates each may disclose Confidential Information that
it has received hereunder to their Affiliates and to those of the personnel and subcontractors of them and their Affiliates who
have a need to such information in order to carry out the work under the Commercialization Plan, or to perform activities under
Article 10 (Intellectual Property);

 

[***] = Indicates confidential information omitted from the exhibit.

 

 

(b)        under appropriate confidentiality provisions substantially equivalent to those in this Agreement: (i) in connection with the performance of its obligations or as reasonably necessary or useful in the exercise of its rights under this Agreement, and (ii) to the extent it believes such disclosure is reasonably necessary in conducting the activities contemplated under this Agreement;

 

(c)    
     to the extent such disclosure is to a governmental authority as
reasonably necessary in filing or prosecuting patent applications in accordance with this Agreement, prosecuting or defending
litigation in accordance with this Agreement, complying with applicable governmental regulations with respect to performance
under this Agreement, filing regulatory filings, obtaining Regulatory Approval or fulfilling post-approval regulatory
obligations for the Product or otherwise required by Law, provided, however, that if a Party is required by Law or the rules
of any securities exchange or automated quotation system to make any such disclosure of any other Parties’ Confidential
Information it will, except where impracticable for necessary disclosures (for example, in the event of medical emergency),
give reasonable advance notice to such other Party of such disclosure requirement and, in the case of each of the foregoing,
will use its reasonable efforts to secure confidential treatment of such Confidential Information required to be
disclosed;

 

(d)         to advisors (including lawyers and accountants) or funding or investment entities (including the Government of Ontario) on a need to know basis, in each case, to the extent permissible under applicable Law, under appropriate confidentiality provisions or professional standards of confidentiality; or

 

(e)         to the extent mutually agreed to by the Parties.

 

11.3      Confidential Treatment of Terms and Conditions. Subject to the exceptions set out in Section 11.2, no Party shall disclose the terms and conditions of this Agreement except as may be required by Law or as necessary to effect terms of this Agreement.

 

11.4      Attorney-Client Privilege. No Party is waiving, nor will be deemed to have waived or diminished, any of its attorney work product protections, attorney-client privileges or similar protections and privileges as a result of disclosing information pursuant to this Agreement, or any of its Confidential Information (including Confidential Information related to pending or threatened litigation) to the receiving Party, regardless of whether the disclosing Party has asserted, or is or may be entitled to assert, such privileges and protections. The Parties:

 

(a)        share a common legal and commercial interest in such disclosure that is subject to such privileges and protections;

 

(b)        may become joint defendants in proceedings to which the information covered by such protections and privileges relates;

 

(c)        intend that such privileges and protections remain intact should either Party become subject to any actual or threatened proceeding to which the disclosing Party’s Confidential Information covered by such protections and privileges relates; and

 

(d)        intend that after the Effective Date both the receiving Party and the disclosing Party will have the right to assert such protections and privileges.

 

11.5      Publication

 

(a)        It is anticipated that all or part of the Licensed Technology will be published or presented by the Licensor. Licensor shall have the right to publish and disclose the Licensed Technology in peer-reviewed journals, conferences, meetings or any other type of public forums for educational and academic purposes as is customary for such matters.

 

[***] = Indicates confidential information omitted from the exhibit.

 

 

(b)        The Parties will include appropriate individuals in the authorship of and/or acknowledgment in scientific publications relating to the Licensed Technology , such as papers, articles, manuscripts, posters, abstracts and presentations (each a “Publication”) in accordance with the generally accepted standards for authorship and acknowledgement including the Guidelines of the International Committee of Medical Journal Editors (ICMJE).

 

(c)        The Party submitting the Publication will provide the other Party with a copy of any draft Publication prior to submission for publication at least [***] business days (abstracts and presentations) and at least [***] business days in advance (all other Publications) of such submission for review and comment. At the other Party’s request, the submitting Party shall (1) remove any unpublished Know-How or Intellectual Property of the other Party as requested, but which removal does not destroy the scientific relevance of the Publication or result in the rejection of the Publication by the applicable journal and (2) shall delay publication for up to an additional [***] business days to permit the filing of a patent application by the relevant Party with respect to any Intellectual Property disclosed in such draft Publication. The Parties also may agree of pre-approval of specified publications (particularly, abstracts and presentations) that would not require submission of the draft Publication to other Parties. Neither Party shall publish any Confidential Information of the other Party, without such Party’s prior written approval, which approval will not be unreasonably withheld.

 

12.        Representations, Warranties and Covenants.

 

12.1      Mutual Representations and Warranties. In addition to the representations and warranties made by a Party elsewhere in this Agreement, each Party hereby represents and warrants to the other Parties that:

 

(a)             As of the Effective Date, it is duly organized and validly existing under the Laws of its
jurisdiction of organization and it has full corporate power and authority and has taken all corporate action necessary to enter
into and perform this Agreement;

 

(b)            As of the Effective Date, this Agreement is a legal and valid obligation binding upon such Party and enforceable in accordance with its terms; the execution, delivery and performance of the Agreement by such Party does not conflict with any agreement, instrument or understanding, oral or written, by which it is bound, nor to its knowledge as of the Effective Date violate any Law; and the person or persons executing this Agreement on such Party’s behalf have been duly authorized to do so by all requisite corporate action;

 

(c)            To each Party’s knowledge, the execution and delivery of this Agreement, the performance of its obligations hereunder, as applicable, and the licenses and sublicenses to be granted pursuant to this Agreement (i) do not and will not conflict with or violate any requirement of applicable Law existing as of the Effective Date, and as of the Effective Date; (ii) do not and will not conflict with or violate the certificate of incorporation or by-laws of such Party; and (iii) do not and will not conflict with, violate, breach or constitute a material default under any contractual obligations of such Party or any of its Affiliates existing as of the Effective Date.

 

(d)            As of the Effective Date, none of such Party’s employees or consultants:

 

(i)         is debarred under Section 306(a) or 306(b) of the FD&C Act or by the analogous Laws of any Regulatory Authority;

 

(ii)        has, to such Party’s knowledge, been charged with, or convicted of, any felony or misdemeanor within the ambit of 42 U.S.C. §§ 1320a-7(a), 1320a-7(b)(l)-(3), or pursuant to the analogous Laws of any Regulatory Authority, or is proposed for exclusion, or the subject of exclusion or debarment proceedings by a Regulatory Authority; and

 

[***] = Indicates confidential information omitted from the exhibit.

 

 

(iii)       is excluded, suspended or debarred from participation, or otherwise ineligible to participate, in any Canadian, U.S. or non-U.S. health care programs (or has been convicted of a criminal offense that falls within the scope of 42 U.S.C. §1320a-7 but not yet excluded, debarred, suspended, or otherwise declared ineligible), or excluded, suspended or debarred by a Regulatory Authority from participation, or otherwise ineligible to participate, in any procurement or non-procurement programs.

 

12.2      Licensor Representations, Warranties and Covenants. In addition to the representations and warranties made by the Licensor above and elsewhere in this Agreement, the Licensor hereby represents, warrants, and covenants to POINT in regards to the extent of their obligations herein that:

 

(a)        As of the Effective Date, it has, or will have during the Term of this Agreement, the full right, power and authority to grant to POINT the licenses hereunder granted in this Agreement;

 

(b)    Disclaimer of Warranties. EXCEPT AS OTHERWISE SET FORTH IN ARTICLE 10 OF THIS AGREEMENT, THE LICENSOR EXPRESSLY DISCLAIMS ANY AND ALL REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, WITH RESPECT TO THE PATENT RIGHTS, INFORMATION AND ANY OTHER SUBJECT MATTER RELATING TO THIS AGREEMENT, INCLUDING ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OR NON-INFRINGEMENT OF INTELLECTUAL PROPERTY.

 

12.3      POINT Representations, Warranties and Covenants.

 

(a)        POINT shall at all times comply with all applicable Laws, including but not limited to those laws governing its business related to the manufacture, distribution and sale of the Product and as set out in Schedule D (Compliance Schedule). POINT shall adhere to and comply with all Applicable Laws regarding protection of personal information, including, but not limited to, Personal Information Protection and Electronic Documents Act, S.C. 2000, c. 5 (“PIPEDA”), Ontario’s Personal Health Information Protection Act, 2004, S.O. 2004, c. 3 (“PHIPA”), and any Applicable Laws concerning the protection of personal health information (collectively, “Privacy Laws”). POINT shall use or disclose any personal health information (“PHI”) received under this Agreement except in accordance with the informed consent for the purposes of fulfilling its obligation under this Agreement or as required by Law.

 

(b)        POINT has the liquidity to meet and comply with its foreseeable payment obligations under this Agreement and it has sufficient resources to perform (or have performed on its behalf) all of its obligations and activities, including all of its Development, commercialization and diligence obligations, as applicable, under this Agreement.

 

[***] = Indicates confidential information omitted from the exhibit.

 

 

13.           Indemnification.

 

13.1         Indemnification by Licensor. Licensor hereby agrees to defend, hold harmless and indemnify (collectively, “Indemnify”) POINT and its Affiliates, and its and their directors, officers, employees, contractors and agents (collectively, the “POINT Indemnitees”) from and against any liability or expense (including reasonable legal expenses, costs of litigation and attorneys’ fees), damages, or judgments, whether for money or equitable relief (collectively, “Losses”) resulting from suits, proceedings, claims, actions, demands, or threatened claims, actions or demands, in each case brought by a Third Party (each, a “Third Party Claim”) against a POINT Indemnitee, including, for each of clauses (a), (b) and (c), below, bodily injury, risk of bodily injury, death, property damage, and product liability Third Party Claims or the failure to comply with Law arising out of or relating to, directly or indirectly:

 

(a)          The Licensor’s, its Affiliates or subcontractors’ (collectively, the “Licensor Parties”) activities under the Commercialization Plan;

 

(b)         The Licensor Parties’ negligence, recklessness, intentional misconduct or intentional acts or omissions; provided that the foregoing shall not apply to any action or omission undertaken at the direction or request of any POINT Indemnitee outside of the Commercialization Plan; or

 

(c)           The Licensor’s material and uncured breach of any representation, warranty or covenant set out in this Agreement.

 

(d)          Licensor’s obligation to Indemnify the POINT Indemnitees pursuant to this Section 13.1 shall not apply to the extent that any such Losses (i) arise from the negligence or intentional misconduct of any POINT Indemnitee; (ii) arise from any material breach by POINT of this Agreement; or (iii) arise out of POINT’s activities under the Commercialization Plan.

 

13.2         Indemnification by POINT. POINT hereby agrees to Indemnify UHN, CPDC, CanProbe and their respective Affiliates, and their directors, officers, employees, contractors and agents (the “Licensor Indemnitees”) from and against any and all Losses resulting from Third Party Claims, including, for each of clauses (a), (b) and (c), below, bodily injury, risk of bodily injury, death, property damage, and product liability Third Party Claims or the failure to comply with Law arising out of or relating to, directly or indirectly:

 

(a)         POINT’s, its Affiliates’, Sublicensees’, wholesalers’, distributors’ or sub-contractors’ (collectively, the “POINT Parties”) activities (including Development) under the Commercialization Plan, use, Development, manufacture, commercialization, transfer, labelling, handling or storage, promotion, marketing, distribution, offer for sale, sale, import or export of any Product in the Territory;

 

(b)        the POINT Parties’ negligence, recklessness, intentional misconduct or intentional acts or omissions; provided that the foregoing shall not apply to any action or omission undertaken at the direction or request of any Licensor Indemnitee outside of the Commercialization Plan; or

 

(c)         POINT’s material and uncured breach of any representation, warranty or covenant set out in this Agreement.

 

POINT’s obligation to Indemnify the Licensor Indemnitees pursuant to the foregoing sentence shall not apply to the extent that any such Losses (i) arise from the negligence or intentional misconduct of any Licensor Indemnitee; (ii) arise from any material breach by the Licensor of this Agreement; or (iii) arising out of the Licensor’s activities under the Commercialization Plan.

 

13.3       Claim for Indemnification. Whenever any Third Party Claim or Loss arises for which a POINT Indemnitee or a Licensor Indemnitee (the “Indemnified Party”) may seek indemnification under this Article 13 (Indemnification), the Indemnified Party will promptly notify the other Party (the “Indemnifying Party”) of the Third Party Claim or Loss and, when known, the facts constituting the basis for the Third Party Claim or Loss; provided, however, that the failure by an Indemnified Party to give such notice or to otherwise meet its obligations under this Section 13.3 (Claim for Indemnification) does not relieve the Indemnifying Party of its indemnification obligations under this Agreement except and only to the extent that the Indemnifying Party is actually prejudiced as a result of such failure. The Indemnifying Party has exclusive control of the defense and settlement of all Third Party Claims for which it is responsible for indemnification and shall assume the defense thereof at its own expense promptly upon notice of such Third Party Claim or Loss. The Indemnified Party shall not settle or compromise any Third Party Claim for which it is entitled to indemnification without the prior written consent of the Indemnifying Party, unless the Indemnifying Party is in breach of its obligation to defend hereunder. In no event can the Indemnifying Party settle any Third Party Claim without the prior written consent of the Indemnified Party if such settlement does not include a complete release from liability on such Third Party Claim or if such settlement would involve undertaking an obligation other than the payment of money, would bind or impair the Indemnified Party, or includes any admission of wrongdoing or that any Intellectual Property or proprietary right of the Indemnified Party is invalid or unenforceable. The Indemnified Party shall reasonably cooperate with the Indemnifying Party at the Indemnifying Party’s expense and shall make available to the Indemnifying Party reasonably requested information under the control of the Indemnified Party, which information is subject to Article 11 (Confidentiality). The Indemnifying Party shall permit the Indemnified Party to participate in (but not to control) the Third Party Claim through counsel of its choosing (to the extent it has the ability to do so). Notwithstanding any other provision of this subsection, if an Indemnified Party withholds consent to a bona fide settlement offer, where but for such action, the Indemnifying Party could have settled such Third Party Claim, the Indemnifying Party shall be required to indemnify the Indemnified Party only up to a maximum of the bona fide settlement offer for which the Indemnifying Party could have settled such Third Party Claim.

 

[***] = Indicates confidential information omitted from the exhibit.

 

 

14.        Limitations of Liability; Insurance.

 

14.1      Limitations of Liability. IN NO
EVENT WILL ANY PARTY BE LIABLE TO THE OTHER PARTIES FOR ANY INDIRECT, SPECIAL, INCIDENTAL, EXEMPLARY, MULTIPLE, CONSEQUENTIAL,
OR PUNITIVE DAMAGES OF ANY KIND ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT, OR FOR ANY LOSS OR INJURY TO A PARTY’S
PROFITS OR GOODWILL, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY (WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY
OR OTHERWISE), EVEN IF SUCH PARTY WAS ADVISED OR OTHERWISE AWARE OF THE LIKELIHOOD OF SUCH DAMAGES, EXCEPT WITH RESPECT TO CONSEQUENTIAL
DAMAGES (WHICH IN NO EVENT WILL INCLUDE ANY PUNITIVE DAMAGES) AWARDED TO A PARTY THAT THE NON-BREACHING PARTY DEMONSTRATES RESULTED
FROM A BREACH OF SECTION 11.1 (CONFIDENTIALITY; EXCEPTIONS), OR SECTION 11.2 (AUTHORIZED DISCLOSURE). NOTHING IN THIS
SECTION 14.1 (LIMITATIONS OF LIABILITY) IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER
PARTY UNDER ARTICLE 13 (INDEMNIFICATION) WITH RESPECT TO ANY DAMAGES PAID BY THE OTHER PARTY TO A THIRD PARTY IN CONNECTION
WITH A THIRD PARTY CLAIM. NOTWITHSTANDING THE FOREGOING, CANPROBE’S LIABILITY TO ANY PARTY UNDER THIS AGREEMENT SHALL
BE CAPPED AT CANPROBE’S LEVEL OF AVAILABLE INSURANCE. The Parties acknowledge that this Section 14.1 reflects
the allocation of risk set forth in this Agreement and that CanProbe would not enter into this Agreement on the terms hereof without
these limitations on its liability.

 

14.2      Licensor Insurance Obligations. UHN, CPDC, and CanProbe shall each procure and maintain insurance, including product liability insurance, with respect to its activities hereunder and which are consistent with normal business practices of prudent companies similarly situated at all times during which the Product is being clinically tested in human subjects or commercially distributed or sold. Each of UHN, CPDC and CanProbe shall provide POINT with written evidence or written confirmation of such insurance upon request. Each of UHN, CPDC and CanProbe shall provide POINT with written notice at least [***] days prior to the cancellation, non-renewal or material change in such insurance or self-insurance which materially adversely affects the rights of POINT hereunder.

 

14.3      POINT Insurance Obligations. During the Term, upon the commencement of clinical use, production, sale,
or transfer, whichever occurs first, of Product, POINT shall obtain and carry in full force and effect general liability
insurance which shall protect the Licensor, in regard to events covered by Article 13. Such insurance shall be written by a
reputable insurance company, shall be endorsed to include product liability coverage, broad form contractual liability
coverage for POINT’s indemnification under this Agreement, and coverage for litigation costs. The limits of such
insurance shall not be less than [***] per occurrence with an annual aggregate of [***] for personal injury, death or
property damage. POINT shall provide the Licensor with certificates of insurance evidencing the same within [***] days of the
date that such insurance is required by the foregoing. Additionally, POINT shall provide the Licensor with written notice of
at least [***] days prior to the cancellation, non-renewal or material change in such insurance. POINT’s failure to
procure and maintain insurance in accordance with this Section 14.3 shall be grounds for Licensor to terminate this Agreement
pursuant to Section 15.2(b). The minimum amounts of insurance coverage required herein shall not be construed to create a
limit of POINT’s liability with respect to its indemnification under this Agreement. POINT shall maintain such
commercial general liability insurance beyond the expiration or termination of this Agreement during: (i) the period that any
Product Developed pursuant to this Agreement is being commercially distributed or sold by POINT or by an Affiliate or a
Sublicensee; and (ii) the five (5) year period immediately after such period POINT represents and warrants that it has such
insurance in effect as of the Effective Date and has provided to the Licensor a copy of the certificate of insurance
evidencing such insurance on or prior to the Effective Date. It is understood that such insurance shall not be construed to
create a limit of POINT’s liability with respect to its indemnification obligations under Article 13.

 

[***] = Indicates confidential information omitted from the exhibit.

 

 

15.        Term and Termination.

 

15.1      Term. The Agreement shall remain in full force and effect from the effective date of the Agreement until expiry or termination thereof, as described in Termination below:

 

15.2      Termination by any Party. This Agreement may be terminated by any Party to the other Parties under the following conditions:

 

(a)          Mutual Agreement. The Parties may terminate this Agreement upon (90) days (or earlier if mutually agreed by the Parties) prior written notice and mutual written agreement.

 

(b)         Breach. In the event of any material breach by any Party of this Agreement; provided that the Party
proposing to terminate this Agreement provides notice of such breach to the allegedly breaching Party specifying the nature of
the alleged breach and such breach has not been cured by such Party within sixty (60) days after such notice thereof; provided
that, in the case of payments to be made by POINT to the Licensor such breach will be triggered upon POINT’s failure to
make any payment hereunder within twenty (20) business days of POINT’s receipt of notice.

 

15.3      Termination by the Licensor.

 

(a)        The Licensor may terminate this Agreement upon written notice to POINT:

 

(i)         Termination for Failure to Develop. In respect of any particular Sub-Territory, if POINT has notified as per Section 17.9 (Notices) the Licensor that it has ceased, during at least [***] consecutive calendar months, for any reason, all Development or commercialization activities in such Sub-Territory as outlined in the Commercialization Plan. For clarity, in such situation the termination will apply only to the respective Sub-Territory(ies).

 

(ii)         Termination for Ceased Sales. In respect of any particular Sub-Territory, if POINT has Ceased Sales during at least [***] consecutive calendar months, for any reason, in such Sub-Territory. For clarity, the termination will apply only to the respective Sub-Territory(ies).

 

(iii)        Termination for Failure to Submit an NDS, ANDS, NDA and ANDA. If POINT has not used Commercially Reasonable Efforts to file a New Drug Submission (NDS) and/or Abbreviated New Drug Submission (ANDS) in Canada and a New Drug Application (NDA) and/or Abbreviated New Drug Application (ANDA) in the USA, within [***] months from the first data lock for the Study.

 

15.4      Termination for Insolvency or Bankruptcy.

 

(a)        Insolvency Event; Definition. The Licensor may terminate this Agreement in its entirety upon providing written notice to POINT on or after the time that POINT makes a general assignment for the benefit of creditors, files an insolvency petition in bankruptcy or makes a voluntary assignment in bankruptcy, petitions, applies for or acquiesces to the appointment of any receiver, receiver and manager, interim receiver, trustee or similar officer or official to liquidate or conserve its business or any substantial part of its assets, commences under the laws of any jurisdiction any proceeding involving its insolvency, bankruptcy, reorganization, adjustment of debt, dissolution, liquidation or any other similar proceeding for the release of or other relief for financially distressed debtors, or becomes a party to any proceeding or action of the type described above (each, an “Insolvency Event”).

 

[***] = Indicates confidential information omitted from the exhibit.

 

 

15.5      Effect of Termination or Expiration.

 

(a)        In the event that this Agreement is terminated, in addition to any other remedies available at law or in equity:

 

(i)         all licenses granted to POINT under this Agreement will terminate;

 

(ii)         At POINT’s expense (unless such termination is by POINT due to material breach by the Licensor pursuant to Section 15.2(b), in which case at the Licensor’s request and at its expense), POINT shall promptly:

 

(A)        return to the Licensor all relevant data, records and materials received from the Licensor and in POINT’s possession or control containing the Licensor’s Confidential Information (provided that POINT may keep one copy of such Confidential Information for archival purposes only); and

 

(B)        diligently wind down, according to good clinical practice, any clinical trials with respect to the Product that are ongoing at the time of notice of such termination or, at the Licensor’s reasonable request and expense, POINT will use Commercially Reasonable Efforts to assure a smooth transition to the Licensor, without interruption, of any ongoing clinical trials with respect to the Product being conducted by or on behalf of POINT (or its Affiliate or Sublicensee) at the time of notice of termination which POINT determines to continue in compliance with the applicable Laws and ethical guidelines applicable to the transfer or termination of such studies, provided that nothing herein shall require POINT to undertake any new Development, manufacture or commercialization or other activities.

 

(b)        POINT’s Obligations Upon Amendment or Termination of Agreement. The Licensor shall have the right, exercisable upon written notice by the Licensor to POINT given within [***] days after (i) the effective date of termination of this Agreement or (ii) the effective date of amendment in the case where Licensor has amended POINT’s rights to a Field or particular Sub-Territory pursuant to Section 2.1(c), to elect any or all of the following with respect to such Product previously marketed in the Territory where the affected Product in each case shall be referenced as “Terminated Product”, the affected Field shall be referenced as the “Terminated Field” and the affected Sub-Territory shall be referenced as “Terminated Territory”):

 

(i)         POINT shall transfer and assign to the Licensor, or its licensee, all Regulatory Materials, Regulatory Approvals, Branded Elements, related data, trademarks, tradenames and domain names relating to, or necessary to make, use or sell the Terminated Products in the Terminated Territory that are owned or licensed by POINT or its Affiliates or its Sublicensees. Where transfer or assignment is not permitted, POINT, shall cooperate fully with the Licensor to enable the Licensor, or its licensee, to obtain its own regulatory filings and Regulatory Approvals.

 

(ii)         POINT shall promptly provide to the Licensor copies of the Commercialization Data and all material data, records and materials generated by POINT, its Affiliates or Sublicensees to the extent related to Terminated Product marketed in the Terminated Territory.

 

[***] = Indicates confidential information omitted from the exhibit.

 

 

(iii)        If the Terminated Product is being sold at the time of termination or amendment, POINT will continue manufacturing or have manufactured the Terminated Product during a transitional period and with conditions to be mutually agreed in good faith between the Parties. In addition, in connection with any such transfer, the Licensor shall use commercially reasonable efforts to purchase from POINT (or its Affiliates or its Sublicensees) POINT’s inventory of Terminated Product at POINT’s cost of goods (and to purchase all of POINT’s inventory manufactured during the agreed transitional period), provided that such inventory is of marketable condition. POINT shall under no circumstances be obligated to continue activities which implicate a safety issue.

 

(iv)        Subject to the remaining provisions of this Section, POINT hereby grants to the Licensor, effective as of the effective date of such termination, a non-exclusive, perpetual, irrevocable, transferable, sublicenseable and royalty free license in the Terminated Field in the Terminated Territory or Sub-Territory, to any, POINT Technology solely to Develop and commercialize any Terminated Product that is in active clinical development or has been commercialized by POINT or its Affiliates or Sublicensees at the time of termination or amendment.

 

15.6      Accrued Rights. Expiration or termination of this Agreement (or any provision hereof) for any reason is without prejudice to any right that shall have accrued to the benefit of a Party prior to such expiration or termination, including damages arising from any breach under this Agreement. Expiration or termination of this Agreement does not relieve a Party from any obligation that is expressly indicated to survive such expiration or termination.

 

15.7      Survival. The following provisions shall survive termination or expiration of this Agreement: Article 1 (to the extent defined terms are contained in the following surviving Articles and Sections), Articles 8, 9, 11, 12, 13, 14 and 16 and Sections 10.1, 10.3, 10.6, 15.5 -15.7.

 

16.        Dispute Resolution.

 

(a)        Reasonable Efforts. The Parties agree to use reasonable efforts to resolve amicably among themselves any dispute arising out of this Agreement.

 

(b)        Referral for Resolution. If the Parties are unable to resolve the dispute under Section 16(a), the dispute shall be referred to the senior executive of the Licensor (or designate) and POINT (or designate) for their discussion and resolution. The Parties may agree to mediation of the dispute.

 

(c)        Arbitration. Any dispute which cannot be settled amicably between the Parties as provided in Sections 16(a) and 16(b) shall be submitted to arbitration, by an arbitrator to be mutually agreed upon by the Parties, in accordance with the provisions of the Arbitration Act, 1991, S.O. 1991, c.17, as amended from time to time. The arbitration will take place in the City of Toronto.

 

(d)        Language. The language of the arbitration shall be in English.

 

(e)        Judgment. Judgment upon the award rendered by such arbitrators shall be binding on the Parties and may be entered by any court having jurisdiction thereof.

 

(f)          Injunctive Relief. Any Party may apply to the arbitrators or a court of competent jurisdiction for interim injunctive relief until the arbitration award is rendered or the controversy is otherwise resolved. Nothing in this Agreement shall prevent any Party from seeking provisional measures, including a temporary restraining order or preliminary injunction, from any court of competent jurisdiction, and any such request shall not be deemed incompatible with the agreement to arbitrate or a waiver of the right to arbitrate.

 

[***] = Indicates confidential information omitted from the exhibit.

 

 

(g)        No Punitive Damages. The arbitrators shall be bound by the limitation of liability provisions in Section 14.1 and the arbitrators shall have no authority to award punitive or any other type of damages not measured by a Party’s compensatory damages; except as expressly provided otherwise under Section 14.1.

 

(h)        Award. The arbitrator(s) shall issue a brief, reasoned award. It is the intent of the Parties that barring extraordinary circumstances the award should be issued within six (6) months following appointment of the arbitrator(s) as provided above. The arbitrator(s) must agree to the foregoing deadlines before accepting appointment. The Parties may agree to extend this time limit or the arbitrators may do so in their discretion if they determine that the interest of justice so requires. The arbitrators shall use their best efforts to issue the final award or awards within such time period. Failure to adhere to this time limit shall not be a basis for challenging the award.

 

(i)         Confidentiality. Except to the extent necessary to confirm an award or as may be required by law, neither Party nor any arbitrator may disclose the existence, content, or results of an arbitration without the prior written consent of both Parties.

 

16.2      Patent Dispute Resolution. Any Dispute relating to the ownership, scope, validity, enforceability or infringement of any Patent Rights shall be submitted to a court of competent jurisdiction in which such Patent Rights exist.

 

16.3      Payment Dispute Resolution. Notwithstanding the provisions of Section 16(c), any dispute, controversy or claim relating to the calculation of Net Sales or a payment made pursuant to this Agreement shall be submitted for resolution to a member (the “Arbitrator”) of an accounting firm of national standing selected by both Parties (and which shall not be the auditor of either of the Parties) within [***] days after notice of the dispute is received or deemed to be received by a Party. If the Parties cannot agree on an Arbitrator, the provisions of Section 16(c) shall apply. The Parties shall make submissions to the Arbitrator within [***] days after the selection of the Arbitrator and the Arbitrator will select one Party’s submission. If the Parties cannot agree on a member of the accounting firm, the provisions of Section 16(c) shall apply. The decision of the Arbitrator in selecting on Party’s submission shall be final and binding on both Parties.

 

16.4      UNLESS EXPRESSLY STATED OR PERMITTED OTHERWISE IN THIS AGREEMENT, EACH PARTY HERETO WAIVES ITS RIGHT TO TRIAL UNDER ANY ISSUE BY JURY WITH RESPECT TO ANY DISPUTE BROUGHT UNDER THIS AGREEMENT.

 

17.        Miscellaneous.

 

17.1      Affiliates and Designees. Each Party has the right to exercise their respective rights, perform their respective obligations and/or receive performance of the other Parties’ obligations hereunder through their Affiliates or Sublicensees.

 

17.2      Assignment. Subject to the written consent of the Licensor (which consent shall not be unreasonably withheld), POINT may assign its rights and obligations under this Agreement to a Third Party (which for this purpose further includes an Affiliate) in connection with the merger, consolidation, reorganization, or sale of all or substantially all of its assets or that portion of its business to which the Agreement relates (respectively a “License Transfer”); but any such consent shall be conditional on the receipt by the Licensor of the License Transfer Fee (as subsequently defined). In the event of a License Transfer, a “License Transfer Fee” shall be payable to the Licensor equal to [***] percent ([***]%) of proceeds from the License Transfer. The License Transfer Fee payable in respect of the License Transfer will be due within [***] days of the closing of the License Transfer. The Licensor may assign its rights and obligations under this Agreement to a Third Party (which for this purpose further includes an Affiliate) with written notice to POINT.

 

[***] = Indicates confidential information omitted from the exhibit.

 

 

17.3      Construction. The Parties acknowledge and agree that: (a) each Party and its representatives have reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision; and (b) the terms and provisions of this Agreement will be construed fairly as to each Party hereto and not in favor of or against any Party regardless of which Party was generally responsible for the preparation or drafting of this Agreement. Unless the context of this Agreement otherwise requires: (i) words of any gender include each other gender; (ii) words using the singular or plural number also include the plural or singular number, respectively; (iii) the terms “hereof,” “herein,” “hereby,” and derivative or similar words refer to this entire Agreement; (iv) the terms “Article,” “Section,” “Exhibit,” “Schedule,” or “clause” refer to the specified Article, Section, Exhibit, Schedule, or clause of this Agreement; (v) “or” is disjunctive but not necessarily exclusive; and (vi) the term “including” or “includes” means “including without limitation” or “includes without limitation.” Whenever this Agreement refers to a number of days, such number shall refer to calendar days unless Business Days are specified.

 

17.4      Counterparts/Execution. This Agreement may be executed by original signatures or industry standard electronic signature software, and/or in any number of counterparts, each of which is deemed an original and all of which, taken together, shall constitute one and the same document. Alternatively, the Agreement may be executed and exchanged as a single document in electronic format (e.g. “pdf”).

 

17.5      Entire Agreement. This Agreement shall be binding upon and shall inure to the benefit of the Parties hereto and their respective successors and assigns permitted under this Agreement. This Agreement, including the attached Schedules constitutes the entire agreement between the Parties as to the subject matter of this Agreement, and supersedes and merges all prior discussions, representations, agreements and understandings regarding the same.

 

17.6      Force Majeure. No Party shall be liable for a delay or failure in the performance of any of its obligations hereunder (other than the payment of money) if such delay or failure is due to causes beyond its reasonable control, including acts of God (including, without limitation, any pandemic, epidemic or disease outbreak), fires, floods, earthquakes, labor strikes, acts of war, terrorism or civil unrest (“Force Majeure”); provided, however, that the affected Party notifies the other Parties in writing within [***] days of the Force Majeure event (and continues to provide monthly status updates to the other Parties for the duration of the effect); further provided that the affected Party will use its reasonable efforts to avoid or remove such causes of non-performance and to mitigate the effect of such occurrence, and will continue performance with reasonable dispatch whenever such causes are removed.

 

17.7      Further Assurances. Each Party agrees to do and perform all such further acts and things and will execute and deliver such other agreements, certificates, instruments and documents necessary or that the other Parties may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and to evidence, perfect or otherwise confirm its rights hereunder.

 

17.8       Headings. Headings and captions are for convenience only and are not to be used in the interpretation of this Agreement.

 

17.9      Notices. Any notice required or permitted to be given by this Agreement will be in writing, in English, and will be delivered by hand or overnight courier with tracking capabilities addressed as set forth below unless changed by notice so given:

 

If to the Licensor:                                      

 

Angela Lauretani, CA, CPA
Senior Director, Finance & Administration

CanProbe

C/O Centre for Probe Development and Commercialization (CPDC)

1280 Main St. W, NRB A308,

Hamilton, ON

L8S 4K1

 

[***] = Indicates confidential information omitted from the exhibit.

 

 

(with a copy to UHN)

 

Director, Technology Development & Commercialization
University Health Network
101 College Street – Suite 150
Heritage Building – MaRS Centre
Toronto, Ontario M5G 1L7 Canada
T: [***]
F: [***]
E: [***]

 

(with a copy to CPDC)       Angela Lauretani, CA, CPA
Senior Director, Finance & Administration

 

 Centre for Probe Development and Commercialization (CPDC)
 1280 Main St. W., NRB A308, 
 Hamilton, ON
 L8S 4K1
 B: [***]

 

 C: [***]
 E: [***]
 www.imagingprobes.ca

 

If to POINT:                         Bill Demers
Chief Financial Officer
POINT Biopharma Inc. 
22 St. Clair Avenue East,#1201
Toronto, Ontario, Canada
M4T 2S3

 

Any such notice will be deemed given on the date delivered. A Party may add, delete (so long as at least one person is remaining), or change the person or address to which notices should be sent at any time upon written notice delivered to the other Parties in accordance with this Section 17.9 (Notices).

 

17.10    Relationship of the Parties. Each Party is an independent contractor under this Agreement. Nothing contained herein is intended or is to be construed so as to constitute POINT and the Licensor as partners, agents or joint venturers. No Party has any express or implied right or authority to assume or create any obligations on behalf of or in the name of the other Parties or to bind the other Parties to any contract, agreement or undertaking with any Third Party.

 

17.11    Severability.
If any one or more of the provisions of this Agreement is held to be invalid or unenforceable, the provision will be considered
severed from this Agreement and will not serve to invalidate any remaining provisions hereof. The Parties will negotiate in good
faith to replace any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated
by the Parties when entering this Agreement may be realized.

 

[***] = Indicates confidential information omitted from the exhibit.

 

 

17.12   Third Party Beneficiaries. Except as expressly provided with respect to the Licensor Indemnitees or POINT Indemnitees in Article 13 (Indemnification) (for whom the Licensor and POINT, respectively, hold such rights in trust), there are no third party beneficiaries intended hereunder and no Third Party will have any right or obligation hereunder.

 

17.13    Waivers and Modifications. The failure of any Party to insist on the performance of any obligation hereunder is not be deemed to be a waiver of such obligation. Waiver of any breach of any provision hereof is not be deemed to be a waiver of any other breach of such provision or any other provision on such occasion or any other occasion. No waiver, modification, release or amendment of any right or obligation under or provision of this Agreement will be valid or effective unless in writing and signed by all Parties hereto.

 

17.14    Governing Law. This Agreement and any dispute hereunder will be governed by the laws of the Province of Ontario and the federal laws of Canada applicable therein. Subject to the provisions of Article 16, the Parties assent to the non-exclusive jurisdiction of the courts of the Province of Ontario.

 

[remainder of page intentionally left blank]

 

[***] = Indicates confidential information omitted from the exhibit.

 

     

     

    

 

TO WITNESS their agreement, the Parties have duly executed this Agreement.

 

	POINT
    BIOPHARMA INC	 	CANADIAN
    MOLECULAR PROBE CONSORTIUM
	 	 	 
	Per:	/s/
    Joe McCann	 	Per:	/s/
    Luke Brzozowski, Ph.D.
	 	Name: 	Joe McCann	 	 	Name:	 Luke Brzozowski,
Ph.D.
	 	Title: 	CEO	 	 	Title: 	President,

 

	CENTRE
    FOR PROBE DEVELOPMENT AND COMMERCIALIZATION	 	UNIVERSITY
    HEALTH NETWORK
	 	 	 
	Per:	/s/
    Bruno Paquin, Ph.D.	 	Per:	/s/
    Bradly G. Wouters, Ph.D.
	 	Name: 	Bruno Paquin,
Ph.D.	 	 	Name:	 Bradly G. Wouters,
Ph.D.
	 	Title: 	Interim CEO	 	 	Title: 	EVP - Science
 & Research

 

[***] = Indicates confidential information omitted from the exhibit.Exhibit 10.17

 

 

 

LOAN AND SECURITY AGREEMENT

 

dated as of July 10, 2020

 

between

 

WEST 78th STREET, LLC

as Borrower,

 

and

 

CIBC BANK USA,

as Lender

 

 

     

     

    

 

	SECTION
    1	 	DEFINITIONS	1
	1.1	 	Definitions	1
	1.2	 	Other Interpretive Provisions	16
	1.3	 	Accounting Terms; Changes in GAAP;
    Rates	16
	 	 	 	 
	SECTION
    2	 	COMMITMENTS OF LENDER; BORROWING
    AND CONVERSION PROCEDURES; EVIDENCING OF LOANS	17
	2.1	 	Commitments	17
	 	 	2.1.1	[Reserved]	17
	 	 	2.1.2	Term Loan Commitment	17
	 	 	2.1.3 	[Reserved]	17
	2.2	 	Loan Procedures	17
	 	 	2.2.1	Various Types
    of Loans	17
	 	 	2.2.2 	Borrowing Procedures	17
	 	 	2.2.3 	Conversion and
    Continuation Procedures	18
	 	 	2.2.4	[Reserved]	18
	2.3	 	[Reserved]	19
	2.4	 	Notes	19
	2.5	 	Recordkeeping	19
	 	 	 	 
	SECTION
    3	 	INTEREST	19
	3.1	 	Interest Rates	19
	3.2	 	Interest Payment Dates	19
	3.3	 	Setting and Notice of LIBO Rates	19
	3.4	 	Computation of Interest	20
	 	 	 	 
	SECTION
    4	 	FEES	20
	4.1	 	[Reserved]	20
	4.2	 	[Reserved]	20
	4.3	 	[Reserved]	20
	4.4	 	Commitment Fee	20
	 	 	 	 
	SECTION
    5	 	PREPAYMENTS	20
	5.1	 	[Reserved]	20
	5.2	 	Prepayments	20
	 	 	5.2.1	Voluntary Prepayments	20
	 	 	5.2.2 	Mandatory Prepayments	20
	5.3	 	Manner of Prepayments	21
	5.4	 	Repayments	21
	 	 	5.4.1	[Reserved]	21
	 	 	5.4.2 	Term Loan	21
	 	 	 	 
	SECTION
    6	 	MAKING AND PRORATION OF PAYMENTS;
    SETOFF; TAXES	21
	6.1	 	Making of Payments	21
	6.2	 	Application of Certain Payments	21
	6.3	 	Due Date Extension	21
	6.4	 	Setoff	21
	6.5	 	Taxes	22

 

    i

     

    

 

	SECTION
    7	 	INCREASED COSTS; SPECIAL
    PROVISIONS FOR LIBOR LOANS	23
	7.1	 	Increased Costs	24
	7.2	 	Basis for Determining Interest Rate Inadequate
    or Unfair	24
	7.3	 	Changes in Law Rendering LIBOR Loans Unlawful	24
	7.4	 	Funding Losses	24
	7.5	 	Right of Lender to Fund through Other Offices	25
	7.6	 	Discretion of Lender as to Manner of Funding	25
	7.7	 	Mitigation of Circumstances	25
	7.8	 	Conclusiveness of Statements;
    Survival of Provisions	25
	7.9	 	Effect of Benchmark	26
	 	 	 	 
	SECTION 8	 	COLLATERAL AND COLLATERAL ADMINISTRATION	29
	8.1	 	Grant	29
	8.3	 	[Reserved]	29
	8.4	 	Communications with Obligors; Loan Parties Remain
    Liable	29
	8.5	 	[Reserved]	29
	8.6	 	[Reserved]	29
	8.7	 	[Reserved]	29
	8.8	 	[Reserved]	29
	8.9	 	[Reserved]	29
	8.10	 	[Reserved]	29
	8.11	 	[Reserved]	29
	8.12	 	[Reserved]	29
	8.13	 	Acknowledgements	29
	8.14	 	Additional Parties	30
	8.15	 	Releases	30
	8.16	 	Obligations and Liens Absolute and Unconditional	30
	8.17	 	Reinstatement	31
	 	 	 	 
	SECTION 9	 	REPRESENTATIONS AND WARRANTIES	31
	9.1	 	Organization	31
	9.2	 	Authorization; No Conflict	31
	9.3	 	Validity and Binding Nature	32
	9.4	 	Financial Condition	32
	9.5	 	No Material Adverse Change	32
	9.6	 	Litigation and Contingent Liabilities	32
	9.7	 	Ownership of Properties; Liens	32
	9.8	 	Equity Ownership; Subsidiaries	32
	9.9	 	Employee Benefit Plans	33
	9.10	 	Investment Company Act	33
	9.11	 	Compliance with Laws	33
	9.12	 	Regulation U	33
	9.13	 	Taxes	33
	9.14	 	Solvency, etc	33
	9.15	 	Environmental Matters	34
	9.16	 	Insurance	34
	9.17	 	[Reserved]	34
	9.18	 	Information	34

 

    ii

     

    

 

	9.19	 	Intellectual Property	34
	9.20	 	Burdensome
    Obligations	35
	9.21	 	Labor
    Matters	35
	9.22	 	Anti-Terrorism
    Laws	35
	9.23	 	No Default	35
	9.24	 	Sanctions;
    Anti-Corruption	35
	9.25	 	Patriot Act	36
	9.26	 	Certificate
    of Beneficial Ownership	36
	9.28	 	[Reserved]	37
	9.29	 	Loan Party Information	37
	9.30	 	Certain Property	37
	 	 	 	 
	SECTION 10	 	AFFIRMATIVE COVENANTS	37
	10.1	 	Reports, Certificates and Other
    Information	37
	 	 	10.1.1
    	[Reserved]	37
	 	 	10.1.2	Interim Reports	37
	 	 	10.1.3 	Compliance Certificates	37
	 	 	10.1.4	[Reserved]	38
	 	 	10.1.5	Notice of Default,
    Litigation, ERISA and other Matters	38
	 	 	10.1.6	[Reserved]	39
	 	 	10.1.7	Management Reports	39
	 	 	10.1.8	Tax Returns	39
	 	 	10.1.9	Brokerage Account
    Statements	39
	 	 	10.1.11 	Certificate
    of Beneficial Ownership	39
	 	 	10.1.12 	Personal Net
    Worth Statement	39
	 	 	10.1.13	Other Information	39
	10.2	 	Books, Records and Inspections	39
	10.3	 	Maintenance of Property; Insurance	40
	10.4	 	Compliance with Laws; Payment of
    Taxes and Liabilities	41
	10.5	 	Maintenance of Existence, etc	41
	10.6	 	Use of Proceeds	41
	10.7	 	Employee Benefit Plans 
	10.8	 	Environmental Matters	41
	10.9	 	Further Assurances	41
	10.10	 	[Reserved]	41
	10.12	 	[Reserved]	41
	10.13	 	[Reserved]	41
	10.14	 	[Reserved]	42
	10.15	 	[Reserved]	42
	10.16	 	[Reserved]	42
	10.17	 	[Reserved]	42
	10.18	 	[Reserved]	42
	10.19	 	This Agreement	42
	 	 	 	 
	SECTION 11	 	NEGATIVE COVENANTS	42
	11.2	 	Liens	42
	11.3	 	[Reserved]	42
	11.6	 	Modification of Organizational Documents	42

 

    iii

     

    

 

	11.7	 	Transactions with Affiliates	43
	11.8	 	Unconditional Purchase Obligations	43
	11.9	 	Inconsistent Agreements	43
	11.10	 	[Reserved]	43
	11.12	 	Restriction of Amendments to Certain
    Documents	43
	11.13	 	Fiscal Year	43
	11.14	 	Minimum Liquidity	43
	 	 	 	 
	SECTION 12	 	EFFECTIVENESS; CONDITIONS OF LENDING,
    ETC	43
	12.1	 	Initial Credit Extension	44
	 	 	12.1.1
    	Repayment
    of Debt to be Repaid	44
	 	 	12.1.2	Related Transactions	44
	 	 	12.1.3 	Documentation	44
	12.2	 	Conditions	46
	 	 	12.2.1	Compliance with
    Warranties, No Default, etc	46
	 	 	12.2.2 	Confirmatory
    Certificate	46
	 	 	 	 
	SECTION 13	 	EVENTS OF DEFAULT AND THEIR EFFECT	47
	13.1	 	Events of Default	47
	 	 	13.1.1 	Non-Payment
    of the Loans, etc	47
	 	 	13.1.2 	Non-Payment
    of Other Debt	47
	 	 	13.1.3 	Other Material
    Obligations	47
	 	 	13.1.4 	Bankruptcy,
    Insolvency, etc	47
	 	 	13.1.5 	Non-Compliance
    with Loan Documents	47
	 	 	13.1.6 	Representations;
    Warranties	47
	 	 	13.1.7	Pension Plans
    	48
	 	 	13.1.8	Judgments	48
	 	 	13.1.9	Invalidity of
    Collateral Documents, etc	48
	 	 	13.1.10 	[Reserved]	48
	 	 	13.1.11 	Change of Control	48
	 	 	13.1.12 	Material Adverse
    Effect	48
	13.2	 	Effect of Event of Default	48
	13.3	 	[Reserved]	48
	 	 	 	 
	SECTION 14	 	GENERAL	48
	14.1	 	Waiver; Amendments	48
	14.2	 	Confirmations	49
	14.3	 	Notices	49
	14.4	 	Acknowledgement and Consent to Bail-In
    of EEA Financial Institutions	49
	14.5	 	Costs and Expenses	49
	14.6	 	GOVERNING LAW	50
	14.7	 	Confidentiality	50
	14.8	 	Severability	51
	14.9	 	Nature of Remedies	51
	14.10	 	Entire Agreement	51
	14.11	 	Counterparts	51
	14.12	 	Successors and Assigns	52
	14.13	 	Assignments; Participations	52

 

    iv

     

    

 

	 	 	14.13.1
    	Assignments	52
	 	 	14.13.2 	Participations	53
	14.14	 	Captions	53
	14.15	 	Customer Identification - USA Patriot
    Act Notice	53
	14.16	 	INDEMNIFICATION BY LOAN PARTIES	54
	14.17	 	Nonliability of Lender	54
	14.19	 	WAIVER OF JURY TRIAL	55

 

    v

     

    

 

ANNEXES

 

	ANNEX A	Addresses for Notices
	 	 
	SCHEDULES
	 	 
	SCHEDULE 9.6	Litigation and Contingent Liabilities
	SCHEDULE 9.8	Subsidiaries
	SCHEDULE 9.16	Insurance
	SCHEDULE 9.21	Labor Matters
	SCHEDULE 9.29	Grantor Information
	SCHEDULE 12.1	Debt to be Repaid
	 	 
	EXHIBITS
	 	 
	EXHIBIT A	Form of Note (Section 2.4)
	EXHIBIT B	Form of Notice of Borrowing (Section 2.2.2)
	EXHIBIT C	Form of Notice of Conversion/Continuation (Section
    2.2.3)

 

     

     

    

 

LOAN AND SECURITY AGREEMENT

 

THIS LOAN AND SECURITY AGREEMENT dated as
of July 10, 2020 (this “Agreement”) is entered into among WEST 78th STREET, LLC, an Indiana limited
liability company (“Borrower”), and CIBC BANK USA (“CIBC US”), as Lender.

 

Lender has agreed to make available to Borrower
a term loan upon the terms and conditions set forth herein.

 

In consideration of the mutual agreements
herein contained, the parties hereto agree as follows:

 

SECTION 1       DEFINITIONS.

 

1.1               Definitions.     When
used herein the following terms shall have the following meanings:

 

Acquisition means any transaction
or series of related transactions for the purpose of or resulting, directly or indirectly, in (a) the acquisition of all or a substantial
portion of the assets of a Person, or of all or a substantial portion of any business unit, line of business, or division of a
Person, (b) the acquisition of in excess of 50% of the Capital Securities of any Person, or otherwise causing any Person to become
a Subsidiary, or (c) a merger or consolidation or any other combination with another Person (other than a Person that is already
a Subsidiary).

 

Affected Loan is defined in Section
7.3.

 

Affiliate of any Person means (a)
any other Person which, directly or indirectly, controls or is controlled by or is under common control with such Person, (b) any
officer or director of such Person and (c) with respect to Lender, any entity administered or managed by Lender or an Affiliate
or investment advisor thereof and which is engaged in making, purchasing, holding or otherwise investing in commercial loans. A
Person shall be deemed to be “controlled by” any other Person if such Person possesses, directly or indirectly, power
to vote 5% or more of the securities (on a fully diluted basis) having ordinary voting power for the election of directors or managers
or power to direct or cause the direction of the management and policies of such Person whether by contract or otherwise. Unless
expressly stated otherwise herein, Lender shall not be deemed an Affiliate of any Loan Party. For purposes of clarity, Canadian
Imperial Bank of Commerce and each of its direct and indirect subsidiaries are “Affiliates” of CIBC Bank USA.

 

Agreement is defined in the preamble
of this Agreement.

 

Applicable Margin means, for any
day, the rate per annum equal to the following: (i) for LIBOR Loans, 2.85% (the “LIBOR Margin”), and (ii) for
Base Rate Loans, 0.00% (the “Base Rate Margin”).

 

Assigned Agreements means each of
the Related Agreements.

 

     

     

    

 

Assignee is defined in Section
14.13.1.

 

Attorney Costs means, with respect
to any Person, all reasonable fees and charges of any counsel to such Person, all reasonable disbursements of such internal counsel
and all court costs and similar legal expenses.

 

Bail-In Action means the exercise
of any Write-Down and Conversion Powers by the applicable EEA Resolution Authority in respect of any liability of an EEA Financial
Institution.

 

Bail-In Legislation means, with respect
to any EEA Member Country implementing Article 55 of Directive 2014/59/EU of the European Parliament and of the Council of the
European Union, the implementing law for such EEA Member Country from time to time which is described in the EU Bail-In Legislation
Schedule.

 

Bank Product Agreements means those
certain cash management service agreements entered into from time to time between any Loan Party and Lender or its Affiliates in
connection with any of the Bank Products.

 

Bank Product Obligations means all
obligations, liabilities, contingent reimbursement obligations, fees, and expenses owing by the Loan Parties to Lender or its Affiliates
pursuant to or evidenced by the Bank Product Agreements and irrespective of whether for the payment of money, whether direct or
indirect, absolute or contingent, due or to become due, now existing or hereafter arising, and including all such amounts that
a Loan Party is obligated to reimburse to Lender as a result of Lender purchasing participations or executing indemnities or reimbursement
obligations with respect to the Bank Products provided to the Loan Parties pursuant to the Bank Product Agreements.

 

Bank Products means any service or
facility extended to any Loan Party by Lender or its Affiliates, including, without limitation, (a) deposit accounts, (b) cash
management services, including, without limitation, controlled disbursement, lockbox, electronic funds transfers (including, without
limitation, book transfers, fedwire transfers, ACH transfers), online reporting and other services relating to accounts maintained
with Lender or its Affiliates, (c) debit cards and credit cards and (d) Hedging Agreements.

 

Base Rate means at any time the Prime
Rate.

 

Base Rate Loan means any Loan which
bears interest at or by reference to the Base Rate.

 

Base Rate Margin is defined in the
definition of Applicable Margin.

 

Beneficial Ownership Regulation means
31 C.F.R. § 1010.230.

 

Borrower is defined in the preamble
of this Agreement.

 

Borrower Obligations means all Obligations
of Borrower.

 

BSA is defined in Section 10.4.

 

    2 

     

    

 

Business Day means any day on which
CIBC US is open for commercial banking business in Chicago, Illinois and, in the case of a Business Day which relates to a LIBOR
Loan, on which dealings are carried on in the London interbank Eurodollar market.

 

Capital Expenditures means all expenditures
which, in accordance with GAAP, would be required to be capitalized and shown on the consolidated balance sheet of Borrower, including
expenditures in respect of Capital Leases, but excluding expenditures made in connection with the replacement, substitution or
restoration of assets to the extent financed (a) from insurance proceeds (or other similar recoveries) paid on account of the loss
of or damage to the assets being replaced or restored or (b) with awards of compensation arising from the taking by eminent domain
or condemnation of the assets being replaced.

 

Capital Lease means, with respect
to any Person, any lease of (or other agreement conveying the right to use) any real or personal property by such Person that,
in conformity with GAAP, is accounted for as a capital lease or finance lease on the balance sheet of such Person.

 

Capital Securities means, with respect
to any Person, all shares, interests, participations or other equivalents (however designated, whether voting or non-voting) of
such Person’s capital, whether now outstanding or issued or acquired after the Closing Date, including common shares, preferred
shares, membership interests in a limited liability company, limited or general partnership interests in a partnership, interests
in a trust, interests in other unincorporated organizations or any other equivalent of such ownership interest.

 

Cash Equivalent Investment means,
at any time, (a) any evidence of Debt, maturing not more than one year from date of acquisition, issued or guaranteed by the United
States government or any agency thereof, (b) commercial paper, maturing not more than 270 days from the date of issue, or corporate
demand notes, in each case (unless issued by Lender or its holding company) rated at least A-I
by Standard & Poor’s Ratings Services, a division of The McGraw-Hill Companies, Inc. or P-I
by Moody’s Investors Service, Inc., (c) any certificate of deposit, time deposit or banker’s acceptance, maturing not
more than 180 days after such time, or any overnight Federal Funds transaction that is issued or sold by Lender or its holding
company (or by a commercial banking institution that is a member of the Federal Reserve System and has a combined capital and surplus
and undivided profits of not less than $500,000,000), (d) any repurchase agreement entered into with Lender (or commercial banking
institution of the nature referred to in clause (c)) which (i) is secured by a fully perfected security interest in any
obligation of the type described in any of clauses (a) through (c) above and (ii) has a market value at the time
such repurchase agreement is entered into of not less than 100% of the repurchase obligation of Lender (or other commercial banking
institution) thereunder, (e) money market accounts or mutual funds which invest exclusively in assets satisfying the foregoing
requirements, and (f) other short term liquid investments approved in writing by Lender.

 

Certificate of Beneficial Ownership
means a certificate regarding beneficial ownership delivered pursuant to Section 12.1.3(m), as from time to time updated
in accordance with the terms of this Agreement, as required by the Beneficial Ownership Regulation.

 

    3 

     

    

 

CFC means (i) a controlled foreign
corporation within the meaning of Section 957 of the Code in which any Loan Party is a “United States shareholder”
within the meaning of Section 951(b) of the Code; and (ii) any Subsidiary whose sole assets (other than a de minimis amount)
are equity of one or more entities described in clause (i) of this definition.

 

Change in Law means the occurrence,
after the date of this Agreement, of any of the following: (a) the adoption or taking effect of any law, rule, regulation or treaty,
(b) any change in any law, rule, regulation or treaty or in the administration, interpretation, implementation or application thereof
by any Governmental Authority or (c) the making or issuance of any request, rule, guideline or directive (whether or not having
the force of law) by any Governmental Authority; provided that notwithstanding anything herein to the contrary, (x) the Dodd-Frank
Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection
therewith and (y) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel
Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities,
in each case pursuant to Basel III, shall in each case be deemed to be a “Change in Law”, regardless of the date enacted,
adopted or issued.

 

Change of Control means the occurrence
of any of the following events: (a) PBI shall cease to own and control 100% of the outstanding Capital Securities of Borrower,
(b) the acquisition of ownership, directly or indirectly, beneficially or of record, by any Person or group (within the meaning
of the Securities Exchange Act of 1934 and the rules of the Securities and Exchange Commission thereunder as in effect on the date
hereof), of Capital Securities representing more than 51% of the aggregate ordinary voting power represented by the issued and
outstanding Capital Securities of PBI, or (c) occupation at any time of a majority of the seats (other than vacant seats) on the
board of directors of PBI by Persons who were not (i) directors of PBI on the date of this Agreement or (ii) appointed by directors
so nominated or appointed.

 

CIBC US is defined in the preamble
of this Agreement.

 

Closing Date is defined in Section
12.1.

 

Code means the Internal Revenue Code
of 1986, as amended from time to time and any successor statute.

 

Collateral means the Mortgaged Property
defined and described in the Mortgage. Where the context requires, terms relating to the Collateral or any part thereof, when used
in relation to a Loan Party, shall refer to such Loan Party’s Collateral or the relevant part thereof.

 

Collateral Documents means, collectively,
the Mortgage and any other agreement or instrument pursuant to which Borrower, any Subsidiary, any other Loan Party or any other
Person grants or purports to grant collateral to Lender or otherwise relates to such collateral.

 

Commitment means Lender’s commitment
to make the Term Loan. The initial amount of Lender’s Commitment is $3,562,500.00.

 

    4 

     

    

 

Commodity Exchange Act means the
Commodity Exchange Act (7 U.S.C. § 1 et seq.), as amended from time to time and any successor statute.

 

Contingent Liability means, with
respect to any Person, each obligation and liability of such Person and all such obligations and liabilities of such Person incurred
pursuant to any agreement, undertaking or arrangement by which such Person: (a) guarantees, endorses or otherwise becomes or is
contingently liable upon (by direct or indirect agreement, contingent or otherwise, to provide funds for payment, to supply funds
to, or otherwise to invest in, a debtor, or otherwise to assure a creditor against loss) the indebtedness, dividend, obligation
or other liability of any other Person in any manner (other than by endorsement of instruments in the course of collection), including
any indebtedness, dividend or other obligation which may be issued or incurred at some future time; (b) guarantees the payment
of dividends or other distributions upon the Capital Securities of any other Person; (c) undertakes or agrees (whether contingently
or otherwise): (i) to purchase, repurchase, or otherwise acquire any indebtedness, obligation or liability of any other Person
or any property or assets constituting security therefor, (ii) to advance or provide funds for the payment or discharge of any
indebtedness, obligation or liability of any other Person (whether in the form of loans, advances, stock purchases, capital contributions
or otherwise), or to maintain solvency, assets, level of income, working capital or other financial condition of any other Person,
or (iii) to make payment to any other Person other than for value received; (d) agrees to lease property or to purchase securities,
property or services from such other Person with the purpose or intent of assuring the owner of such indebtedness or obligation
of the ability of such other Person to make payment of the indebtedness or obligation; (e) to induce the issuance of, or
in connection with the issuance of, any letter of credit for the benefit of such other Person; or (f) undertakes or agrees otherwise
to assure a creditor against loss. The amount of any Contingent Liability shall (subject to any limitation set forth herein) be
deemed to be the outstanding principal amount (or maximum permitted principal amount, if larger) of the indebtedness, obligation
or other liability guaranteed or supported thereby.

 

Controlled Group means all members
of a controlled group of corporations, all members of a controlled group of trades or businesses (whether or not incorporated)
under common control and all members of an affiliated service group which, together with Borrower or any of its Subsidiaries, are
treated as a single employer under Section 414 of the Code or Section 4001 of ERISA.

 

Debt of any Person means, without
duplication, (a) all indebtedness of such Person for borrowed money, (b) all indebtedness evidenced by bonds, debentures, notes
or similar instruments, (c) all obligations of such Person as lessee under Capital Leases which have been or should be recorded
as liabilities on a balance sheet of such Person in accordance with GAAP, (d) all obligations of such Person to pay the deferred
purchase price of property or services (excluding trade accounts payable in the ordinary course of business), (e) all indebtedness
secured by a Lien on the property of such Person, whether or not such indebtedness shall have been assumed by such Person; provided
that if such Person has not assumed or otherwise become liable for such indebtedness, such indebtedness shall be measured at the
fair market value of such property securing such indebtedness at the time of determination, (f) all obligations, contingent or
otherwise, with respect to the face amount of all letters of credit (whether or not drawn), bankers’ acceptances and similar
obligations issued for the account of such Person (including the letters of credit), (g) all Hedging Obligations of such Person, (h) all Contingent Liabilities of
such Person, (i) all Debt of any partnership of which such Person is a general partner, (j) all non-compete payment obligations,
earn-outs and similar obligations and (k) any Capital Securities or other equity instrument, whether or not mandatorily redeemable,
that under GAAP is characterized as debt, whether pursuant to financial accounting standards board issuance No. 150 or otherwise.

 

    5 

     

    

 

Debt to be Repaid means Debt listed
on Schedule 12.1.

 

Default means any event or condition
that, if it continues uncured, will, with lapse of time or notice or both, constitute an Event of Default.

 

Designated Proceeds is defined in
Section 5.2.2(a).

 

Dollar and the sign
 “$” mean lawful money of the United States of America.

 

EEA Financial Institution means (a)
any credit institution or investment firm established in any EEA Member Country which is subject to the supervision of an EEA Resolution
Authority, (b) any entity established in an EEA Member Country which is a parent of an institution described in clause (a) of this
definition, or (c) any financial institution established in an EEA Member Country which is a subsidiary of an institution described
in clauses (a) or (b) of this definition and is subject to consolidated supervision with its parent.

 

EEA Member Country means any of the
member states of the European Union, Iceland, Liechtenstein, and Norway.

 

EEA Resolution Authority means any
public administrative authority or any person entrusted with public administrative authority of any EEA Member Country (including
any delegee) having responsibility for the resolution of any EEA Financial Institution.

 

Environmental Claims means all claims,
contingent or otherwise, however asserted, by any Governmental Authority or other Person alleging potential liability or responsibility,
directly or indirectly, for violation of any Environmental Law, or for release or injury to the environment.

 

Environmental Laws means all present
or future federal, state, local or foreign laws, statutes, common law duties, rules, regulations, ordinances and codes, together
with all administrative or judicial orders, consent agreements, directed duties, requests, licenses, authorizations and permits
of, and agreements with, any Governmental Authority, in each case relating to any matter arising out of or relating to public health
and safety, or pollution or protection of the environment or workplace, including any of the foregoing relating to the presence,
use, production, generation, handling, transport, treatment, storage, disposal, distribution, discharge, emission, release, threatened
release, control or cleanup of any Hazardous Substance.

 

ERISA means the Employee Retirement
Income Security Act of 1974, as amended from time to time and any successor statute.

 

    6 

     

    

 

EU Bail-In Legislation Schedule means
the EU Bail-In Legislation Schedule published by the Loan Market Association (or any successor person), as in effect from time
to time.

 

Event of Default means any of the
events described in Section 13.1.

 

Excluded Hedging Obligation means,
with respect to any Loan Party (other than Borrower), any Hedging Obligation constituting a Swap Obligation if, and to the extent
that, all or a portion of the guaranty of such Loan Party of, or the grant by such Loan Party of a security interest to secure,
such Hedging Obligation (or any guarantee thereof) is or becomes illegal under the Commodity Exchange Act or any rule, regulation
or order of the Commodity Futures Trading Commission (or the application or official interpretation of any thereof) by virtue of
such Loan Party’s failure for any reason to constitute an “eligible contract participant” as defined in the Commodity
Exchange Act and the regulations thereunder at the time the guaranty of such Loan Party or the grant of such security interest
becomes effective with respect to such Hedging Obligation. If any Hedging Obligation constituting a Swap Obligation arises under
a master agreement governing more than one such Hedging Obligation, such exclusion shall apply only to the portion of such Hedging
Obligation that is attributable to swaps for which such guaranty or security interest is or becomes illegal.

 

Excluded Taxes means any of the following
Taxes imposed on or with respect to a Recipient or required to be withheld or deducted from a payment to a Recipient, (a) Taxes
imposed on or measured by net income (however denominated), franchise Taxes, and branch profits Taxes, in each case, (i) imposed
as a result of such Recipient being organized under the laws of, or having its principal office or, in the case of Lender, its
applicable lending office located in, the jurisdiction imposing such Tax (or any political subdivision thereof) or (ii) that are
Other Connection Taxes, (b) in the case of Lender, U.S. federal withholding Taxes imposed on amounts payable to or for the account
of Lender with respect to an applicable interest in a Loan or Commitment pursuant to the applicable law in effect on the date on
which (i) Lender acquires such interest in the Loan or Commitment (other than pursuant to an assignment made at the request of
any Loan Party) or (ii) Lender changes its lending office (other than change in lending office made at the request of any Loan
Party), except in each case to the extent that, pursuant to Section 6.5, amounts with respect to such Taxes were payable
either to Lender’s assignor immediately before Lender became a party hereto or to Lender immediately before it changed its
lending office, (c) United States federal withholding Taxes that would not have been imposed but for such Recipient’s failure
to comply with Section 6.5 and (d) any U.S. federal withholding Taxes imposed under FATCA.

 

Extraordinary Receipts means any
cash or Cash Equivalents received by or paid to or for the account of any Loan Party not in the ordinary course of business including
without limitation amounts received in respect of foreign, United States, state or local tax refunds, purchase price adjustments,
indemnification payments, and pension plan reversions.

 

FATCA shall mean Sections 1471 through
1474 of the Code, as of the date of this Agreement (or any amended or successor or version that is substantially compatible and
not materially more onerous to comply with), any current or future regulations or official interpretations thereof and any agreements
entered into by the United States pursuant to Section 1471(b)(1) of the Code and any fiscal or regulatory legislation, rules or
practices adopted pursuant to any intergovernmental agreement, treaty or convention among Governmental Authorities entered into in connection with the
implementation of the foregoing.

 

    7 

     

    

 

FCPA is defined in Section 9.24(c).

 

Fiscal Quarter means a fiscal quarter
of a Fiscal Year.

 

Fiscal Year means the fiscal year
of Borrower and its Subsidiaries, which period shall be the 12-month period ending on December 31 of each year.

 

Fixtures means all of the following,
whether now owned or hereafter acquired by a Loan Party: plant fixtures; business fixtures; other fixtures and storage facilities,
wherever located; and all additions and accessories thereto and replacements therefor.

 

FRB means the Board of Governors
of the Federal Reserve System or any successor thereto.

 

GAAP means generally accepted accounting
principles set forth from time to time in the opinions and pronouncements of the Accounting Principles Board and the American Institute
of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board (or agencies with
similar functions of comparable stature and authority within the U.S. accounting profession), which are applicable to the circumstances
as of the date of determination.

 

Governmental Authority means the
government of the United States of America or any other nation, or of any political subdivision thereof, whether state or local,
and any agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative,
judicial, taxing, regulatory or administrative powers or functions of or pertaining to government (including any supra-national
bodies such as the European Union or the European Central Bank).

 

Group is defined in Section 2.2.1.

 

Hazardous Substances means hazardous
waste, hazardous substance, pollutant, contaminant, toxic substance, oil, hazardous material, chemical or other substance regulated
by or with respect to which liability or standards of conduct are imposed pursuant to any Environmental Law.

 

Hedging Agreement means any agreement
with respect to any swap, collar, cap, future, forward or derivative transaction, whether exchange-traded, over-the-counter or
otherwise, including any involving, or settled by reference to, one or more interest rates, currencies, commodities, equity or
debt instruments, any economic, financial or pricing index or basis, or any similar transaction, including any option with respect
to any of these transactions and any combination of these transactions.

 

Hedging Obligation means, with respect
to any Person, any liability of such Person under any Hedging Agreement, including any and all cancellations, buy backs, reversals,
terminations or assignments under any Hedging Agreement.

 

    8 

     

    

 

Indemnified Liabilities is defined
in Section 14.16.

 

Indemnified Taxes means (a) Taxes,
other than Excluded Taxes, imposed on or with respect to any payment made by, or on account of any obligation of, any Loan Party
under any Loan Document and (b) to the extent not otherwise described in (a), Other Taxes.

 

Interest Period means, as to any
LIBOR Loan, the period commencing on the date such Loan is borrowed or continued as, or converted into, a LIBOR Loan and ending
on the date one (1), two (2) or, three (3) months thereafter as selected by Borrower pursuant to Section 2.2.2 or 2.2.3,
as the case may be; provided that:

 

(a)       if
any Interest Period would otherwise end on a day that is not a Business Day, such Interest Period shall be extended to the following
Business Day unless the result of such extension would be to carry such Interest Period into another calendar month, in which event
such Interest Period shall end on the preceding Business Day;

 

(b)       any
Interest Period that begins on a day for which there is no numerically corresponding day in the calendar month at the end of such
Interest Period shall end on the last Business Day of the calendar month at the end of such Interest Period;

 

(c)       [Reserved];

 

(d)       Borrower
may not select any Interest Period for a Term Loan if, after giving effect to such selection, the aggregate principal amount such
Term Loan having an Interest Period ending after any date on which an installment of such Term Loan is scheduled to be repaid would
exceed the aggregate principal amount of such Term Loan scheduled to be outstanding after giving effect to such repayment; and

 

(e)       Lender
may, in its discretion, require that the first Interest Period under this Agreement be a period less than one (1) month (determined
by Lender).

 

Investment means, with respect to
any Person, any direct or indirect acquisition or investment in another Person, whether by acquisition of any debt or Capital Security,
by making any loan or advance, by becoming obligated with respect to a Contingent Liability in respect of obligations of such other
Person (other than travel and similar advances to employees in the ordinary course of business) or by making an Acquisition.

 

Lender is defined in the preamble
of this Agreement. In addition to the foregoing, for the purpose of identifying the Persons entitled to share in the Collateral
and the proceeds thereof under, and in accordance with the provisions of, this Agreement and the Collateral Documents, the term
 “Lender” shall include Affiliates of Lender providing a Bank Product.

 

Lender Party is defined in Section
14.16.

 

LIBOR Loan means any Loan which bears
interest at a rate determined by reference to the LIBO Rate.

 

LIBOR Margin is defined in the definition
of Applicable Margin.

 

    9 

     

    

 

 

LIBOR Office means the office or
offices of Lender which shall be making or maintaining the LIBOR Loans of Lender hereunder. A LIBOR Office of Lender may be, at
the option of Lender, either a domestic or foreign office.

 

LIBO Rate means a rate of interest
equal to the greater of (a) (i) the per annum rate of interest at which United States dollar deposits for a period equal to the
relevant Interest Period are offered in the London Interbank Eurodollar market at 11:00 A.M. (London time) two (2) Business Days
prior to the commencement of such Interest Period (or three (3) Business Days prior to the commencement of such Interest Period
if banks in London, England were not open and dealing in offshore United States dollars on such second preceding Business Day),
as displayed in the Bloomberg Financial Markets system (or other authoritative source selected by Lender in its sole discretion),
divided by (ii) a number determined by subtracting from 1.00 the then stated maximum reserve percentage for determining reserves
to be maintained by member banks of the Federal Reserve System for Eurocurrency funding or liabilities as defined in Regulation
D (or any successor category of liabilities under Regulation D), or as LIBOR is otherwise determined by Lender in its sole and
absolute discretion; and (b) 0.25% per annum. Lender’s determination of the LIBO Rate shall be conclusive, absent manifest
error and shall remain fixed during such Interest Period.

 

Lien means, with respect to any Person,
any interest granted by such Person in any real or personal property, asset or other right owned or being purchased or acquired
by such Person (including an interest in respect of a Capital Lease) which secures payment or performance of any obligation and
shall include any mortgage, lien, encumbrance, title retention lien, charge or other security interest of any kind, whether arising
by contract, as a matter of law, by judicial process or otherwise.

 

Liquidity means the sum of all unencumbered
cash, Cash Equivalent Investments and publicly traded/quoted marketable securities as shown on the most recent brokerage statements
provided to Lender pursuant to Section 10.1.9 below.

 

Loan or Loans means the Term Loan.

 

Loan Documents means, collectively,
this Agreement, the Note, the Collateral Documents, all Hedging Agreements in favor of Lender or any of its Affiliates, and all
documents, instruments and agreements delivered in connection with the foregoing.

 

Loan Guarantor means each Loan Party
other than Borrower.

 

Loan Guarantor Obligations means,
collectively, with respect to each Loan Guarantor, all Obligations of such Loan Guarantor; provided, however, that with respect
to any Loan Guarantor, the Loan Guarantor Obligations shall exclude all of such Loan Guarantor’s Excluded Hedging Obligations.

 

Loan Guaranty means each separate
guarantee, in form and substance satisfactory to Lender, delivered by a Loan Guarantor, as it may be amended or modified and in
effect from time to time.

 

Loan Parties means Borrower,
the Loan Guarantors (other than Allan C. Silber, except for the purposes of Sections 6.5, 9.18, 9.22, 9.23, 13.1, 14.5
and 14.16) and any other Person who becomes a party to this Agreement pursuant to a joinder agreement or a Loan
Guaranty or otherwise and their successors and assigns; provided however, for the avoidance of doubt, no CFC shall be
a guarantor of, or pledge any assets to support, an “obligation of a United States person” as defined for
purposes of Section 956(c) of the Code.

 

    10 

     

    

 

Mandatory Prepayment Event is defined
in Section 5.2.2(a).

 

Margin Stock means any “margin
stock” as defined in Regulation U.

 

Material Adverse Effect means (a)
a material adverse change in, or a material adverse effect upon, the financial condition, operations, assets, business, properties
or prospects of the Loan Parties taken as a whole, (b) a material impairment of the ability of any Loan Party to perform any of
the Obligations under any Loan Document, (c) a material adverse effect upon any substantial portion of the Collateral under the
Loan Documents or upon the legality, validity, binding effect or enforceability against any Loan Party of any Loan Document or
(d) a material impairment of Lender’s rights and remedies under this Agreement and the other Loan Documents.

 

Mortgage means the Mortgage, Security
Agreement, Assignment of Leases and Rents and Fixture Filing of even date herewith from the Borrower in favor of the Lender, given
to secure the Obligations, as the same may be modified, amended or replaced from time to time.

 

Mortgaged Property shall have the
same meaning ascribed to such term in the Mortgage.

 

Multiemployer Pension Plan means
a multiemployer plan, as defined in Section 4001(a)(3) of ERISA, to which Borrower or any other member of the Controlled Group
(i) is or may be obligated to make contributions, (ii) during the preceding five plan years has made or been obligated to make
contributions, or (iii) has any liability.

 

Note means a promissory note substantially
in the form of Exhibit A.

 

Notice of Borrowing is defined in
Section 2.2.2.

 

Notice of Conversion/Continuation
is defined in Section 2.2.3.

 

Obligations means all advances
to, and debts, liabilities, obligations, covenants and duties (monetary (including post-petition interest, allowed or not) or
otherwise) of any Loan Party under this Agreement and any other Loan Document including Attorney Costs and any reimbursement
obligations of each Loan Party in respect of letters of credit and surety bonds, all Hedging Obligations permitted hereunder
which are owed to Lender or its Affiliates, and all other Bank Products Obligations, all in each case howsoever created,
arising or evidenced, whether direct or indirect, absolute or contingent, now or hereafter existing, or due or to become due
and including interest and fees that accrue after the commencement by or against Borrower or any Affiliate thereof of any
proceeding under any debtor relief laws naming such Person as the debtor in such proceeding, regardless of whether such
interest and fees are allowed claims in such proceeding. Without limiting the foregoing, the Obligations include (a) the
obligation to pay principal, interest, charges, expenses, fees, indemnities and other amounts payable by Borrower under any
Loan Document and (b) the obligation of Borrower to reimburse any amount in respect of any of the foregoing that Lender, in
its sole discretion, may elect to pay or advance on behalf of Borrower.

 

    11 

     

    

 

OFAC is defined in Section 10.4.

 

Other Connection Taxes means, with
respect to any Recipient, Taxes imposed as a result of a present or former connection between such Recipient and the jurisdiction
imposing such Tax (other than connections arising from such Recipient having executed, delivered, become a party to, performed
its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction
pursuant to or enforced any Loan Document, or sold or assigned an interest in any Loan or Loan Document).

 

Other Taxes means all present or
future stamp, court, transfer, value added, excise or documentary, intangible, recording, filing or similar Taxes that arise from
any payment made under, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection
of a security interest under, or otherwise with respect to, any Loan Document, except any such Taxes that are Other Connection
Taxes imposed with respect to an assignment (other than an assignment made pursuant to Section 7.7).

 

Paid in Full means (a) the payment
in full in cash and performance of all Secured Obligations, and (b) the termination of all Commitments.

 

Participant is defined in Section
14.13.2.

 

Patriot Act is defined in Section
14.15.

 

PBGC means the Pension Benefit Guaranty
Corporation and any entity succeeding to any or all of its functions under ERISA.

 

PBI means Point Biopharma Inc., a
Delaware corporation.

 

Pension Plan means a “pension
plan”, as such term is defined in Section 3(2) of ERISA, which is subject to Title IV of ERISA or the minimum funding standards
of ERISA (other than a Multiemployer Pension Plan), and as to which Borrower or any member of the Controlled Group may have any
liability, including any liability by reason of having been a substantial employer within the meaning of Section 4063 of ERISA
at any time during the preceding five years, or by reason of being deemed to be a contributing sponsor under Section 4069 of ERISA.

 

Permitted Lien means a Lien expressly
permitted hereunder pursuant to Section 11.2.

 

Permitted Tax Distributions
shall mean, with respect to each calendar year, the aggregate federal and state income taxes which are payable by the holders
of membership or other ownership interests of Borrower for such calendar year, based upon the highest applicable marginal
federal and state income tax rates attributable to such holders, on the taxable income derived from Borrower, which must be
taken into account by such holders under applicable provisions of the Code (as reflected on the Schedule K-I’s
provided by Borrower to such holders, copies of which will be supplied to Lender upon request), taking into account for this
purpose any tax credits or tax credit carryovers derived as the result of having an ownership interest in Borrower that is
available to offset such federal and state income taxes. For purposes of calculating the Permitted Tax Distributions for any
calendar year, (i) it is assumed that state income taxes will be fully deductible for federal income tax purposes and (ii)
net losses from prior years derived from Borrower, whether or not used by the holder on the holder’s federal or state
tax income tax return for such prior year, shall be treated as reducing taxable income for the current year on which such
Permitted Tax Distributions are computed (to the extent such net losses did not previously reduce taxable income on which
Permitted Tax Distributions were computed).

 

    12 

     

    

 

Person means any natural person,
corporation, partnership, trust, limited liability company, association, Governmental Authority, or any other entity, whether acting
in an individual, fiduciary or other capacity.

 

Plan means an “employee benefit
plan” within the meaning of Section 3(3) of ERISA, maintained for employees of Borrower or any Subsidiary, or any such plan
to which any Loan Party has an obligation to make contributions on behalf of any of its employees or with respect to which Borrower
or any Subsidiary has any liability.

 

Prime Rate means, for any day, the
rate of interest in effect for such day as announced from time to time by Lender as its prime rate (whether or not such rate is
actually charged by Lender), which is not intended to be Lender’s lowest or most favorable rate of interest at any one time.
Lender may make commercial loans or other loans at rates of interest at, above or below the Prime Rate. Any change in the Prime
Rate announced by Lender shall take effect at the opening of business on the day specified in the public announcement of such change;
provided that Lender shall not be obligated to give notice of any change in the Prime Rate.

 

Proceeds means all “proceeds”
as such term is defined in Section 9-102(a)(64) of the UCC.

 

Qualified ECP Guarantor means, in
respect of any Hedging Obligation constituting a Swap Obligation, each Grantor that constitutes an “eligible contract participant”
under the Commodity Exchange Act or any regulations promulgated thereunder and can cause another person to qualify as an “eligible
contract participant” at such time by entering into a keepwell under Section 1 a(18)(A)(v)(II)
of the Commodity Exchange Act at the time the relevant guaranty or grant of the relevant security interest becomes effective with
respect to such Swap Obligation.

 

Recipient means Lender.

 

Regulation D means Regulation D of
the FRB, as in effect from time to time and all official rulings and interpretations thereunder or thereof.

 

Regulation U means Regulation U of
the FRB, as in effect from time to time and all official rulings and interpretations thereunder or thereof.

 

Related Agreements means that
certain Purchase Agreement - Commercial/Industrial Real Estate, dated as of March 20, 2020, by and between Allan C. Silber
and Delco Realty, LLC, as amended by the First Amendment to Purchase Agreement, dated as of May 7, 2020, and the Second
Amendment to Purchase Agreement, dated as of June 30, 2020, and all documents, instruments and agreements delivered in
connection with the foregoing.

 

    13 

     

    

 

Related Transactions means the transactions
contemplated by the Related Agreements.

 

Reportable Event means a reportable
event as defined in Section 4043 of ERISA and the regulations issued thereunder as to which the PBGC has not waived the notification
requirement of Section 4043(a), or the failure of a Pension Plan to meet the minimum funding standards of Section 412 of the Code
(without regard to whether the Pension Plan is a plan described in Section 4021(a)(2) of ERISA) or under Section 302 of ERISA.

 

Sanctions is defined in Section
9.24(a).

 

SEC means the Securities and Exchange
Commission or any other Governmental Authority succeeding to any of the principal functions thereof.

 

Secured Obligations means, collectively,
the Borrower Obligations and the Loan Guarantor Obligations.

 

Securities Act means the Securities
Act of 1933, as amended.

 

Senior Officer means, with respect
to any Loan Party, any of the chief executive officer, the chief financial officer, the chief operating officer or the treasurer
of such Loan Party.

 

Subordinated Debt means any unsecured
Debt of Borrower and its Subsidiaries which has subordination terms, covenants, pricing and other terms which have been approved
in writing by Lender.

 

Subsidiary means, with respect to
any Person, a corporation, partnership, limited liability company, association, joint venture or other business entity of which
such Person owns, directly or indirectly, such number of outstanding Capital Securities as have more than 50% of the ordinary voting
power for the election of directors or other managers of such corporation, partnership, limited liability company or other entity
(other than securities or interest having such power only by reason of the happening of a contingency). Unless the context otherwise
requires, each reference to Subsidiaries herein shall be a reference to Subsidiaries of Borrower.

 

Swap Obligation means, with respect
to any Loan Guarantor, any obligation to pay or perform under any agreement, contract or transaction that constitute a “swap”
within the meaning of Section 1a(47) of the Commodity Exchange Act.

 

Taxes means any and all present and
future taxes, duties, levies, imposts, deductions, assessments, charges or withholdings (including backup withholding), and any
and all liabilities (including interest and penalties and other additions to taxes) with respect to the foregoing.

 

Term Loan Commitment means $3,562,500.00.

 

    14 

     

    

 

Term Loan is defined in Section
2.1.2.

 

Termination Date means the earlier
to occur of (a) January 10, 2022, which date may be extended at the request of Borrower with the written consent of Lender without
the need for any formal amendment hereto, or (b) such other date on which the Commitments terminate pursuant to Section 5
or Section 13.

 

Termination Event means, with respect
to a Pension Plan that is subject to Title IV of ERISA, (a) a Reportable Event, (b) the withdrawal of Borrower or any other member
of the Controlled Group from such Pension Plan during a plan year in which Borrower or any other member of the Controlled Group
was a “substantial employer” as defined in Section 4001(a)(2) of ERISA or was deemed such under Section 4068(f) of
ERISA, (c) the termination of such Pension Plan, the filing of a notice of intent to terminate the Pension Plan or the treatment
of an amendment of such Pension Plan as a termination under Section 4041 of ERISA, (d) the institution by the PBGC of proceedings
to terminate such Pension Plan or (e) any event or condition that might constitute grounds under Section 4042 of ERISA for the
termination of, or appointment of a trustee to administer, such Pension Plan.

 

Total Plan Liability means, at any
time, the present value of all vested and unvested accrued benefits under all Pension Plans, determined as of the then most recent
valuation date for each Pension Plan, using PBGC actuarial assumptions for single employer plan terminations.

 

Type is defined in Section 2.2.1.

 

UCC means the Uniform Commercial
Code as in effect on the date hereof and from time to time in the State of Indiana, provided that if by reason of mandatory
provisions of law, the perfection or the effect of perfection or non-perfection of the security interests in any Collateral or
the availability of any remedy hereunder is governed by the Uniform Commercial Code as in effect on or after the date hereof in
any other jurisdiction, “UCC” means the Uniform Commercial Code as in effect in such other jurisdiction for purposes
of the provisions hereof relating to such perfection or effect of perfection or non-perfection or availability of such remedy.

 

Unfunded Liability means the amount
(if any) by which the present value of all vested and unvested accrued benefits under all Pension Plans exceeds the fair market
value of all assets allocable to those benefits, all determined as of the then most recent valuation date for each Pension Plan,
using PBGC actuarial assumptions for single employer plan terminations.

 

Wholly-Owned Subsidiary means, as
to any Person, a Subsidiary all of the Capital Securities of which (except directors’ qualifying Capital Securities and shares
issued to foreign nationals to the extent required by applicable law) are at the time directly or indirectly owned by such Person
and/or another Wholly-Owned Subsidiary of such Person.

 

Write-Down and Conversion Powers
means, with respect to any EEA Resolution Authority, the Write-Down and Conversion Powers of such EEA Resolution Authority from
time to time under the Bail-In Legislation for the applicable EEA Member Country, which write-down and conversion powers are described
in the EU Bail-In Legislation Schedule.

 

    15 

     

    

 

1.2       Other
Interpretive Provisions, (a) The meanings of defined terms are equally applicable to the singular and plural forms of the defined
terms.

 

(b)       Section,
Annex, Schedule and Exhibit references are to this Agreement unless otherwise specified.

 

(c)       The
term “including” is not limiting and means “including without limitation.”

 

(d)       In
the computation of periods of time from a specified date to a later specified date, the word “from” means “from
and including”; the words “to” and “until” each mean “to but excluding”, and the word
 “through” means “to and including.”

 

(e)       Unless
otherwise expressly provided herein, (i) references to agreements (including this Agreement and the other Loan Documents) and other
contractual instruments shall be deemed to include all subsequent amendments, restatements, supplements and other modifications
thereto, but only to the extent such amendments, restatements, supplements and other modifications are not prohibited by the terms
of any Loan Document, and (ii) except as provided elsewhere herein, references to any statute or regulation shall be construed
as including all statutory and regulatory provisions amending, replacing, supplementing or interpreting such statute or regulation.

 

(f)       This
Agreement and the other Loan Documents may use several different limitations, tests or measurements to regulate the same or similar
matters. All such limitations, tests and measurements are cumulative and each shall be performed in accordance with its terms.

 

(g)       This
Agreement and the other Loan Documents are the result of negotiations among and have been reviewed by counsel to Lender, the Loan
Parties and the other parties thereto and are the products of all parties. Accordingly, they shall not be construed against Lender
merely because of Lender’s involvement in their preparation.

 

1.3       Accounting
Terms; Changes in GAAP; Rates

 

(a)       Accounting
Terms. Except as otherwise expressly provided herein, all accounting terms not otherwise defined herein shall be construed
in conformity with GAAP. Financial statements and other information required to be delivered by Borrower to Lender pursuant to
Section 10.1.1 and Section 10.1.2 shall be prepared in accordance with GAAP as in effect at the time of such preparation.
Notwithstanding the foregoing, for purposes of determining compliance with any covenant (including the computation of any financial
covenant) contained herein, Debt of Borrower and its Subsidiaries shall be deemed to be carried at 100% of the outstanding principal
amount thereof and the effects of FASB ASC 825 and FASB ASC 470-20 on financial liabilities shall be disregarded.

 

(b)       Changes
in GAAP. If Borrower notifies Lender that Borrower requests an amendment to any provision hereof to eliminate the effect
of any change occurring after the date hereof in GAAP or in the application thereof on the operation of such provision (or if
Lender notifies Borrower that Lender requests an amendment to any provision hereof for such purpose), regardless of whether
any such notice is given before or after such change in GAAP or in the application thereof, then such provision shall be
interpreted on the basis of GAAP as in effect and applied immediately before such change shall have become effective until
such notice shall have been withdrawn or such provision amended in accordance herewith.

 

    16 

     

    

 

(c)       Rates.
Lender does not warrant, nor accept responsibility, nor shall Lender have any liability with respect to the administration, submission
or any other matter related to the rates in the definition of “LIBO Rate” or with respect to any comparable successor
rate thereto.

 

SECTION 2       COMMITMENTS OF LENDER; BORROWING
AND CONVERSION PROCEDURES; EVIDENCING OF LOANS.

 

2.1       Commitments.
On and subject to the terms and conditions of this Agreement, Lender agrees to make loans to Borrower as follows:

 

2.1.1       [Reserved].

 

2.1.2       Term
Loan Commitment. Lender agrees to make a loan to Borrower (“Term Loan”) on the Closing Date. The Commitment
of Lender to make the Term Loan shall expire concurrently with the making of the Term Loan on the Closing Date.

 

2.1.3       [Reserved].

 

2.2       Loan
Procedures.

 

2.2.1       Various
Types of Loans. The Term Loan may be divided into tranches which are, either a Base Rate Loan or a LIBOR Loan (each a “type”
of Loan), as Borrower shall specify in the related notice of borrowing or conversion pursuant to Section 2.2.2 or 2.2.3.
LIBOR Loans having the same Interest Period which expire on the same day are sometimes called a “Group” or collectively
 “Groups”. Base Rate Loans and LIBOR Loans may be outstanding at the same time, provided that not more
than three different Groups of LIBOR Loans shall be outstanding at any one time.

 

2.2.2       Borrowing
Procedures.

 

(a)       Borrower
shall give written notice (each such written notice, a “Notice of Borrowing”) substantially in the form of Exhibit
B or telephonic notice (followed immediately by a Notice of Borrowing) to Lender of each proposed Base Rate or LIBOR borrowing
not later than (a) in the case of a Base Rate borrowing, 11:00 A.M., Chicago time, on the proposed date of such borrowing, and
(b) in the case of a LIBOR borrowing, 11:00 A.M., Chicago time, at least three (3) Business Days prior to the proposed date of
such borrowing. Each such notice shall be effective upon receipt by Lender, shall be irrevocable, and shall specify the date, amount
and type of borrowing and, in the case of a LIBOR borrowing, the initial Interest Period therefor. Each borrowing shall be on a
Business Day. Each Base Rate borrowing shall be in an aggregate amount of at least $100,000 and an integral multiple of $50,000,
and each LIBOR borrowing shall be in an aggregate amount of at least $1,000,000 and an integral multiple of at least $500,000.

 

    17 

     

    

 

 

(b)       Lender
may, at its option, charge Obligations against any operating, investment or other account of Borrower maintained with Lender or
any of its Affiliates.

 

2.2.3       Conversion
and Continuation Procedures. (a) Subject to Section 2.2.1, Borrower may, upon irrevocable written notice to Lender in
accordance with clause (b) below:

 

(i)       elect,
as of any Business Day, to convert any Loans (or any part thereof in an aggregate amount not less than $1,000,000 and a higher
integral multiple of $500,000) into Loans of the other type; or

 

(ii)       elect,
as of the last day of the applicable Interest Period, to continue any LIBOR Loans having Interest Periods expiring on such day
(or any part thereof in an aggregate amount not less than $1,000,000 or a higher integral multiple of $500,000) for a new Interest
Period;

 

provided that after giving effect to any prepayment,
conversion or continuation, the aggregate principal amount of each Group of LIBOR Loans shall be at least $1,000,000 and an integral
multiple of $500,000.

 

(b)       Borrower
shall give written notice (each such written notice, a “Notice of Conversion/Continuation”) substantially in
the form of Exhibit C or telephonic notice (followed immediately by a Notice of Conversion/Continuation) to Lender of each
proposed conversion or continuation not later than (i) in the case of conversion into Base Rate Loans, 11:00 A.M., Chicago time,
on the proposed date of such conversion, and (ii) in the case of conversion into or continuation of LIBOR Loans, 11:00 A.M., Chicago
time, at least three (3) Business Days prior to the proposed date of such conversion or continuation, specifying in each case:

 

(i)        the proposed
date of conversion or continuation;

 

(ii)        the aggregate
amount of Loans to be converted or continued;

 

(iii)       the type
of Loans resulting from the proposed conversion or continuation; and

 

(iv)       in the
case of conversion into, or continuation of, LIBOR Loans, the duration of the requested Interest Period therefor.

 

(c)       If
upon the expiration of any Interest Period applicable to LIBOR Loans, Borrower has failed to select timely a new Interest Period
to be applicable to such LIBOR Loans, Borrower shall be deemed to have elected to convert such LIBOR Loans into Base Rate Loans
effective on the last day of such Interest Period.

 

(d)       Any
conversion of a LIBOR Loan on a day other than the last day of an Interest Period therefor shall be subject to Section 7.4.

 

2.2.4       [Reserved].

 

    18 

     

    

 

2.3       [Reserved].

 

2.4       Notes.
At Lender’s request, the Loans shall be evidenced by a Note, with appropriate insertions, payable to the order of Lender
in a face principal amount equal to the principal amount of the Term Loan.

 

2.5       Recordkeeping.
Lender shall record in its records, the date and amount of each Loan made by Lender, each repayment or conversion thereof and,
in the case of each LIBOR Loan, the dates on which each Interest Period for such Loan shall begin and end. The aggregate unpaid
principal amount so recorded shall be rebuttably presumptive evidence of the principal amount of the Loans owing and unpaid. The
failure to so record any such amount or any error in so recording any such amount shall not, however, limit or otherwise affect
the Obligations of Borrower hereunder or under any Note to repay the principal amount of the Loans hereunder, together with all
interest accruing thereon.

 

SECTION 3

     INTEREST.

 

3.1       Interest
Rates. Borrower promises to pay interest on the unpaid principal amount of each Loan for the period commencing on the date
of such Loan until such Loan is paid in full as follows:

 

(a) at all times while such Loan is a Base
Rate Loan, at a rate per annum equal to the sum of the Base Rate from time to time in effect plus the Base Rate Margin from time
to time in effect; and

 

(b) at all times while such Loan is a LIBOR
Loan, at a rate per annum equal to the sum of the LIBO Rate applicable to each Interest Period for such Loan plus the LIBOR Margin
from time to time in effect;

 

provided that at any time an Event of Default exists,
at Lender’s election, the interest rate applicable to each Loan shall be increased by 2% (and, in the case of Obligations
not bearing interest, such Obligations shall bear interest at the Base Rate applicable to the Term Loan plus 2%). Notwithstanding
the foregoing, upon the occurrence of an Event of Default under Sections 13.1.1 or 13.1.4, such increase shall occur automatically.
In no event shall interest payable by Borrower to Lender hereunder exceed the maximum rate permitted under applicable law, and
if any such provision of this Agreement is in contravention of any such law, such provision shall be deemed modified to limit such
interest to the maximum rate permitted under such law.

 

3.2       Interest
Payment Dates. Accrued interest on each Base Rate Loan shall be payable in arrears on the first day of each calendar quarter
and at maturity. Accrued interest on each LIBOR Loan shall be payable on the first day of each calendar quarter, upon a prepayment
of such Loan, and at maturity. After maturity, and at any time an Event of Default exists, accrued interest on all Loans shall
be payable on demand.

 

3.3       Setting
and Notice of LIBO Rates. The applicable LIBO Rate for each Interest Period shall be determined by Lender, and notice
thereof shall be given by Lender promptly to Borrower. Each determination of the applicable LIBO Rate by Lender shall be
conclusive and binding upon the parties hereto, in the absence of demonstrable error. Lender shall, upon written request of
Borrower, deliver to Borrower a statement showing the computations used by Lender in determining any applicable LIBO Rate
hereunder.

 

    19 

     

    

 

3.4       Computation
of Interest. Interest shall be computed for the actual number of days elapsed on the basis of a year of (a) 360 days for interest
calculated at the LIBO Rate and (b) 365/366 days for interest calculated at the Base Rate. The applicable interest rate for each
Base Rate Loan shall change simultaneously with each change in the Base Rate.

 

SECTION 4

     FEES.

 

4.1       [Reserved].

 

4.2       [Reserved].

 

4.3       [Reserved].

 

4.4       Commitment
Fee. Borrower agrees to pay to Lender a commitment fee in the amount of $17,810.00, which shall be fully earned and due and
payable on the Closing Date.

 

SECTION 5

     PREPAYMENTS.

 

5.1       [Reserved].

 

5.2       Prepayments.

 

5.2.1       Voluntary
Prepayments. Borrower may from time to time prepay the Loans in whole or in part; provided that Borrower shall give
Lender notice thereof not later than 11:00 A.M., Chicago time, on the day of such prepayment (which shall be a Business Day), specifying
the Loans to be prepaid and the date and amount of prepayment. Any such partial prepayment shall be in an amount equal to $100,000
or a higher integral multiple of $50,000.

 

5.2.2       Mandatory
Prepayments.

 

(a)       Borrower
shall make prepayments of the Term Loan until paid in full upon the occurrence of any of the following (each a “Mandatory
Prepayment Event”) at the following times and in the following amounts (such applicable amounts being referred to as
 “Designated Proceeds”):

 

(i)       Concurrently
with the receipt by any Loan Party of any cash proceeds from any sale or transfer of Collateral, in an amount equal to 100% of
such cash proceeds net of (1) the direct costs relating to such sale or transfer (including sales commissions and legal, accounting
and investment banking fees), (2) taxes paid or reasonably estimated by Borrower to be payable as a result thereof (after taking
into account any available tax credits or deductions and any tax sharing arrangements) and (3) amounts required to be applied to
the repayment of any Debt secured by a Lien on the asset subject to such sale or transfer (other than the Loans).

 

    20 

     

    

 

(ii)       Concurrently
with the receipt by any Loan Party of any proceeds from any issuance of any Debt of any Loan Party secured by the Collateral (excluding
Debt permitted by Section 11.1), in an amount equal to 100% of such proceeds.

 

5.3       Manner
of Prepayments. Each voluntary partial prepayment shall be in a principal amount of $100,000 or a higher integral multiple
of $50,000. Any partial prepayment of a Group of LIBOR Loans shall be subject to the proviso to Section 2.2.3(a). Any prepayment
of a LIBOR Loan on a day other than the last day of an Interest Period therefor shall include interest on the principal amount
being repaid and shall be subject to Section 7.4. Except as otherwise provided by this Agreement, all principal payments
in respect of the Loans shall be applied first, to repay outstanding Base Rate Loans and then to repay outstanding LIBO Rate Loans
in direct order of Interest Period maturities.

 

5.4       Repayments.

 

5.4.1       [Reserved].

 

5.4.2       Term
Loan. The outstanding principal balance of the Term Loan shall be paid in full on the Termination Date.

 

SECTION 6
     MAKING
AND PRORATION OF PAYMENTS; SETOFF; TAXES.

 

6.1       Making
of Payments. All payments of principal or interest on the Note(s), and of all fees, shall be made by Borrower to Lender in
immediately available funds at the office specified by Lender not later than noon, Chicago time, on the date due; and funds received
after that hour shall be deemed to have been received by Lender on the following Business Day. All payments under Section 7.1 shall
be made by Borrower directly to Lender without setoff, counterclaim or other defense.

 

6.2       Application
of Certain Payments. So long as no Default or Event of Default has occurred and is continuing, (a) payments matching specific
scheduled payments then due shall be applied to those scheduled payments and (b) voluntary and mandatory prepayments shall be applied
as set forth in Sections 5.2 and 5.3. After the occurrence and during the continuance of a Default or Event of Default,
all amounts collected or received by Lender as proceeds from the sale of, or other realization upon, all or any part of the Collateral
shall be applied as Lender shall determine in its discretion.

 

6.3       Due
Date Extension. If any payment of principal or interest with respect to any of the Loans, or of any fees, falls due on a day
which is not a Business Day, then such due date shall be extended to the immediately following Business Day (unless, in the case
of a LIBOR Loan, such immediately following Business Day is the first Business Day of a calendar month, in which case such due
date shall be the immediately preceding Business Day) and, in the case of principal, additional interest shall accrue and be payable
for the period of any such extension.

 

6.4       Setoff.
Borrower and each other Loan Party agrees that Lender has all rights of set-off and bankers’ lien provided by
applicable law, and in addition thereto, Borrower and each other Loan Party agrees that at any time any Event of Default
exists, Lender may apply to the payment of any Obligations of Borrower and each other Loan Party hereunder, whether or not
then due, any and all balances, credits, deposits, accounts or moneys of Borrower and each other Loan Party then or
thereafter with Lender.

 

    21 

     

    

 

6.5       Taxes.

 

(a)       All
payments made by a Loan Party hereunder or under any Loan Documents shall be made without setoff, counterclaim, or other defense.
To the extent permitted by applicable law, all payments hereunder or under the Loan Documents (including any payment of principal,
interest, or fees) to, or for the benefit, of any person shall be made by a Loan Party free and clear of and without deduction
or withholding for, or account of, any Taxes now or hereinafter imposed by any taxing authority.

 

(b)       If
a Loan Party shall be required by applicable law to deduct any Taxes from or in respect of any sum payable to any Recipient hereunder
or any other Loan Document: (i) such Loan Party shall make such deductions; (ii) such Loan Party shall pay the full amount deducted
to the relevant taxing or other authority in accordance with applicable law; and (iii) if the Taxes are Indemnified Taxes, the
sum payable shall be increased by the Loan Party as much as shall be necessary so that after making all the required deductions
(including deductions applicable to additional sums payable under this Section 6.5), the Recipient receives an amount equal
to the sum it should have received had no such deductions been made. In addition, the Loan Parties shall timely pay to the relevant
Governmental Authority in accordance with applicable law, or at the option of Lender timely reimburse it for the payment of, any
Other Taxes. As soon as practicable after any payment of Taxes by the Loan Parties to a Governmental Authority pursuant to this
Section, Borrower shall deliver to Lender the original or a certified copy of a receipt issued by such Governmental Authority evidencing
such payment, a copy of the return reporting such payment or other evidence of such payment reasonably satisfactory to Lender.

 

(c)       The
Loan Parties shall jointly and severally indemnify, and within ten (10) days of demand therefor, pay Lender and each other Recipient
for the full amount of Indemnified Taxes and other liabilities, expenses and costs related thereto (including without limitation,
reasonable attorneys’ or tax advisors’ fees and disbursements and Taxes imposed on amounts received under this Section
6.5) that are paid by, or imposed on, Lender or such other Recipient (and any of their respective affiliates), whether or not such
Indemnified Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A demand as to the amount
of such payment or liability delivered to the Loan Parties by a Lender, shall be conclusive absent manifest error.

 

(d)       If
Borrower makes any payment hereunder or under any Loan Document in respect of which it is required by applicable law to
deduct or withhold any Taxes, Borrower shall increase the payment hereunder or under any such Loan Document such that after
the reduction for the amount of Taxes withheld (and any taxes withheld or imposed with respect to the additional payments
required under this Section 6.5(d)), the amount paid to Lender equals the amount that was payable hereunder or under
any such Loan Document without regard to this Section 6.5(d). To the extent Borrower withholds any Taxes on payments
hereunder or under any Loan Document, Borrower shall pay the full amount deducted to the relevant taxing authority within the
time allowed for payment under applicable law and shall deliver to Lender within 30 days after it has made payment to such
authority a receipt issued by such authority (or other evidence satisfactory to Lender) evidencing the payment of all amounts
so required to be deducted or withheld from such payment.

 

    22 

     

    

 

SECTION 7
     INCREASED COSTS; SPECIAL PROVISIONS FOR LIBOR LOANS.

 

7.1       Increased
Costs, (a) If, after the date hereof, any Change in Law: (i) shall impose, modify or deem applicable any reserve (including
any reserve imposed by the FRB, but excluding any reserve included in the determination of the LIBO Rate pursuant to Section
3), special deposit, compulsory loan, insurance charge or similar requirement against assets of, deposits with or for the account
of, or credit extended or participated in by Lender; (ii) subject any Recipient to any Taxes (other than Indemnified Taxes and
Excluded Taxes) on its loan, loan principal, letters of credit, commitments or other obligations, or its deposit reserves, other
liabilities or capital attributable thereto; or (iii) shall impose on Lender any other condition affecting its LIBOR Loans, its
Note or its obligation to make LIBOR Loans; and the result of anything described in clauses (i), (ii) and (iii) above is to increase
the cost to (or to impose a cost on) Lender (or any LIBOR Office of Lender) of making or maintaining any LIBOR Loan, or to reduce
the amount of any sum received or receivable by Lender (or its LIBOR Office) (whether of principal, interest or any other amount)
under this Agreement or under its Note with respect thereto, then upon demand by Lender (which demand shall be accompanied by a
statement setting forth the basis for such demand and a calculation of the amount thereof in reasonable detail), Borrower shall
pay directly to Lender such additional amount as will compensate Lender for such increased cost or such reduction, so long as such
amounts have accrued on or after the day which is nine months prior to the date on which Lender first made demand therefor (except
that, if the Change in Law giving rise to such increased costs or reductions is retroactive, then the nine-month period referred
to above shall be extended to include the period of retroactive effect thereof).

 

(b)       If
Lender shall reasonably determine that any Change in Law regarding capital adequacy, affecting Lender, or any lending office of
Lender, or Lender’s holding company, if any, has or would have the effect of reducing the rate of return on Lender’s
or Lender’s holding company’s, if any, capital as a consequence of Lender’s obligations hereunder to a level
below that which Lender or such controlling Person could have achieved but for such Change in Law (taking into consideration Lender’s
or such controlling Person’s policies with respect to capital adequacy) by an amount deemed by Lender or such controlling
Person to be material, then from time to time, upon demand by Lender (which demand shall be accompanied by a statement setting
forth the basis for such demand and a calculation of the amount thereof in reasonable detail), Borrower shall pay to Lender such
additional amount as will compensate Lender or such controlling Person for such reduction so long as such amounts have accrued
on or after the day which is nine months prior to the date on which Lender first made demand therefor (except that, if the Change
in Law giving rise to such increased costs or reductions is retroactive, then the nine-month period referred to above shall be
extended to include the period of retroactive effect thereof).

 

    23 

     

    

 

 

 

7.2      
Basis for Determining Interest Rate Inadequate or Unfair. If on or prior to the first day of any Interest Period:

 

(a)       Lender
reasonably determines (which determination shall be binding and conclusive on Borrower) that by reason of circumstances affecting
the interbank LIBOR market adequate and reasonable means do not exist for ascertaining the applicable LIBO Rate; or

 

(b)       Lender
reasonably determines (which determination shall be binding and conclusive on Borrower) that for any reason in connection with
any request for a LIBOR Loan or a conversion thereto or a continuation thereof that Dollar deposits are not being offered to banks
in the London interbank Eurodollar market for the applicable amount and Interest Period of such LIBOR Loans, the LIBO Rate as determined
by Lender will not adequately and fairly reflect the cost to Lender of maintaining or funding LIBOR Loans for such Interest Period
or that the making or funding of LIBOR Loans has become impracticable as a result of an event occurring after the date of this
Agreement which in the opinion of Lender materially affects such Loans;

 

then Lender shall promptly notify Borrower and, so long
as such circumstances shall continue, (i) Lender shall not be under any obligation to make or convert any Base Rate Loans into
LIBOR Loans and (ii) on the last day of the current Interest Period for each LIBOR Loan, such Loan shall, unless then repaid in
full, automatically convert to a Base Rate Loan, until Lender revokes such notice.

 

7.3       Changes
in Law Rendering LIBOR Loans Unlawful. If any Change in Law should make it (or in the good faith judgment of Lender cause a
substantial question as to whether it is) unlawful, or that any Governmental Authority has asserted that it is unlawful, for Lender
to make, maintain or fund LIBOR Loans or determine or charge interest rates based on the LIBO Rate, or any Governmental Authority
has imposed material restrictions on the authority of Lender to purchase or sell, or to take deposits of, Dollars in the London
interbank market, then Lender shall promptly notify each of the other parties hereto and, so long as such circumstances shall continue,
(a) Lender shall have no obligation to make or continue LIBOR Loans or convert any Base Rate Loan into a LIBOR Loan (but shall
make Base Rate Loans concurrently with the making of or conversion of Base Rate Loans into LIBOR Loans by Lender which are not
so affected, in each case in an amount equal to the amount of LIBOR Loans which would be made or converted into by Lender at such
time in the absence of such circumstances) and (b) on the last day of the current Interest Period for each LIBOR Loan of Lender
(or, in any event, on such earlier date as may be required by the relevant law, regulation or interpretation), such LIBOR Loan
shall, unless then repaid in full, automatically convert to a Base Rate Loan. Each Base Rate Loan made by Lender which, but for
the circumstances described in the foregoing sentence, would be a LIBOR Loan (an “Affected Loan”) shall remain
outstanding for the period corresponding to the Group of LIBOR Loans of which such Affected Loan would be a part absent such circumstances.

 

7.4       Funding
Losses. Borrower hereby agrees that upon demand by Lender (which demand shall be accompanied by a statement setting forth
the basis for the amount being claimed, Borrower will indemnify Lender against any net loss or expense which Lender may
sustain or incur (including any net loss or expense incurred by reason of the liquidation or reemployment of deposits or
other funds acquired by Lender to fund or maintain any LIBOR Loan), as reasonably determined by Lender, as a result of (a)
any payment, prepayment or conversion of any LIBOR Loan of Lender on a date other than the last day of an Interest Period for
such Loan (including any conversion pursuant to Section 7.3), (b) any failure of Borrower to borrow, prepay, convert
or continue any Loan on a date specified therefor in a notice of borrowing, prepayment, conversion or continuation pursuant
to this Agreement, (c) the conversion of any LIBOR Loan other than on the last day of the Interest Period applicable thereto,
or (d) the assignment of any LIBOR Loan other than on the last day of the Interest Period. For this purpose, all notices to
Lender pursuant to this Agreement shall be deemed to be irrevocable and conclusive absent manifest error. Borrower shall pay
Lender the amount shown as due on any such notice within 10 days after receipt thereof.

 

    24

     

    

 

7.5       Right
of Lender to Fund through Other Offices. Lender may, if it so elects, fulfill its commitment as to any LIBOR Loan by causing
a foreign branch or Affiliate of Lender to make such Loan; provided that in such event for the purposes of this Agreement
such Loan shall be deemed to have been made by Lender and the obligation of Borrower to repay such Loan shall nevertheless be to
Lender and shall be deemed held by it, to the extent of such Loan, for the account of such branch or Affiliate.

 

7.6       Discretion
of Lender as to Manner of Funding. Notwithstanding any provision of this Agreement to the contrary, Lender shall be entitled
to fund and maintain its funding of all or any part of its Loans in any manner it sees fit, it being understood, however, that
for the purposes of this Agreement all determinations hereunder shall be made as if Lender had actually funded and maintained each
LIBOR Loan during each Interest Period for such Loan through the purchase of deposits having a maturity corresponding to such Interest
Period and bearing an interest rate equal to the LIBO Rate for such Interest Period.

 

7.7       Mitigation
of Circumstances. Lender shall promptly notify Borrower of any event of which it has knowledge which will result in, and will
use reasonable commercial efforts available to it (and not, in Lender’s sole judgment, otherwise disadvantageous to Lender)
to mitigate or avoid, (i) any obligation by Borrower to pay any amount pursuant to Sections 6.5 or 7.1 or (ii) the
occurrence of any circumstances described in Sections 7.2 or 7.3 (and, if Lender has given notice of any such event
described in clause (i) or (ii) above and thereafter such event ceases to exist, Lender shall promptly so notify Borrower). Without
limiting the foregoing, Lender will designate a different funding office if such designation will avoid (or reduce the cost to
Borrower of) any event described in clause (i) or (ii) above and such designation will not, in Lender’s sole judgment, be
otherwise disadvantageous to Lender. Borrower hereby agrees to pay all reasonable costs and expenses incurred by any Lender in
connection with any such designation or assignment.

 

7.8       Conclusiveness
of Statements; Survival of Provisions. Determinations and statements of Lender pursuant to Sections 7.1, 7.2,
7.3 or 7.4 shall be conclusive absent demonstrable error. Lender may use reasonable averaging and attribution methods
in determining compensation under Sections 7.1 and 7.4, and the provisions of such Sections shall survive repayment
of the Obligations, cancellation of any Note(s), and termination of this Agreement.

 

    25

     

    

 

7.9       Effect
of Benchmark Transition Event.

 

(a)       Benchmark
Replacement. Notwithstanding anything to the contrary herein or in any other Loan Document, upon the occurrence of a Benchmark
Transition Event or an Early Opt-in Election, as applicable, Lender (without any action or consent by any other party to this Agreement)
may amend this Agreement to replace the LIBO Rate with a Benchmark Replacement. Any such amendment with respect to a Benchmark
Transition Event will become effective at 5:00 p.m. (Chicago time) on the fifth (5th) Business Day after Lender has provided notice
of such proposed amendment to Borrower. Any such amendment with respect to an Early Opt-in Election will become effective on the
date that Borrower has delivered to Lender written notice that Borrower accepts such amendment. No replacement of the LIBO Rate
with a Benchmark Replacement pursuant to this Section 7.9 will occur prior to the applicable Benchmark Transition Start Date.

 

(b)       Benchmark
Replacement Conforming Changes. In connection with the implementation of a Benchmark Replacement, Lender will have the right
to make Benchmark Replacement Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any
other Loan Document, any amendments implementing such Benchmark Replacement Conforming Changes will become effective without any
further action or consent of any other party to this Agreement.

 

(c)       Notices;
Standards for Decisions and Determinations. Lender will promptly notify Borrower of (i) any occurrence of a Benchmark Transition
Event or an Early Opt-in Election, as applicable, and its related Benchmark Replacement Date and Benchmark Transition Start Date,
(ii) the implementation of any Benchmark Replacement, (iii) the effectiveness of any Benchmark Replacement Conforming Changes and
(iv) the commencement or conclusion of any Benchmark Unavailability Period. Any determination, decision or election that may be
made by Lender pursuant to this Section 7.9, including any determination with respect to a tenor, rate or adjustment or of the
occurrence or non-occurrence of an event, circumstance or date and any decision to take or refrain from taking any action, will
be conclusive and binding absent manifest error and may be made in its sole discretion and without consent from any other party
hereto, except, in each case, as expressly required pursuant to this Section 7.9.

 

(d)       Benchmark
Unavailability Period. Upon Borrower’s receipt of notice of the commencement of a Benchmark Unavailability Period, Borrower
will be deemed to have converted any pending request for a LIBOR Loan, and any conversion to or continuation of any LIBOR Loans
to be made, converted or continued during any Benchmark Unavailability Period into a request for a borrowing of or conversion to
Base Rate Loans.

 

(e)       Certain
Defined Terms. As used in this Section 7.9:

 

“Benchmark
Replacement” means the sum of: (a) the alternate benchmark rate (which may include Term SOFR) that has been
selected by Lender in consultation with Borrower giving due consideration to (i) any selection or recommendation of a
replacement rate or the mechanism for determining such a rate by the Relevant Governmental Body or (ii) any evolving or
then-prevailing market convention for determining a rate of interest as a replacement to the LIBO Rate for U.S.
dollar-denominated credit facilities and (b) the Benchmark Replacement Adjustment; provided that, if the Benchmark
Replacement as so determined would be less than 0.25%, the Benchmark Replacement will be deemed to be 0.25% for the purposes
of this Agreement.

 

    26

     

    

 

“Benchmark Replacement
Adjustment” means, with respect to any replacement of the LIBO Rate with an Unadjusted Benchmark Replacement for each
applicable Interest Period, the spread adjustment, or method for calculating or determining such spread adjustment (which may be
a positive or negative value or zero) that has been selected by Lender in consultation with Borrower giving due consideration to
(i) any selection or recommendation of a spread adjustment, or method for calculating or determining such spread adjustment, for
the replacement of the LIBO Rate with the applicable Unadjusted Benchmark Replacement by the Relevant Governmental Body or (ii)
any evolving or then-prevailing market convention for determining a spread adjustment, or method for calculating or determining
such spread adjustment, for the replacement of the LIBO Rate with the applicable Unadjusted Benchmark Replacement for U.S. dollar-denominated
credit facilities at such time.

 

“Benchmark Replacement
Conforming Changes” means, with respect to any Benchmark Replacement, any technical, administrative or operational changes
(including changes to the definition of “Interest Period,” timing and frequency of determining rates and making payments
of interest and other administrative matters) that Lender decides may be appropriate to reflect the adoption and implementation
of such Benchmark Replacement and to permit the administration thereof by Lender in a manner substantially consistent with market
practice (or, if Lender decides that adoption of any portion of such market practice is not administratively feasible or if Lender
determines that no market practice for the administration of the Benchmark Replacement exists, in such other manner of administration
as Lender decides is reasonably necessary in connection with the administration of this Agreement).

 

“Benchmark Replacement
Date” means the earlier to occur of the following events with respect to the LIBO Rate:

 

(1)       in
the case of clause (1) or (2) of the definition of “Benchmark Transition Event,” the later of (a) the date of the public
statement or publication of information referenced therein and (b) the date on which the administrator of the LIBO Rate permanently
or indefinitely ceases to provide the LIBO Rate; or

 

(2)      in
the case of clause (3) of the definition of “Benchmark Transition Event,” the date of the public statement or publication
of information referenced therein.

 

“Benchmark Transition
Event” means the occurrence of one or more of the following events with respect to the LIBO Rate:

 

(1)      a
public statement or publication of information by or on behalf of the administrator of the LIBO Rate announcing that such
administrator has ceased or will cease to provide the LIBO Rate, permanently or indefinitely, provided that, at the time of
such statement or publication, there is no successor administrator that will continue to provide the LIBO Rate;

 

    27

     

    

 

(2)       a
public statement or publication of information by the regulatory supervisor for the administrator of the LIBO Rate, the U.S. Federal
Reserve System, an insolvency official with jurisdiction over the administrator for the LIBO Rate, a resolution authority with
jurisdiction over the administrator for the LIBO Rate or a court or an entity with similar insolvency or resolution authority over
the administrator for the LIBO Rate, which states that the administrator of the LIBO Rate has ceased or will cease to provide the
LIBO Rate permanently or indefinitely, provided that, at the time of such statement or publication, there is no successor administrator
that will continue to provide the LIBO Rate; or

 

(3)       a
public statement or publication of information by the regulatory supervisor for the administrator of the LIBO Rate announcing that
the LIBO Rate is no longer representative.

 

“Benchmark Transition
Start Date” means (a) in the case of a Benchmark Transition Event, the earlier of (i) the applicable Benchmark Replacement
Date and (ii) if such Benchmark Transition Event is a public statement or publication of information of a prospective event, the
90th day prior to the expected date of such event as of such public statement or publication of information (or if the expected
date of such prospective event is fewer than 90 days after such statement or publication, the date of such statement or publication)
and (b) in the case of an Early Opt-in Election, the date specified by Lender by notice to Borrower.

 

“Benchmark Unavailability
Period” means, if a Benchmark Transition Event and its related Benchmark Replacement Date have occurred with respect
to the LIBO Rate and solely to the extent that the LIBO Rate has not been replaced with a Benchmark Replacement, the period (x)
beginning at the time that such Benchmark Replacement Date has occurred if, at such time, no Benchmark Replacement has replaced
the LIBO Rate for all purposes hereunder in accordance with Section 7.9 and (y) ending at the time that a Benchmark Replacement
has replaced the LIBO Rate for all purposes hereunder pursuant to Section 7.9.

 

“Early Opt-in Election” means the
occurrence of:

 

(1)       a
determination by Lender that U.S. dollar-denominated credit facilities being executed at such time, or that include language similar
to that contained in this Section 7.9 are being executed or amended, as applicable, to incorporate or adopt a new benchmark interest
rate to replace the LIBO Rate, and

 

(2)       the
election by Lender to declare that an Early Opt-in Election has occurred and the provision by Lender of written notice of such
election to Borrower.

 

“Federal Reserve Bank
of New York’s Website” means the website of the Federal Reserve Bank of New York at http://www.newyorkfed.org,
or any successor source.

 

    28

     

    

 

“Relevant Governmental
Body” means the Federal Reserve Board and/or the Federal Reserve Bank of New York, or a committee officially endorsed
or convened by the Federal Reserve Board and/or the Federal Reserve Bank of New York or any successor thereto.

 

“SOFR” with
respect to any day means the secured overnight financing rate published for such day by the Federal Reserve Bank of New York, as
the administrator of the benchmark, (or a successor administrator) on the Federal Reserve Bank of New York’s Website.

 

“Term SOFR”
means the forward-looking term rate based on SOFR that has been selected or recommended by the Relevant Governmental Body.

 

“Unadjusted Benchmark
Replacement” means the Benchmark Replacement excluding the Benchmark Replacement Adjustment.

 

SECTION 8  COLLATERAL AND COLLATERAL ADMINISTRATION.

 

8.1       Grant.
The Obligations of the Borrower will be secured by liens on the Mortgaged Property described in the Mortgage.

 

8.2       [Reserved].

 

8.3       [Reserved].

 

8.4       Communications
with Obligors; Loan Parties Remain Liable. Lender in its own name or in the name of others may at any time after the occurrence
and during the continuance of an Event of Default communicate with obligors under the Mortgaged Property to verify with them to
Lender’s satisfaction the existence, amount and terms of any amounts due to Borrower with respect to the Mortgage Property.

 

8.5       [Reserved].

 

8.6       [Reserved].

 

8.7       [Reserved].

 

8.8       [Reserved].

 

8.9       [Reserved].

 

8.10     [Reserved].

 

8.11     [Reserved].

 

8.12     [Reserved].

 

8.13     Acknowledgements.
Each Loan Party hereby acknowledges that:

 

    29

     

    

 

(a)       it
has been advised by counsel in the negotiation, execution and delivery of this Agreement and the other Loan Documents to which
it is a party;

 

(b)       Lender
has no fiduciary relationship with or duty to any Loan Party arising out of or in connection with this Agreement or any of the
other Loan Documents, and the relationship between the Loan Parties, on the one hand, and Lender, on the other hand, in connection
herewith or therewith is solely that of debtor and creditor; and

 

(c)       no
joint venture is created hereby or by the other Loan Documents or otherwise exists by virtue of the transactions contemplated hereby
the Loan Parties and Lender.

 

8.14       Additional
Parties. Each Loan Party that is required to become a party to this Agreement pursuant to Section 10.9 of this Agreement
shall become a Loan Party for all purposes of this Agreement upon execution and delivery by such Loan Party of a joinder agreement
in a form acceptable to Lender.

 

8.15      Releases.
(a) At such time as the Secured Obligations have been Paid in Full, the Collateral shall be released from the Liens created hereby,
and this Agreement and all obligations (other than those expressly stated to survive such termination) of Lender and each Loan
Party hereunder shall terminate, all without delivery of any instrument or performance of any act by any party, and all rights
to the Collateral shall revert to the Loan Party. At the request and sole expense of any Loan Party following any such termination,
Lender shall deliver to the Loan Parties any Collateral held by Lender hereunder, and execute and deliver to the Loan Parties such
documents as the Loan Parties shall reasonably request to evidence such termination.

 

(b)       If
any of the Collateral shall be sold, transferred or otherwise disposed of by any Loan Party in a transaction permitted by this
Agreement, then Lender, at the request and sole expense of such Loan Party, shall execute and deliver to such Loan Party all releases
or other documents reasonably necessary or desirable for the release of the Liens created hereby on such Collateral. At the request
and sole expense of Borrower, a Loan Guarantor shall be released from its obligations hereunder in the event that all the equity
interests of such Loan Guarantor shall be sold, transferred or otherwise disposed of in a transaction permitted by this Agreement;
provided that Borrower shall have delivered to Lender, with reasonable notice prior to the date of the proposed release,
a written request for release identifying the relevant Loan Guarantor and the terms of the sale or other disposition in reasonable
detail, including the price thereof and any expenses in connection therewith, together with a certification by Borrower stating
that such transaction is in compliance with this Agreement and the other Loan Documents.

 

8.16       Obligations
and Liens Absolute and Unconditional. Each Loan Party understands and agrees that the obligations of each Loan Party
under this Agreement shall be construed as continuing, absolute and unconditional without regard to (a) the validity or
enforceability of any Loan Document, any of the Secured Obligations or any other collateral security therefor or guaranty or
right of offset with respect thereto at any time or from time to time held by Lender, (b) any defense, set-off or
counterclaim (other than a defense of payment or performance) which may at any time be available to or be asserted by any
Loan Party or any other Person against Lender, or (c) any other circumstance whatsoever (with or without notice to or
knowledge of any Loan Party) which constitutes, or might be construed to constitute, an equitable or legal discharge of any
Loan Party for the Secured Obligations, in bankruptcy or in any other instance. When making any demand hereunder or otherwise
pursuing its rights and remedies hereunder against any Loan Party or Lender may, but shall be under no obligation to, make a
similar demand on or otherwise pursue such rights and remedies as it may have against any other Loan Party or any other
Person or against any collateral security or guaranty for the Secured Obligations or any right of offset with respect
thereto, and any failure by Lender to make any such demand, to pursue such other rights or remedies or to collect any
payments from any other Loan Party or any other Person or to realize upon any such collateral security or guaranty or to
exercise any such right of offset, or any release of any other Loan Party or any other Person or any such collateral
security, guaranty or right of offset, shall not relieve any Loan Party of any obligation or liability hereunder, and shall
not impair or affect the rights and remedies, whether express, implied or available as a matter of law, of Lender against any
Loan Party. For the purposes hereof “demand” shall include the commencement and continuance of any legal
proceedings.

 

    30

     

    

 

8.17       Reinstatement.
This Agreement shall remain in full force and effect and continue to be effective should any petition be filed by or against any
Loan Party for liquidation or reorganization, should any Loan Party become insolvent or make an assignment for the benefit of creditors
or should a receiver or trustee be appointed for all or any significant part of a Loan Party’s assets, and shall continue
to be effective or be reinstated, as the case may be, if at any time payment and performance of the Secured Obligations, or any
part thereof, is, pursuant to applicable law, rescinded or reduced in amount, or must otherwise be restored or returned by any
obligee of the Secured Obligations, whether as a “voidable preference”, “fraudulent conveyance”, or otherwise,
all as though such payment or performance had not been made. In the event that any payment, or any part thereof, is rescinded,
reduced, restored or returned, the Secured Obligations shall be reinstated and deemed reduced only by such amount paid and not
so rescinded, reduced, restored or returned.

 

SECTION 9   REPRESENTATIONS AND WARRANTIES.

 

To induce Lender to enter into this Agreement
and to induce Lender to make Loans hereunder, each Loan Party represents and warrants to Lender that:

 

9.1       Organization.
Each Loan Party is validly existing and in good standing (or equivalent) under the laws of its jurisdiction of organization; and
each Loan Party is duly qualified to do business in each jurisdiction where, because of the nature of its activities or properties,
such qualification is required, except for such jurisdictions where the failure to so qualify would not have a Material Adverse
Effect.

 

9.2       Authorization;
No Conflict. Each Loan Party is duly authorized to execute and deliver each Loan Document to which it is a party,
Borrower is duly authorized to borrow monies hereunder and each Loan Party is duly authorized to perform its Obligations
under each Loan Document to which it is a party. The execution, delivery and performance by each Loan Party of each Loan
Document to which it is a party, and the borrowings by Borrower hereunder, do not and will not (a) require any consent or
approval of any Governmental Authority (other than any consent or approval which has been obtained and is in full force and
effect), (b) conflict with (i) any provision of law, (ii) the charter, by-laws or other organizational documents of any Loan
Party or (iii) any agreement, indenture, instrument or other document, or any judgment, order or decree, which is binding
upon any Loan Party or any of their respective properties or (c) require, or result in, the creation or imposition of any
Lien on any asset of any Loan Party (other than Liens in favor of Lender created pursuant to the Collateral Documents).

 

    31

     

    

 

9.3       Validity
and Binding Nature. Each of this Agreement and each other Loan Document to which any Loan Party is a party is the legal, valid
and binding obligation of such Person, enforceable against such Person in accordance with its terms, subject to bankruptcy, insolvency
and similar laws affecting the enforceability of creditors’ rights generally and to general principles of equity.

 

9.4       Financial
Condition. The internally-prepared financial statements of PBI and its Subsidiaries delivered to Lender prior to the Closing
Date present fairly the consolidated financial condition of PBI and its Subsidiaries as at the dates reflected therein and the
results of their operations for the periods then ended.

 

9.5       No
Material Adverse Change. There has been no material adverse change in the financial condition, operations, assets, business,
properties or prospects of the Loan Parties taken as a whole.

 

9.6       Litigation
and Contingent Liabilities. No litigation (including derivative actions), arbitration proceeding or governmental investigation
or proceeding is pending or, to any Loan Parties’ knowledge, threatened against any Loan Party which could reasonably be
expected to have a Material Adverse Effect, except as set forth in Schedule 9.6. Other than any liability incident to such
litigation or proceedings, no Loan Party has any material Contingent Liabilities not listed on Schedule 9.6 or permitted
by Section 11.1.

 

9.7       Ownership
of Properties; Liens. Each Loan Party owns good and, in the case of real property, marketable title to all of its properties
and assets, real and personal, tangible and intangible, of any nature whatsoever (including patents, trademarks, trade names, service
marks and copyrights), free and clear of all Liens, charges and claims (including infringement claims with respect to patents,
trademarks, service marks, copyrights and the like) except as permitted by Section 11.2. No financing statement or other
public notice with respect to all or any part of the Collateral is on file or of record in any public office, except filings evidencing
Permitted Liens and filings for which termination statements have been delivered to Lender or payoff letters satisfactory to Lender
in its reasonable determination have been delivered to Lender with respect to the Debt to be repaid.

 

9.8       Equity
Ownership; Subsidiaries. All issued and outstanding Capital Securities of each Loan Party are duly authorized and validly
issued, fully paid, non-assessable, and free and clear of all Liens other than those in favor of Lender, and such securities
were issued in compliance with all applicable state and federal laws concerning the issuance of securities. Schedule
9.8 sets forth the issued authorized Capital Securities of each Loan Party as of the Closing Date. As of the Closing
Date, except as set forth on Schedule 9.8, there are no pre-emptive or other outstanding rights, options, warrants,
conversion rights or other similar agreements or understandings for the purchase or acquisition of any Capital Securities of
any Loan Party.

 

    32

     

    

 

9.9       Employee
Benefit Plans. No Loan Party has created or maintained for its employees nor has an obligation to make contributions to any
Plan.

 

9.10     Investment
Company Act. No Loan Party is an “investment company” or a company “controlled” by an “investment
company” or a “subsidiary” of an “investment company,” within the meaning of the Investment Company
Act of 1940.

 

9.11     Compliance
with Laws. Each Loan Party and each Subsidiary thereof is in compliance in all material respects with the requirements of all
laws and all orders, writs, injunctions and decrees applicable to it or to its properties, except in such instances in which (a)
such requirement of law or order, writ, injunction or decree is being contested in good faith by appropriate proceedings diligently
conducted or (b) the failure to comply therewith, either individually or in the aggregate, could not reasonably be expected to
have a Material Adverse Effect.

 

9.12     Regulation
U. Borrower is not engaged principally, or as one of its important activities, in the business of extending credit for the
purpose of purchasing or carrying Margin Stock.

 

9.13     Taxes.
Each Loan Party has timely filed all Tax returns and reports required by law to have been filed by it and has paid all Taxes and
governmental charges due and payable with respect to such return or otherwise owing by a Loan Party, except any such Taxes which
are being diligently contested in good faith by appropriate proceedings and for which adequate reserves in accordance with GAAP
shall have been set aside on its books and such proceedings stay the enforcement and collection upon any Lien for such Taxes. The
Loan Parties have made adequate reserves on their books and records in accordance with GAAP for all Taxes that have accrued but
which are not yet due and payable. No Loan Party has participated in any transaction that relates to a year of the taxpayer (which
is still open under the applicable statute of limitations) which is a “reportable transaction” within the meaning of
Treasury Regulation Section 1.6011- 4(b)(2) (irrespective of the date when the transaction was entered into).

 

9.14     Solvency,
etc. On the Closing Date, and immediately prior to and after giving effect to each borrowing hereunder and the use of the proceeds
thereof, with respect to each Loan Party, individually, (a) the fair value of its assets is greater than the amount of its liabilities
(including disputed, contingent and unliquidated liabilities) as such value is established and liabilities evaluated in accordance
with GAAP, (b) the present fair saleable value of its assets is not less than the amount that will be required to pay the probable
liability on its debts as they become absolute and matured, (c) it is able to realize upon its assets and pay its debts and other
liabilities (including disputed, contingent and unliquidated liabilities) as they mature in the normal course of business, (d)
it does not intend to, and does not believe that it will, incur debts or liabilities beyond its ability to pay as such debts and
liabilities mature and (e) it is not engaged in business or a transaction, and is not about to engage in business or a transaction,
for which its property would constitute unreasonably small capital.

 

    33

     

    

 

 

 

9.15       Environmental
Matters. The on-going operations of each Loan Party comply in all respects with all Environmental Laws, except such non-compliance
which could not (if enforced in accordance with applicable law) reasonably be expected to result, either individually or in the
aggregate, in a Material Adverse Effect. Each Loan Party has obtained, and maintains in good standing, all licenses, permits, authorizations,
registrations and other approvals required under any Environmental Law and required for their respective ordinary course operations,
and for their reasonably anticipated future operations, and each Loan Party is in compliance with all terms and conditions thereof,
except where the failure to do so could not reasonably be expected to result in material liability to any Loan Party and could
not reasonably be expected to result, either individually or in the aggregate, in a Material Adverse Effect. No Loan Party or any
of its properties or operations is subject to, or reasonably anticipates the issuance of, any written order from or agreement with
any Governmental Authority, nor subject to any judicial or docketed administrative or other proceeding, respecting any Environmental
Law, Environmental Claim or Hazardous Substance. There are no Hazardous Substances or other conditions or circumstances existing
with respect to any property, arising from operations prior to the Closing Date, or relating to any waste disposal, of any Loan
Party that would reasonably be expected to result, either individually or in the aggregate, in a Material Adverse Effect. No Loan
Party has any underground storage tanks that are not properly registered or permitted under applicable Environmental Laws or that
at any time have released, leaked, disposed of or otherwise discharged Hazardous Substances.

 

9.16       Insurance.
Each Loan Party and its properties are insured with financially sound and reputable insurance companies which are not Affiliates
of the Loan Parties, in such amounts, with such deductibles and covering such risks as are customarily carried by companies engaged
in similar businesses and owning similar properties in localities where such Loan Parties operate.

 

9.17       [Reserved].

 

9.18       Information.
All information heretofore or contemporaneously herewith furnished in writing by any Loan Party to Lender for purposes of or in
connection with this Agreement and the transactions contemplated hereby is, and all written information hereafter furnished by
or on behalf of any Loan Party to Lender pursuant hereto or in connection herewith will be, true and accurate in every material
respect on the date as of which such information is dated or certified, and none of such information is or will be incomplete by
omitting to state any material fact necessary to make such information not misleading in light of the circumstances under which
made (it being recognized by Lender that any projections and forecasts provided by Borrower are based on good faith estimates and
assumptions believed by Borrower to be reasonable as of the date of the applicable projections or assumptions and that actual results
during the period or periods covered by any such projections and forecasts may differ from projected or forecasted results).

 

9.19       Intellectual
Property. Each Loan Party owns and possesses or has a license or other right to use all patents, patent rights,
trademarks, trademark rights, trade names, trade name rights, service marks, service mark rights and copyrights as are
necessary for the conduct of the businesses of the Loan Parties, without any infringement upon rights of others which could
reasonably be expected to have a Material Adverse Effect.

 

     34

     

    

 

9.20       Burdensome
Obligations. No Loan Party is a party to any agreement or contract or subject to any restriction contained in its organizational
documents which could reasonably be expected to have a Material Adverse Effect.

 

9.21       Labor
Matters. Except as set forth on Schedule 9.21, no Loan Party is subject to any labor or collective bargaining agreement.
There are no existing or threatened strikes, lockouts or other labor disputes involving any Loan Party that singly or in the aggregate
could reasonably be expected to have a Material Adverse Effect. Hours worked by and payment made to employees of the Loan Parties
are not in violation of the Fair Labor Standards Act or any other applicable law, rule or regulation dealing with such matters.

 

9.22       Anti-Terrorism
Laws. (a) No Loan Party (and, to the knowledge of each Loan Party, no joint venture or subsidiary thereof) is in violation
in any material respects of any United States Requirements of Law relating to terrorism, sanctions or money laundering (the “Anti-Terrorism
Law”), including the United States Executive Order No. 13224 on Terrorist Financing (the “Anti-Terrorism Order”)
and the Patriot Act.

 

(b)       No
Loan Party (and, to the knowledge of each Loan Party, no joint venture or subsidiary thereof) (i) is listed in the annex to, or
is otherwise subject to the provisions of, the Anti-Terrorism Order, (ii) is owned or controlled by, or acting for or on behalf
of, any person listed in the annex to, or is otherwise subject to the provisions of, the Anti-Terrorism Order, (iii) commits, threatens
or conspires to commit or supports “terrorism” as defined in the Anti-Terrorism Order or (iv) is named as a “specially
designated national and blocked person” in the most current list published by OFAC.

 

(c)       No
Loan Party (and, to the knowledge of each Loan Party, no joint venture or Affiliate thereof) (i) conducts any business or engages
in making or receiving any contribution of funds, goods or services to or for the benefit of any person described in clauses
(b)(i) through (b)(iv) above, (ii) deals in, or otherwise engages in any transactions relating to, any property or interests
in property blocked pursuant to the Anti-Terrorism Order or (iii) engages in or conspires to engage in any transaction that evades
or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the prohibitions set forth in any Anti-Terrorism
Law.

 

9.23       No
Default. No Default or Event of Default exists or would result from the incurrence by any Loan Party of any Debt hereunder
or under any other Loan Document.

 

9.24       Sanctions;
Anti-Corruption.

 

(a)       Sanctioned
Persons. None of Borrower, any of its Subsidiaries or, to the knowledge of Borrower, any director, officer, employee,
agent, or affiliate of Borrower or any of its Subsidiaries is an individual or entity that is, or is owned or controlled by
Persons that are: (i) the subject of any sanctions administered or enforced by the U.S. Department of the Treasury’s
Office of Foreign Assets Control (“OFAC”), the U.S. Department of State, or other relevant sanctions
authority (collectively, “Sanctions”), or (ii) located, organized or resident in a country or territory
that is, or whose government is, the subject of Sanctions (including, without limitation, currently, Crimea, Cuba, Iran,
North Korea, Sudan and Syria).

 

     35

     

    

 

(b)       Dealings
with Sanctioned Persons. For the past five years, neither Borrower nor any of its Subsidiaries has knowingly engaged in, or
is now knowingly engaged in any dealings or transactions with any Person, or in any country or territory, that at the time of the
dealing or transaction is or was, or whose government is or was, the subject of Sanctions.

 

(c)       Anti-Corruption
Laws. Borrower, its Subsidiaries and their respective directors, officers and employees and, to the knowledge of Borrower,
the agents of Borrower and its Subsidiaries, are in compliance with the Foreign Corrupt Practices Act of 1977, as amended, and
the rules and regulations thereunder (the “FCPA”) and any other applicable anti-corruption law in all material
respects.

 

9.25       Patriot
Act. To the extent applicable, each of Borrower and its Subsidiaries is in compliance in all material respects with (i) the
Trading with the Enemy Act, as amended, and each of the foreign assets control regulations of the United States Treasury Department
(31 CFR, Subtitle B, Chapter V, as amended), and any other enabling legislation or executive order relating thereto, and (ii) the
Patriot Act.

 

9.26       Certificate
of Beneficial Ownership. As of Closing Date, the information contained in the Certificate of Beneficial Ownership is true,
correct and complete.

 

9.27       Related
Agreements, etc. (a) Borrower has heretofore furnished Lender a true and correct copy of the Related Agreements.

 

(b)       Each
Loan Party and, to each Loan Party’s knowledge, each other party to the Related Agreements, has duly taken all necessary
corporate, partnership or other organizational action to authorize the execution, delivery and performance of the Related Agreements
and the consummation of transactions contemplated thereby.

 

(c)       The
Related Transactions comply with all applicable legal requirements, and all necessary governmental, regulatory, creditor, shareholder,
partner and other material consents, approvals and exemptions required to be obtained by the Loan Parties and, to each Loan Party’s
knowledge, each other party to the Related Agreements in connection with the Related Transactions will be, prior to consummation
of the Related Transactions, duly obtained and will be in full force and effect. As of the date of the Related Agreements, all
applicable waiting periods with respect to the Related Transactions will have expired without any action being taken by any competent
Governmental Authority which restrains, prevents or imposes material adverse conditions upon the consummation of the Related Transactions.

 

(d)       The
execution and delivery of the Related Agreements did not, and the consummation of the Related Transactions will not, violate
any statute or regulation of the United States (including any securities law) or of any state or other applicable
jurisdiction, or any order, judgment or decree of any court or governmental body binding on any Loan Party or, to any Loan
Party’s knowledge, any other party to the Related Agreements, or result in a breach of, or constitute a default under,
any material agreement, indenture, instrument or other document, or any judgment, order or decree, to which any Loan Party is
a party or by which any Loan Party is bound or, to Loan Party’s knowledge, to which any other party to the Related
Agreements is a party or by which any such party is bound.

 

     36

     

    

 

(e)       No
statement or representation made in the Related Agreements by any Loan Party or, to any Loan Party’s knowledge, any other
Person, contains any untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary
in order to make the statements made therein, in light of the circumstances under which they are made, not misleading.

 

9.28       [Reserved].

 

9.29       Loan
Party Information. On the date hereof, Schedule 9.29 sets forth (a) each Loan Party’s jurisdiction of organization,
(b) the location of each Loan Party’s chief executive office, (c) each Loan Party’s exact legal name as it appears
on its organizational documents and (d) each Loan Party’s organizational identification number (to the extent a Loan Party
is organized in a jurisdiction which assigns such numbers) and federal employer identification number.

 

9.30       Certain
Property. None of the Collateral constitutes, or is the Proceeds of, (a) Farm Products, (b) Health Care Insurance Receivables
or (c) vessels, aircraft or any other property subject to any certificate of title or other registration statute of the United
States, any State or other jurisdiction.

 

SECTION 10      AFFIRMATIVE COVENANTS.

 

Until the expiration or termination of the
Commitments and thereafter until all Obligations hereunder and under the other Loan Documents are Paid in Full, each Loan Party
agrees that, unless at any time Lender shall otherwise expressly consent in writing, it will:

 

10.1       Reports,
Certificates and Other Information. Furnish to Lender:

 

10.1.1       [Reserved].

 

10.1.2       Interim
Reports. Promptly when available and in any event within 30 days after the end of each Fiscal Quarter, beginning with the Fiscal
Quarter ending September 30, 2020, consolidated and consolidating balance sheets of PBI and its Subsidiaries as of the end of such
Fiscal Quarter, together with consolidated statements of earnings and cash flows for such Fiscal Quarter and for the period beginning
with the first day of such Fiscal Year and ending on the last day of such Fiscal Quarter, together with a comparison with the corresponding
period of the previous Fiscal Year and a comparison with the budget for such period of the current Fiscal Year, certified by a
Senior Officer of PBI.

 

10.1.3       Compliance
Certificates. Contemporaneously with the furnishing of a copy of each set of quarterly statements pursuant to Section
10.1.2, a duly completed compliance certificate in form acceptable to Lender, with appropriate insertions, dated the date
of such quarterly statements and signed by a Senior Officer of Borrower, containing (i) a statement that such officer has not
become aware of any Default or Event of Default that has occurred and is continuing or, if there is any such event,
describing it and the steps, if any, being taken to cure it and (ii) a written statement of Borrower’s management
setting forth a discussion of Borrower’s financial condition, changes in financial condition and results of
operations.

 

     37

     

    

 

10.1.4       [Reserved].

 

10.1.5       Notice
of Default, Litigation, ERISA and other Matters. Promptly upon becoming aware of any of the following, written notice describing
the same and the steps being taken by the applicable Loan Party or the Subsidiary affected thereby with respect thereto:

 

(a)       the
occurrence of an Event of Default or a Default;

 

(b)       any
litigation, arbitration or governmental investigation or proceeding not previously disclosed by any Loan Party to Lender which
has been instituted or, to the knowledge of any Loan Party, is threatened against any Loan Party or to which any of the properties
of any thereof is subject which might reasonably be expected to have a Material Adverse Effect;

 

(c)       the
institution of any steps by any member of the Controlled Group or any other Person to terminate any Pension Plan, or the failure
of any member of the Controlled Group to make a required contribution to any Pension Plan (if such failure is sufficient to give
rise to a Lien under Section 303(k) of ERISA or Section 430(k) of the Code) or to any Multiemployer Pension Plan, or the taking
of any action with respect to a Pension Plan which could result in the requirement that a Loan Party furnish a bond or other security
to the PBGC or such Pension Plan, or the occurrence of any event with respect to any Plan or Multiemployer Pension Plan which could
result in the incurrence by any member of the Controlled Group of any material liability, fine or penalty (including any claim
or demand for withdrawal liability or partial withdrawal from any Multiemployer Pension Plan), or any material increase in the
contingent liability of a Loan Party with respect to any post-retirement welfare benefit plan or other Plan, or any notice that
any Multiemployer Pension Plan is in reorganization, that increased contributions may be required to avoid a reduction in plan
benefits or the imposition of an excise tax, that any such plan is or has been funded at a rate less than that required under Section
412 of the Code, that any such plan is or may be terminated, or that any such plan is or may become insolvent the receipt of any
notice from a Governmental Authority that any Plan intended to be qualified under Section 401 of the Code is not so qualified or
that damages, fines, excise taxes, or penalties may be imposed on any Loan Party with respect to a Plan;

 

(d)       any
cancellation or material change in any insurance maintained by any Loan Party;

 

(e)       any
other event (including (i) any violation of any Environmental Law or the assertion of any Environmental Claim or (ii) the enactment
or effectiveness of any law, rule or regulation) which might reasonably be expected to have a Material Adverse Effect,

 

     38

     

    

 

(f)       any
Lien (other than Permitted Liens) on any of the Collateral which would adversely affect the ability of Lender to exercise any of
its remedies hereunder; or

 

(g)       the
occurrence of any other event which could reasonably be expected to have a material adverse effect on the aggregate value of the
Collateral or on the Liens created hereby.

 

10.1.6       [Reserved].

 

10.1.7       Management
Reports. Promptly upon receipt thereof, copies of all detailed financial and management reports submitted to PBI or Borrower
by independent auditors in connection with each annual or interim audit made by such auditors of the books of PBI or Borrower.

 

10.1.8       Tax
Returns. As soon as possible and in any event within 5 days of filing thereof, copies of all tax returns filed by Allan C.
Silber with the Canada Revenue Agency.

 

10.1.9       Brokerage
Account Statements. Promptly when available and in any event within 30 days after the end of each calendar quarter, copies
of account statements for any brokerage or investments accounts maintained by Allan C. Silber.

 

10.1.10     Related
Transaction Notices. Promptly following receipt, copies of any material notices (including notices of default) received in
connection with the Related Transactions.

 

10.1.11     Certificate
of Beneficial Ownership. (a) Promptly after any change in the individual(s) identified as a beneficial owner in Certificate
of Beneficial Ownership and in no event later than contemporaneously with the next scheduled delivery of financial statements pursuant
to Section 10.1.1 or 101.2, an updated Certificate of Beneficial Ownership in form and substance acceptable to Lender
and, (b) promptly from time to time, such other information and documentation related to compliance with applicable “know
your customer” and anti-money laundering rules and regulations, including the Patriot Act and the Beneficial Ownership Regulation,
as Lender may reasonably request.

 

10.1.12     Personal
Net Worth Statement. Promptly when available and in any event within 30 days after the end of each calendar year, a statement
of personal net worth for Allan C. Silber, in form and detail acceptable to Lender in its sole discretion.

 

10.1.13     Other
Information. Promptly from time to time, such other information (including, without limitation, business or financial data,
reports, appraisals and projections) concerning the Loan Parties, their properties or business, as Lender may reasonably request.

 

10.2       Books,
Records and Inspections. Keep its books and records in accordance with sound business practices sufficient to allow the
preparation of financial statements in accordance with GAAP; permit Lender or any representative thereof to inspect the
properties and operations of the Loan Parties; and permit at any reasonable time and with reasonable notice (or at any time
without notice if an Event of Default exists), Lender or any representative thereof to visit any or all of its offices, to
discuss its financial matters with its officers and its independent auditors (and each Loan Party hereby authorizes such
independent auditors to discuss such financial matters with Lender or any representative thereof), and to examine (and, at
the expense of the Loan Parties, photocopy extracts from) any of its books or other records; and permit Lender and its
representatives to inspect the Inventory and other tangible assets of the Loan Parties, to perform appraisals of the
equipment of the Loan Parties, and to inspect, audit, check and make copies of and extracts from the books, records, computer
data, computer programs, journals, orders, receipts, correspondence and other data relating to Inventory, Accounts and any
other collateral. All such inspections or audits by Lender shall be at Borrower’s expense, provided that so long
as no Default or Event of Default exists, Borrower shall not be required to reimburse Lender for inspections or audits more
frequently than once each Fiscal Year.

 

     39

     

    

 

10.3       Maintenance
of Property; Insurance. (a) Keep all property useful and necessary in the business of the Loan Parties in good working order
and condition, ordinary wear and tear excepted.

 

(b)       Maintain
with responsible insurance companies, such insurance coverage as may be required by any law or governmental regulation or court
decree or order applicable to it and such other insurance, to such extent and against such hazards and liabilities, as is customarily
maintained by companies similarly situated, but which shall insure against all risks and liabilities of the type identified on
Schedule 9.16 and shall have insured amounts no less than, and deductibles no higher than, those set forth on such schedule;
and, upon request of Lender, furnish to Lender original or electronic copies of policies evidencing such insurance, and a certificate
setting forth in reasonable detail the nature and extent of all insurance maintained by the Loan Parties. Borrower shall cause
each issuer of an insurance policy to provide Lender with an endorsement (i) showing Lender as lender loss payee with respect to
each policy of property or casualty insurance and naming Lender as an additional insured with respect to each policy of liability
insurance, (ii) providing that 30 days’ (except for non-payment of premium, in which case a 10 days’) notice will be
given to Lender prior to any cancellation of, material reduction or change in coverage provided by or other material modification
to such policy and (iii) reasonably acceptable in all other respects to Lender. Each Loan Party shall execute and deliver to Lender
a collateral assignment, in form and substance satisfactory to Lender, of each business interruption insurance policy maintained
by such Loan Party.

 

(c)       UNLESS
BORROWER PROVIDES LENDER WITH EVIDENCE OF THE INSURANCE COVERAGE REQUIRED BY THIS AGREEMENT, LENDER MAY PURCHASE INSURANCE AT BORROWER’S
EXPENSE TO PROTECT LENDER’S INTERESTS IN THE COLLATERAL. THIS INSURANCE MAY, BUT NEED NOT, PROTECT ANY LOAN PARTY’S
INTERESTS. THE COVERAGE THAT LENDER PURCHASES MAY NOT PAY ANY CLAIM THAT IS MADE AGAINST ANY LOAN PARTY IN CONNECTION WITH THE
COLLATERAL. BORROWER MAY LATER CANCEL ANY INSURANCE PURCHASED BY LENDER, BUT ONLY AFTER PROVIDING LENDER WITH EVIDENCE THAT BORROWER
HAS OBTAINED INSURANCE AS REQUIRED BY THIS AGREEMENT. IF LENDER PURCHASES INSURANCE FOR THE COLLATERAL, BORROWER WILL BE RESPONSIBLE
FOR THE COSTS OF THAT INSURANCE, INCLUDING INTEREST AND ANY OTHER CHARGES THAT MAY BE IMPOSED WITH THE PLACEMENT OF THE INSURANCE,
UNTIL THE EFFECTIVE DATE OF THE CANCELLATION OR EXPIRATION OF THE INSURANCE. THE COSTS OF THE INSURANCE MAY BE ADDED TO THE PRINCIPAL
AMOUNT OF THE LOANS OWING HEREUNDER. THE COSTS OF THE INSURANCE MAY BE MORE THAN THE COST OF THE INSURANCE THE LOAN PARTIES MAY
BE ABLE TO OBTAIN ON THEIR OWN.

 

     40

     

    

 

10.4       Compliance
with Laws; Payment of Taxes and Liabilities. (a) Comply in all material respects with all applicable laws, rules, regulations,
decrees, orders, judgments, licenses and permits, except where failure to comply could not reasonably be expected to have a Material
Adverse Effect; (b) without limiting clause (a) above, ensure that no person who owns a controlling interest in or otherwise
controls a Loan Party is or shall be (i) listed on the Specially Designated Nationals and Blocked Person List maintained by the
OFAC, the Department of the Treasury, and/or any other similar lists maintained by OFAC pursuant to any authorizing statute, Executive
Order or regulation or (ii) a person designated under Section 1(b), (c) or (d) of Executive Order No. 13224 (September 23, 2001),
any related enabling legislation or any other similar Executive Orders, (c) without limiting clause (a) above, comply with
all applicable Bank Secrecy Act (“BSA”) and anti-money laundering laws and regulations and (d) pay prior to delinquency,
all Taxes and other governmental charges against it or any of its property, as well as claims of any kind which, if unpaid, could
become a Lien on any of its property; provided that the foregoing shall not require any Loan Party to pay any such tax or
charge so long as it shall contest the validity thereof in good faith by appropriate proceedings and shall set aside on its books
adequate reserves with respect thereto in accordance with GAAP and, in the case of a claim which could become a Lien on any collateral,
such contest proceedings shall stay the foreclosure of such Lien or the sale of any portion of the collateral to satisfy such claim.

 

10.5       Maintenance
of Existence, etc. Maintain and preserve (subject to Section 11.5) (a) its existence and good standing (or equivalent)
in the jurisdiction of its organization and (b) its qualification to do business and good standing in each jurisdiction where the
nature of its business makes such qualification necessary (other than such jurisdictions in which the failure to be qualified or
in good standing could not reasonably be expected to have a Material Adverse Effect).

 

10.6       Use
of Proceeds. Use the proceeds of the Loans, solely to finance the Related Transactions, for working capital purposes, for Capital
Expenditures and for other general business purposes; and not use or permit any proceeds of any Loan to be used, either directly
or indirectly, for the purpose, whether immediate, incidental or ultimate, of “purchasing or carrying” any Margin Stock.

 

10.7       [Reserved].

 

10.8       Environmental
Matters. If any release or threatened release or other disposal of Hazardous Substances shall occur or shall have
occurred on any real property or any other assets of any Loan Party, the applicable Loan Party shall cause the prompt
containment and removal of such Hazardous Substances and the remediation of such real property or other assets as necessary
to comply with all Environmental Laws and to preserve the value of such real property or other assets. Without limiting the
generality of the foregoing, the applicable Loan Party shall comply with any Federal or state judicial or administrative
order requiring the performance at any real property of any Loan Party of activities in response to the release or threatened
release of a Hazardous Substance. To the extent that the transportation of Hazardous Substances is permitted by this
Agreement, each Loan Party shall, and shall cause its Subsidiaries to, dispose of such Hazardous Substances, or of any other
wastes, only at licensed disposal facilities operating in compliance with Environmental Laws.

 

10.9       Further
Assurances. At any time and from time to time, upon the written request of Lender, and at the sole expense of such Loan Party,
such Loan Party will promptly and duly execute and deliver, and have recorded, such further instruments and documents and take
such further actions as Lender may reasonably request for the purpose of obtaining or preserving the full benefits of this Agreement
and of the rights and powers herein granted, including filing any financing or continuation statements under the UCC (or other
similar laws) in effect in any jurisdiction with respect to the security interests created hereby.

 

10.10       [Reserved].

 

10.11       [Reserved].

 

10.12       [Reserved].

 

10.13       [Reserved].

 

     41

     

    

 

10.14       [Reserved].

 

10.15       [Reserved].

 

10.16       [Reserved].

 

10.17       [Reserved].

 

10.18       [Reserved].

 

10.19       This
Agreement. Each of the Loan Parties (other than Borrower) covenants that it will, and, if necessary, will cause or enable Borrower
to, fully comply with each of the covenants and other agreements set forth in this Agreement.

 

SECTION 11      NEGATIVE COVENANTS

 

Until the expiration or termination of the
Commitments and thereafter until all Obligations hereunder and under the other Loan Documents are Paid in Full, each Loan Party
agrees that, unless at any time Lender shall otherwise expressly consent in writing, it will:

 

11.1       Debt.
Not create, incur, assume or suffer to exist any Debt, except:

 

(a)       Obligations
under this Agreement and the other Loan Documents;

 

(b)       Hedging
Obligations approved by Lender and incurred in favor of Lender or an Affiliate thereof for bona fide hedging purposes and not for
speculation; and

 

(c)       Contingent
Liabilities arising with respect to customary indemnification obligations in favor of purchasers in connection with dispositions
permitted under Section 11.5.

 

11.2       Liens.
Not create or permit to exist any Lien on any Collateral (whether now owned or hereafter acquired), except as provided in the Mortgage.

 

11.3       [Reserved].

 

11.4       Restricted
Payments. Not (a) make any distribution to any holders of its Capital Securities, (b) purchase or redeem any of its Capital
Securities, (c) pay any management fees or similar fees to any of its equityholders or any Affiliate thereof, (d) make any redemption,
prepayment (whether mandatory or optional), defeasance, repurchase or any other payment in respect of any Subordinated Debt or
(e) set aside funds for any of the foregoing. Notwithstanding the foregoing, (i) any Subsidiary may pay dividends or make other
distributions to Borrower or to a domestic Wholly-Owned Subsidiary; (ii) so long as no Event of Default is continuing and (a) the
applicable Loan Party shall not be a separately taxable entity for federal income tax purposes, and (b) such Loan Party gives Lender
sufficient documentation to verify compliance with this clause one (1) Business Day prior to the distribution, such Loan Party
may make Permitted Tax Distributions; and (iv) Borrower may make regularly scheduled payments of interest in respect of Subordinated
Debt to the extent permitted under the subordination provisions thereof.

 

11.5       Mergers,
Consolidations, Sales. Not (a) be a party to any merger or consolidation, (b) sell, transfer, dispose of, convey or lease any
of its assets or Capital Securities (including the sale of Capital Securities of any Subsidiary) except for sales of inventory
in the ordinary course of business, or (c) sell or assign with or without recourse any receivables.

 

11.6       Modification
of Organizational Documents. Not amend or modify its charter, by-laws or other organizational documents in any way which could
reasonably be expected to materially adversely affect the interests of Lender; not change its state of formation or its organizational
form.

 

     42

     

    

 

11.7       Transactions
with Affiliates. Not enter into, or cause, suffer or permit to exist any transaction, arrangement or contract with any of its
other Affiliates (other than the Loan Parties) which is on terms which are less favorable than are obtainable from any Person which
is not one of its Affiliates.

 

11.8       Unconditional
Purchase Obligations. Not enter into or be a party to any contract for the purchase of materials, supplies or other property
or services if such contract requires that payment be made by it regardless of whether delivery is ever made of such materials,
supplies or other property or services.

 

11.9       Inconsistent
Agreements. Not enter into any agreement containing any provision which would (a) be violated or breached by any
borrowing by Borrower hereunder or by the performance by any Loan Party of any of its Obligations hereunder or under any
other Loan Document, (b) prohibit any Loan Party from granting to Lender, a Lien on any of its assets or (c) create or permit
to exist or become effective any encumbrance or restriction on the ability of any Subsidiary to (i) pay dividends or make
other distributions to Borrower or any other Subsidiary, or pay any Debt owed to Borrower or any other Subsidiary, (ii) make
loans or advances to any Loan Party or (iii) transfer any of its assets or properties to any Loan Party, other than (A)
customary restrictions and conditions contained in agreements relating to the sale of all or a substantial part of the assets
of any Subsidiary pending such sale, provided that such restrictions and conditions apply only to the Subsidiary to be
sold and such sale is permitted hereunder (B) restrictions or conditions imposed by any agreement relating to purchase money
Debt, Capital Leases and other secured Debt permitted by this Agreement if such restrictions or conditions apply only to the
property or assets securing such Debt and (C) customary provisions in leases and other contracts restricting the assignment
thereof.

 

11.10       [Reserved].

 

11.11       Investments.
Not make or permit to exist any Investment in any other Person, except the following:

 

(a)       Investments
constituting Debt permitted by Section 11.1;

 

(b)       Contingent
Liabilities constituting Debt permitted by Section 11.1 or Liens permitted by Section 11.2;

 

(c)       Cash
Equivalent Investments; and

 

(d)       bank
deposits in the ordinary course of business maintained with Lender;

 

provided that (x) any Investment which when made complies
with the requirements of the definition of the term “Cash Equivalent Investment” may continue to be held notwithstanding
that such Investment if made thereafter would not comply with such requirements; (y) no Investment otherwise permitted by clause
(a) or (b) shall be permitted to be made if, immediately before or after giving effect thereto, any Default or Event of Default
exists.

 

11.12       Restriction
of Amendments to Certain Documents. Not amend or otherwise modify, or waive any rights under any Related Agreements, other
than immaterial amendments, modifications and waivers not materially adverse to the interests of Lender.

 

11.13       Fiscal
Year. Not change its Fiscal Year.

 

11.14       Minimum
Liquidity. Not permit the Liquidity of Allan C. Silber to be less than $2,000,000, determined at the end of each calendar quarter,
beginning with the calendar quarter ending September 30, 2020.

 

SECTION 12       EFFECTIVENESS; CONDITIONS OF
LENDING, ETC.

 

The obligation of Lender to make its Loans
is subject to the following conditions precedent:

 

     43

     

    

 

 

12.1       Initial
Credit Extension. The obligation of Lender to make the initial Loans is, in addition to the conditions precedent specified
in Section 12.2, subject to the conditions precedent, each of which must be satisfied in a manner satisfactory to Lender:

 

12.1.1       Repayment
of Debt to be Repaid. All Debt to be Repaid has been (or concurrently with the initial borrowing will be) paid in full, and
that all agreements and instruments governing the Debt to be Repaid and that all Liens securing such Debt to be Repaid have been
(or concurrently with the initial borrowing will be) terminated;

 

12.1.2       Related
Transactions. Lender shall have received evidence, reasonably satisfactory to Lender, that Borrower has completed, or concurrently
with the initial credit extension hereunder will complete, the Related Transactions in accordance with the terms of the Related
Agreements (without any amendment thereto or waiver thereunder unless consented to by Lender).

 

12.1.3       Documentation.
Lender shall have received all of the following, each duly executed and dated the Closing Date (or such earlier date as shall be
satisfactory to Lender), in form and substance satisfactory to Lender (and the date on which all such conditions precedent have
been satisfied or waived in writing by Lender is called the “Closing Date”):

 

(a)         Agreement
and Notes. This Agreement and, to the extent requested by Lender, a Note.

 

(b)      Authorization
Documents. For each Loan Party, such Person’s (a) charter (or similar formation document), certified by the appropriate
Governmental Authority; (b) good standing certificates (or equivalent) in its state of incorporation (or formation) and in each
other state requested by Lender; (c) bylaws (or similar governing document); (d) resolutions of its board of directors (or similar
governing body) approving and authorizing such Person’s execution, delivery and performance of the Loan Documents to which
it is party and the transactions contemplated thereby; and (e) signature and incumbency certificates of its officers executing
any of the Loan Documents (it being understood that Lender may conclusively rely on each such certificate until formally advised
by a like certificate of any changes therein), all certified by its secretary or an assistant secretary (or similar officer) as
being in full force and effect without modification.

 

(c)       Consents,
etc. Certified copies of all documents evidencing any necessary corporate or partnership action, consents and governmental
approvals (if any) required for the execution, delivery and performance by the Loan Parties of the documents referred to in this
Section 12.

 

(d)        Letter
of Direction. A letter of direction containing funds flow information with respect to the proceeds of the Loans on the Closing
Date.

 

(e)       Real
Estate Documents. With respect to each parcel of real property owned by any Loan Party, a duly executed Mortgage providing
for a fully perfected Lien, in favor of Lender, in all right, title and interest of Borrower or such Subsidiary in such real property,
together with:

 

    44

     

    

 

(i)       an
ALTA Loan Title Insurance Policy, issued by an insurer acceptable to Lender, insuring Lender’s first priority Lien on such
real property and containing such endorsements as Lender may reasonably require (it being understood that the amount of coverage,
exceptions to coverage and status of title set forth in such policy shall be acceptable to Lender);

 

(ii)       copies
of all documents of record concerning such real property as shown on the commitment for the ALTA Loan Title Insurance Policy referred
to above;

 

(iii)       original
or certified copies of all insurance policies required to be maintained with respect to such real property by this Agreement, the
applicable Mortgage or any other Loan Document;

 

(iv)       a
survey certified to Lender meeting such standards as Lender may reasonably establish and otherwise reasonably satisfactory to Lender;

 

(v)       a
flood insurance policy concerning such real property, if required by the Flood Disaster Protection Act of 1973; and

 

(vi)       an
appraisal, prepared by an independent appraiser engaged directly by Lender of such parcel of real property or interest in real
property, which appraisal shall satisfy the requirements of the Financial Institutions Reform, Recovery and Enforcement Act, if
applicable, and shall evidence compliance with the supervisory loan-to-value limits set forth in the Federal Deposit Insurance
Corporation Improvement Act of 1991, if applicable.

 

(f)       Opinions
of Counsel. Opinions of counsel for each Loan Party, including local counsel reasonably requested by Lender.

 

(g)       Insurance.
Evidence of the existence of insurance required to be maintained pursuant to Section 10.3(b), together with evidence that
Lender has been named as a loss payee and an additional insured on all related insurance policies.

 

(h)       Payment
of Fees. Evidence of payment by Borrower of all accrued and unpaid fees, costs and expenses to the extent then due and payable
on the Closing Date, together with all Attorney Costs of Lender to the extent invoiced prior to the Closing Date, plus such
additional amounts of Attorney Costs as shall constitute Lender’s reasonable estimate of Attorney Costs incurred or to be
incurred by Lender through the closing proceedings (provided that such estimate shall not thereafter preclude final settling
of accounts between Borrower and Lender).

 

(i)       Environmental
Reports. Environmental site assessment reports requested by Lender.

 

    45

     

    

 

(j)       Search
Results; Lien Terminations. Certified copies of Uniform Commercial Code search reports dated a date reasonably near to
the Closing Date, listing all effective financing statements which name any Loan Party (under their present names and any
previous names) as debtors, together with (a) copies of such financing statements, (b) payoff letters evidencing repayment in
full of all Debt to be Repaid, the termination of all agreements relating thereto and the release of all Liens granted in
connection therewith, with Uniform Commercial Code or other appropriate termination statements and documents effective to
evidence the foregoing (other than Liens permitted by Section 11.2) and (c) such other Uniform Commercial Code
termination statements as Lender may reasonably request.

 

(k)       Filings,
Registrations and Recordings. Lender shall have received each document (including Uniform Commercial Code financing statements)
required by the Collateral Documents or under law or reasonably requested by Lender to be filed, registered or recorded in order
to create in favor of Lender a perfected Lien on the collateral described therein, prior to any other Liens (subject only to Liens
permitted pursuant to Section 11.2), in proper form for filing, registration or recording.

 

(l)       Closing
Certificate, Consents and Permits. A certificate executed by an officer of Borrower on behalf of Borrower certifying the matters
set forth in Section 12.2.1 as of the Closing Date.

 

(m)       Certificate
of Beneficial Ownership. At least three days prior to the Closing Date, a Certificate of Beneficial Ownership containing information
required by the Beneficial Ownership Regulation with respect to Borrower, addressed to Lender.

 

(n)       Copies
of Documents. Copies of the Related Agreements certified by the secretary or assistant secretary (or similar officer) of Borrower
as being true, accurate and complete.

 

(o)       Other.
Such other documents as Lender may reasonably request.

 

12.2       Conditions.
The obligation of Lender to make each Loan is subject to the following further conditions precedent that:

 

12.2.1       Compliance
with Warranties, No Default, etc. Both before and after giving effect to any borrowing, the following statements shall be true
and correct:

 

(a)       the
representations and warranties of each Loan Party set forth in this Agreement and the other Loan Documents shall be true and correct
in all respects with the same effect as if then made (except to the extent stated to relate to a specific earlier date, in which
case such representations and warranties shall be true and correct as of such earlier date); and

 

(b)       no
Default or Event of Default shall have then occurred and be continuing.

 

12.2.2       Confirmatory
Certificate. If requested by Lender, Lender shall have received a certificate dated the date of such requested Loan and signed
by a duly authorized representative of Borrower as to the matters set out in Section 12.2.1 (it being understood that each
request by Borrower for the making of a Loan shall be deemed to constitute a representation and warranty by Borrower that the conditions
precedent set forth in Section 12.2.1 will be satisfied at the time of the making of such Loan), together with such other
documents as Lender may reasonably request in support thereof.

 

    46

     

    

 

SECTION 13       EVENTS OF DEFAULT AND THEIR
EFFECT.

 

13.1       Events
of Default. Each of the following shall constitute an Event of Default under this Agreement:

 

13.1.1       Non-Payment
of the Loans, etc. Default in the payment when due of the principal of any Loan; or default, and continuance thereof for three
(3) days, in the payment when due of any interest, fee, or other amount payable by Borrower hereunder or under any other Loan Document.

 

13.1.2       Non-Payment
of Other Debt. Any default shall occur under the terms applicable to any Debt of any Loan Party in an aggregate amount (for
all such Debt so affected and including undrawn committed or available amounts and amounts owing to all creditors under any combined
or syndicated credit arrangement) exceeding $500,000 and such default shall (a) consist of the failure to pay such Debt when due,
whether by acceleration or otherwise, or (b) accelerate the maturity of such Debt or permit the holder or holders thereof, or any
trustee or agent for such holder or holders, to cause such Debt to become due and payable (or require any Loan Party to purchase
or redeem such Debt or post cash collateral in respect thereof) prior to its expressed maturity.

 

13.1.3       Other
Material Obligations. Default in the payment when due, or in the performance or observance of, any material obligation of,
or condition agreed to by, any Loan Party with respect to any material purchase or lease of goods or services where such default,
singly or in the aggregate with all other such defaults, might reasonably be expected to have a Material Adverse Effect.

 

13.1.4       Bankruptcy,
Insolvency, etc. Any Loan Party becomes insolvent or generally fails to pay, or admits in writing its inability or refusal
to pay, debts as they become due; or any Loan Party applies for, consents to, or acquiesces in the appointment of a trustee, receiver
or other custodian for such Loan Party or any property thereof, or makes a general assignment for the benefit of creditors; or,
in the absence of such application, consent or acquiescence, a trustee, receiver or other custodian is appointed for any Loan Party
or for a substantial part of the property of any thereof and is not discharged within 60 days; or any bankruptcy, reorganization,
debt arrangement, or other case or proceeding under any bankruptcy or insolvency law, or any dissolution or liquidation proceeding,
is commenced in respect of any Loan Party, and if such case or proceeding is not commenced by such Loan Party, it is consented
to or acquiesced in by such Loan Party, or remains for 60 days undismissed; or any Loan Party takes any action to authorize, or
in furtherance of, any of the foregoing.

 

13.1.5       Non-Compliance
with Loan Documents. (a) Failure by any Loan Party to comply with or to perform any covenant set forth in Sections 10.1,
10.3(b), 10.5, 10.6, 10.11 or Section 11; or (b) failure by any Loan Party to comply with or to perform any other provision
of this Agreement or any other Loan Document (and not constituting an Event of Default under any other provision of this Section
13) and continuance of such failure described in this clause (b) for 30 days.

 

13.1.6       Representations;
Warranties. Any representation or warranty made by any Loan Party herein or any other Loan Document is breached or is
false or misleading in any material respect, or any schedule, certificate, financial statement, report, notice or other
writing furnished by any Loan Party to Lender in connection herewith is false or misleading in any material respect on the
date as of which the facts therein set forth are stated or certified.

 

    47

     

    

 

13.1.7       [Reserved].

 

13.1.8       Judgments.
Final judgments which exceed an aggregate of $250,000 shall be rendered against any Loan Party and shall not have been paid, discharged
or vacated or had execution thereof stayed pending appeal within 30 days after entry or filing of such judgments.

 

13.1.9       Invalidity
of Collateral Documents, etc. Any Collateral Document shall cease to be in full force and effect; or any Loan Party (or any
Person by, through or on behalf of any Loan Party) shall contest in any manner the validity, binding nature or enforceability of
any Collateral Document.

 

13.1.10       [Reserved].

 

13.1.11       Change
of Control. A Change of Control shall occur.

 

13.1.12       Material
Adverse Effect. The occurrence of any event having a Material Adverse Effect.

 

13.2     Effect of Event of
Default. If any Event of Default described in Section 13.1.4 shall occur in respect of Borrower, the Commitments shall
immediately terminate and the Loans and all other Obligations hereunder shall become immediately due and payable, all without presentment,
demand, protest or notice of any kind (provided, however, that notwithstanding the foregoing, Hedging Obligations
shall terminate only in accordance with the terms of the relevant Hedging Agreement); and, if any other Event of Default shall
occur and be continuing, Lender may declare the Commitments to be terminated in whole or in part and/or declare all or any part
of the Loans and all other Obligations hereunder to be due and payable, whereupon the Commitments shall immediately terminate (or
be reduced, as applicable) and/or the Loans and other Obligations hereunder shall become immediately due and payable (in whole
or in part, as applicable), all without presentment, demand, protest or notice of any kind. Lender shall promptly advise Borrower
of any such declaration, but failure to do so shall not impair the effect of such declaration. Any cash collateral delivered to
the Lender shall be held by Lender (without liability for interest thereon) and applied to any Obligations hereunder and any excess
shall be delivered to Borrower or as a court of competent jurisdiction may elect.

 

13.3       [Reserved].

 

SECTION 14       GENERAL.

 

14.1       Waiver;
Amendments. No delay on the part of Lender in the exercise of any right, power or remedy shall operate as a waiver
thereof, nor shall any single or partial exercise by Lender of any right, power or remedy preclude other or further exercise
thereof, or the exercise of any other right, power or remedy. No amendment, modification or waiver of, or consent with
respect to, any provision of this Agreement or the other Loan Documents shall in any event be effective unless the same shall
be in writing and acknowledged by Lender, and then any such amendment, modification, waiver or consent shall be effective
only in the specific instance and for the specific purpose for which given.

 

    48

     

    

 

14.2       Confirmations.
Borrower and each holder of a Note agree from time to time, upon written request received by it from the other, to confirm to the
other in writing the aggregate unpaid principal amount of the Loans then outstanding under such Note.

 

14.3       Notices.
Except as otherwise provided in Sections 2.2.2 and 2.2.3, all notices hereunder shall be in writing (including facsimile
transmission) and shall be sent to the applicable party at its address shown on Annex A or at such other address as such
party may, by written notice received by the other parties, have designated as its address for such purpose. Notices sent by facsimile
transmission shall be deemed to have been given when sent; notices sent by mail shall be deemed to have been given three Business
Days after the date when sent by registered or certified mail, postage prepaid; and notices sent by hand delivery or overnight
courier service shall be deemed to have been given when received. For purposes of Sections 2.2.2 and 2.2.3, Lender
shall be entitled to rely on telephonic instructions from any person that Lender in good faith believes is an authorized officer
or employee of Borrower, and Borrower shall hold Lender harmless from any loss, cost or expense resulting from any such reliance.

 

14.4       Acknowledgement
and Consent to Bail-In of EEA Financial Institutions. Notwithstanding anything to the contrary in any Loan Document or in any
other agreement, arrangement, or understanding among any such parties, each party hereto acknowledges that any liability of any
EEA Financial Institution arising under any Loan Document, to the extent such liability is unsecured, may be subject to the write-down
and conversion powers of an EEA Resolution Authority and agrees and consents to, and acknowledges and agrees to be bound by:

 

(a)       the
application of any Write-Down and Conversion Powers by an EEA Resolution Authority to any such liabilities arising hereunder which
may be payable to it by any party hereto that is an EEA Financial Institution; and

 

(b)       the
effects of any Bail-In Action on any such liability, including, if applicable:

 

(i)       a
reduction in full or in part or cancellation of any such liability;

 

(ii)      a
conversion of all, or a portion of, such liability into shares or other instruments of ownership in such EEA Financial Institution,
its parent undertaking, or a bridge institution that may be issued to it or otherwise conferred on it, and that such shares or
other instruments of ownership will be accepted by it in lieu of any rights with respect to any such liability under this Agreement
or any other Loan Document; or

 

(iii)     the
variation of the terms of such liability in connection with the exercise of the write-down and conversion powers of any EEA Resolution
Authority.

 

    49

     

    

 

14.5       Costs
and Expenses. (a) Each Loan Party, jointly and severally, agrees to pay on demand all reasonable out-of-pocket costs and expenses
of Lender (including Attorney Costs) in connection with the preparation, execution, syndication, delivery and administration (including
perfection and protection of any Collateral and the costs of Intralinks (or other similar service), if applicable) of this Agreement,
the other Loan Documents and all other documents provided for herein or delivered or to be delivered hereunder or in connection
herewith (including any amendment, supplement or waiver to any Loan Document), whether or not the transactions contemplated hereby
or thereby shall be consummated, and all reasonable out-of-pocket costs and expenses (including Attorney Costs) incurred by Lender
after an Event of Default in connection with the collection of the Obligations or the enforcement of this Agreement the other Loan
Documents or any such other documents or during any workout, restructuring or negotiations in respect thereof. In addition, each
Loan Party agrees to pay, and to save Lender harmless from all liability for, any fees of Borrower’s auditors in connection
with any reasonable exercise by Lender of their rights pursuant to Section 10.2. All Obligations provided for in this Section
14.5 shall survive repayment of the Loans, cancellation of the Notes and termination of this Agreement.

 

(b)       Each
Loan Party agrees to pay, and to save Lender harmless from, any and all liabilities with respect to, or resulting from any delay
in paying, any and all stamp, excise, sales or other taxes which may be payable or determined to be payable with respect to any
of the Collateral or in connection with any of the transactions contemplated by this Agreement.

 

(c)       The
agreements in this Section 14.5 shall survive repayment of all (and shall be) Secured Obligations (and termination of all
commitments under this Agreement), any foreclosure under, or any modification, release or discharge of, any or all of the Collateral
Documents and termination of this Agreement.

 

14.6       GOVERNING
LAW. THIS AGREEMENT AND EACH NOTE SHALL BE A CONTRACT MADE UNDER AND GOVERNED BY THE INTERNAL LAWS OF THE STATE OF INDIANA
APPLICABLE TO CONTRACTS MADE AND TO BE PERFORMED ENTIRELY WITHIN SUCH STATE, WITHOUT REGARD TO CONFLICT OF LAWS PRINCIPLES.

 

14.7       Confidentiality.
As required by federal law and Lender’s policies and practices, Lender may need to obtain, verify, and record certain
customer identification information and documentation in connection with opening or maintaining accounts, or establishing or
continuing to provide services. Lender agrees to use commercially reasonable efforts (equivalent to the efforts Lender
applies to maintain the confidentiality of its own confidential information) to maintain as confidential all information
provided to them by any Loan Party and designated as confidential, except that Lender may disclose such information (a) to
Persons employed or engaged by Lender in evaluating, approving, structuring or administering the Loans and the Commitments;
(b) to any assignee or participant or potential assignee or participant that has agreed to comply with the covenant contained
in this Section 14.7 (and any such assignee or participant or potential assignee or participant may disclose such
information to Persons employed or engaged by them as described in clause (a) above); (c) as required or requested by any
federal or state regulatory authority or examiner, or any insurance industry association, or as reasonably believed by Lender
to be compelled by any court decree, subpoena or legal or administrative order or process; (d) as, on the advice of
Lender’s counsel, is required by law; (e) in connection with the exercise of any right or remedy under the Loan
Documents or in connection with any litigation to which Lender is a party; (f) to any nationally recognized rating agency
that requires access to information about Lender’s investment portfolio in connection with ratings issued with respect
to Lender; (g) to any Affiliate of Lender or any other Person who may provide Bank Products to the Loan Parties; (h) to
Lender’s independent auditors and other professional advisors as to which such information has been identified as
confidential; or (i) that ceases to be confidential through no fault of Lender. Notwithstanding the foregoing, Borrower
consents to the publication by Lender of a tombstone or similar advertising material relating to the financing transactions
contemplated by this Agreement, and Lender reserves the right to provide to industry trade organizations information
necessary and customary for inclusion in league table measurements. If any provision of any confidentiality agreement,
non-disclosure agreement or other similar agreement between Borrower and Lender conflicts with or contradicts this Section
14.7 with respect to the treatment of confidential information, this section shall supersede all such prior or
contemporaneous agreements and understandings between the parties.

 

    50

     

    

 

14.8       Severability.
Whenever possible each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Agreement shall be prohibited by or invalid under applicable law, such provision shall be ineffective
to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions
of this Agreement. All obligations of the Loan Parties and rights of Lender expressed herein or in any other Loan Document shall
be in addition to and not in limitation of those provided by applicable law.

 

14.9       Nature
of Remedies. All Obligations of the Loan Parties and rights of Lender expressed herein or in any other Loan Document shall
be in addition to and not in limitation of those provided by applicable law. No failure to exercise and no delay in exercising,
on the part of Lender, any right, remedy, power or privilege hereunder, shall operate as a waiver thereof; nor shall any single
or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise
of any other right, remedy, power or privilege.

 

14.10       Entire
Agreement. This Agreement, together with the other Loan Documents, embodies the entire agreement and understanding among the
parties hereto and supersedes all prior or contemporaneous agreements and understandings of such Persons, verbal or written, relating
to the subject matter hereof and thereof and any prior arrangements made with respect to the payment by the Loan Parties of (or
any indemnification for) any fees, costs or expenses payable to or incurred (or to be incurred) by or on behalf of Lender.

 

14.11       Counterparts.
This Agreement may be executed in any number of counterparts and by the different parties hereto on separate counterparts and
each such counterpart shall be deemed to be an original, but all such counterparts shall together constitute but one and the
same Agreement. Receipt of an executed signature page to this Agreement by facsimile or other electronic transmission shall
constitute effective delivery thereof. Electronic records of executed Loan Documents maintained by Lender shall deemed to be
originals.

 

    51

     

    

 

14.12       Successors
and Assigns. This Agreement shall be binding upon the Loan Parties, Lender and their respective successors and assigns, and
shall inure to the benefit of the Loan Parties, Lender and the successors and assigns of Lender. No other Person shall be a direct
or indirect legal beneficiary of, or have any direct or indirect cause of action or claim in connection with, this Agreement or
any of the other Loan Documents. No Loan Party may assign or transfer any of its rights or Obligations under this Agreement without
the prior written consent of Lender.

 

14.13       Assignments;
Participations.

 

14.13.1       Assignments.
(a) Lender may at any time assign to one or more Persons (any such Person, an “Assignee”) all or any portion
of its Loans and Commitments, with the prior written consent of Borrower, so long as no Event of Default exists (which consent
shall not be unreasonably withheld or delayed and shall not be required for an assignment by Lender to an Affiliate of Lender).
Borrower shall be deemed to have granted its consent to any assignment requiring its consent hereunder unless Borrower has expressly
objected to such assignment within three Business Days after notice thereof.

 

(b)       From
and after the date on which the conditions described above have been met, (i) such Assignee shall be deemed automatically to have
become a party hereto and, to the extent that rights and obligations hereunder have been assigned to such Assignee pursuant to
an assignment agreement between Lender and the Assignee, shall have the rights and obligations of Lender hereunder and (ii) Lender,
to the extent that rights and obligations hereunder have been assigned by it pursuant to such Assignment Agreement, shall be released
from its rights (other than its indemnification rights) and obligations hereunder. Upon the request of the Assignee (and, as applicable,
Lender) pursuant to an effective assignment agreement, Borrower shall execute and deliver to the Assignee (and, as applicable,
Lender) a Note in the principal amount of the Assignee’s pro rata share of the principal amount of the Assignee’s Term
Loan (and, as applicable, a Note in the principal amount of the pro rata share of the principal amount of the Term Loan retained
by Lender). Each such Note shall be dated the effective date of such assignment. Upon receipt by Lender of such Note, Lender shall
return to Borrower any prior Note held by it.

 

(c)       Lender
may at any time pledge or assign a security interest in all or any portion of its rights under this Agreement to secure obligations
of Lender, including any pledge or assignment to secure obligations to a Federal Reserve Bank, and this Section shall not apply
to any such pledge or assignment of a security interest; provided that no such pledge or assignment of a security interest
shall release Lender from any of its obligations hereunder or substitute any such pledgee or assignee for Lender as a party hereto.

 

    52

     

    

 

14.13.2       Participations.
Lender may at any time sell to one or more Persons participating interests in its Loans, Commitments or other interests hereunder
(any such Person, a “Participant”). In the event of a sale by Lender of a participating interest to a Participant,
(a) Lender’s obligations hereunder shall remain unchanged for all purposes, (b) Borrower shall continue to deal solely and
directly with Lender in connection with Lender’s rights and obligations hereunder, (c) all amounts payable by Borrower shall
be determined as if Lender had not sold such participation and shall be paid directly to Lender, and (d) Lender shall maintain
as a non-fiduciary agent of Borrower, a register (the “Participation Register”) as to the participations granted
and transferred under this Section 14.3.2 containing the same information specified in Section 14.13.1 on the Participation
Register as if the participant were a Lender, and no participation may be transferred except as recorded in such Participation
Register. Borrower agrees that if amounts outstanding under this Agreement are due and payable (as a result of acceleration or
otherwise), each Participant shall be deemed to have the right of set-off in respect of its participating interest in amounts
owing under this Agreement; provided that such right of set-off shall be subject to the obligation of each Participant
to share with Lender, and Lender agrees to share with each Participant, on a pro rata basis. Borrower also agrees that each Participant
shall be entitled to the benefits of Section 6.5 or 7 as if it were Lender (provided that on the date of
the participation no Participant shall be entitled to any greater compensation pursuant to Section 6.5 or 7 than
would have been paid to Lender on such date if no participation had been sold and that each Participant complies with Section
6.5(d) as if it were a direct assignee). This Section and Section 14.13.1 shall be construed so that the Loans are
at all times maintained in “registered form” for the purposes of the Code and any related regulations (and any successor
provisions).

 

14.14       Captions.
Section captions used in this Agreement are for convenience only and shall not affect the construction of this Agreement.

 

14.15       Customer
Identification - USA Patriot Act Notice. CIBC US (for itself and not on behalf of any other party) hereby notifies the Loan
Parties that, pursuant to the requirements of the USA Patriot Act, Title III of Pub. L. 107-56, signed into law October 26, 2001
(the “Patriot Act”), it is required to obtain, verify and record information that identifies the Loan Parties, which
information includes the name and address of the Loan Parties and other information that will allow CIBC US, as applicable, to
identify the Loan Parties in accordance with the Act.

 

    53

     

    

 

14.16       INDEMNIFICATION
BY LOAN PARTIES. IN CONSIDERATION OF THE EXECUTION AND DELIVERY OF THIS AGREEMENT BY LENDER AND THE AGREEMENT TO EXTEND
THE COMMITMENTS PROVIDED HEREUNDER, EACH LOAN PARTY HEREBY AGREES TO INDEMNIFY, EXONERATE AND HOLD LENDER AND EACH OF THE
OFFICERS, DIRECTORS, EMPLOYEES, AFFILIATES AND AGENTS OF LENDER (EACH A “LENDER PARTY”) FREE AND HARMLESS FROM
AND AGAINST ANY AND ALL ACTIONS, CAUSES OF ACTION, SUITS, LOSSES, LIABILITIES, DAMAGES AND EXPENSES, INCLUDING ATTORNEY COSTS
(COLLECTIVELY, THE “INDEMNIFIED LIABILITIES”), INCURRED BY LENDER PARTIES OR ANY OF THEM AS A RESULT OF, OR
ARISING OUT OF, OR RELATING TO (A) ANY TENDER OFFER, MERGER, PURCHASE OF CAPITAL SECURITIES, PURCHASE OF ASSETS (INCLUDING
THE RELATED TRANSACTIONS) OR OTHER SIMILAR TRANSACTION FINANCED OR PROPOSED TO BE FINANCED IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, WITH THE PROCEEDS OF ANY OF THE LOANS, (B) THE USE, HANDLING, RELEASE, EMISSION, DISCHARGE, TRANSPORTATION,
STORAGE, TREATMENT OR DISPOSAL OF ANY HAZARDOUS SUBSTANCE AT ANY PROPERTY OWNED OR LEASED BY ANY LOAN PARTY, (C) ANY
VIOLATION OF ANY ENVIRONMENTAL LAWS WITH RESPECT TO CONDITIONS AT ANY PROPERTY OWNED OR LEASED BY ANY LOAN PARTY OR THE
OPERATIONS CONDUCTED THEREON, (D) THE INVESTIGATION, CLEANUP OR REMEDIATION OF OFFSITE LOCATIONS AT WHICH ANY LOAN PARTY OR
THEIR RESPECTIVE PREDECESSORS ARE ALLEGED TO HAVE DIRECTLY OR INDIRECTLY DISPOSED OF HAZARDOUS SUBSTANCES OR (E) THE
EXECUTION, DELIVERY, PERFORMANCE OR ENFORCEMENT OF THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT BY ANY OF LENDER PARTIES, EXCEPT
FOR ANY SUCH INDEMNIFIED LIABILITIES ARISING ON ACCOUNT OF THE APPLICABLE LENDER PARTY’S GROSS NEGLIGENCE OR WILLFUL
MISCONDUCT AS DETERMINED BY A FINAL, NONAPPEALABLE JUDGMENT BY A COURT OF COMPETENT JURISDICTION. IF AND TO THE EXTENT THAT
THE FOREGOING UNDERTAKING MAY BE UNENFORCEABLE FOR ANY REASON, EACH LOAN PARTY HEREBY AGREES TO MAKE THE MAXIMUM CONTRIBUTION
TO THE PAYMENT AND SATISFACTION OF EACH OF THE INDEMNIFIED LIABILITIES WHICH IS PERMISSIBLE UNDER APPLICABLE LAW. ALL
OBLIGATIONS PROVIDED FOR IN THIS SECTION 14.16 SHALL SURVIVE REPAYMENT OF THE LOANS, CANCELLATION OF THE NOTES,
EXPIRATION OR TERMINATION OF THE LETTERS OF CREDIT, ANY FORECLOSURE UNDER, OR ANY MODIFICATION, RELEASE OR DISCHARGE OF, ANY
OR ALL OF THE COLLATERAL DOCUMENTS AND TERMINATION OF THIS AGREEMENT.

 

14.17       Nonliability
of Lender. The relationship between Borrower on the one hand and Lender on the other hand shall be solely that of borrower
and lender. Lender has no fiduciary relationship with or duty to any Loan Party arising out of or in connection with this Agreement
or any of the other Loan Documents, and the relationship between the Loan Parties, on the one hand, and Lender, on the other hand,
in connection herewith or therewith is solely that of debtor and creditor. Lender undertakes no responsibility to any Loan Party
to review or inform any Loan Party of any matter in connection with any phase of any Loan Party’s business or operations.
Each Loan Party agrees that Lender shall have no liability to any Loan Party (whether sounding in tort, contract or otherwise)
for losses suffered by any Loan Party in connection with, arising out of, or in any way related to the transactions contemplated
and the relationship established by the Loan Documents, or any act, omission or event occurring in connection therewith, unless
it is determined in a final non-appealable judgment by a court of competent jurisdiction that such losses resulted from the gross
negligence or willful misconduct of the party from which recovery is sought. NO LENDER PARTY SHALL BE LIABLE FOR ANY DAMAGES
ARISING FROM THE USE BY OTHERS OF ANY INFORMATION OR OTHER MATERIALS OBTAINED THROUGH INTRALINKS OR OTHER SIMILAR INFORMATION TRANSMISSION
SYSTEMS IN CONNECTION WITH THIS AGREEMENT, NOR SHALL ANY LENDER PARTY HAVE ANY LIABILITY WITH RESPECT TO, AND EACH LOAN PARTY HEREBY
WAIVES, RELEASES AND AGREES NOT TO SUE FOR ANY SPECIAL, PUNITIVE, EXEMPLARY, INDIRECT OR CONSEQUENTIAL DAMAGES RELATING TO THIS
AGREEMENT OR ANY OTHER LOAN DOCUMENT OR ARISING OUT OF ITS ACTIVITIES IN CONNECTION HEREWITH OR THEREWITH (WHETHER BEFORE OR AFTER
THE CLOSING DATE). Each Loan Party acknowledges that it has been advised by counsel in the negotiation, execution and delivery
of this Agreement and the other Loan Documents to which it is a party. No joint venture is created hereby or by the other Loan
Documents or otherwise exists by virtue of the transactions contemplated hereby among the Loan Parties and Lender.

 

    54

     

    

 

14.18       FORUM
SELECTION AND CONSENT TO JURISDICTION. ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH THIS AGREEMENT
OR ANY OTHER LOAN DOCUMENT, SHALL BE BROUGHT AND MAINTAINED EXCLUSIVELY IN THE COURTS OF THE STATE OF INDIANA, LOCATED IN MARION
COUNTY OR IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF INDIANA, LOCATED IN MARION COUNTY; PROVIDED THAT
NOTHING IN THIS AGREEMENT SHALL BE DEEMED OR OPERATE TO PRECLUDE LENDER FROM BRINGING SUIT OR TAKING OTHER LEGAL ACTION IN ANY
OTHER JURISDICTION TO ENFORCE A JUDGMENT OR REALIZE ON ANY COLLATERAL. EACH LOAN PARTY HEREBY EXPRESSLY AND IRREVOCABLY SUBMITS
TO THE JURISDICTION OF THE COURTS OF THE STATE OF INDIANA, LOCATED IN MARION COUNTY OR IN THE UNITED STATES DISTRICT COURT FOR
THE SOUTHERN DISTRICT OF INDIANA, LOCATED IN MARION COUNTY FOR THE PURPOSE OF ANY SUCH LITIGATION AS SET FORTH ABOVE. EACH LOAN
PARTY FURTHER IRREVOCABLY CONSENTS TO THE SERVICE OF PROCESS BY REGISTERED MAIL, POSTAGE PREPAID, OR BY PERSONAL SERVICE WITHIN
OR WITHOUT THE STATE OF INDIANA. EACH LOAN PARTY HEREBY EXPRESSLY AND IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW,
ANY OBJECTION WHICH IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY SUCH LITIGATION BROUGHT IN THE COURTS OF THE STATE
OF INDIANA, LOCATED IN MARION COUNTY OR IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF INDIANA, LOCATED IN MARION
COUNTY AND ANY CLAIM THAT ANY SUCH LITIGATION HAS BEEN BROUGHT IN AN INCONVENIENT FORUM.

 

14.19       WAIVER
OF JURY TRIAL. EACH LOAN PARTY AND LENDER HEREBY WAIVES ANY RIGHT TO A TRIAL BY JURY IN ANY ACTION OR PROCEEDING TO ENFORCE
OR DEFEND ANY RIGHTS UNDER THIS AGREEMENT, ANY NOTE, ANY OTHER LOAN DOCUMENT AND ANY AMENDMENT, INSTRUMENT, DOCUMENT OR AGREEMENT
DELIVERED OR WHICH MAY IN THE FUTURE BE DELIVERED IN CONNECTION HEREWITH OR THEREWITH OR ARISING FROM ANY LENDING RELATIONSHIP
EXISTING IN CONNECTION WITH ANY OF THE FOREGOING, AND AGREES THAT ANY SUCH ACTION OR PROCEEDING SHALL BE TRIED BEFORE A COURT AND
NOT BEFORE A JURY.

 

[Signature page follows]

 

    55

     

    

 

The parties hereto have caused this Agreement
to be duly executed and delivered by their duly authorized officers as of the date first set forth above.

 

	 	WEST 78TH
    STREET, LLC, 
	 	as Borrower 
	 	 	 
	 	By:	 /s/
    Allan C. Silber
	 	 	Allan C. Silber, Manager
	 	 	 
	 	CIBC BANK USA,
	 	as Lender 
	 	 	 
	 	By:	/s/ Scott
    Dvornik
	 	 	Scott Dvornik, Managing Director

 

Signature Page to Loan and Security
Agreement

 

     

     

    

 

ANNEX A

 

ADDRESSES FOR NOTICES

 

WEST 78th STREET, LLC

 

c/o Point Biopharma Inc.

22 St. Clair Avenue East, Suite 1201

Toronto, Ontario M4T 2S3

Canada

 

With a copy to:

 

Bose McKinney & Evans LLP

111 Monument Circle, Suite 2700

Indianapolis, Indiana 46204

Attn: Bryan B. Woodruff

Telephone: 317-684-5271

Facsimile: 317-223-0271

 

CIBC BANK USA, as Lender

 

10 W. Market St., Suite 1820

Indianapolis, IN 46204

Attention: Scott Dvornik

Telephone: (317) 396-8899

 

With a copy to:

 

Faegre Drinker Biddle & Reath LLP

600 E. 96th Street, Suite 600

Indianapolis, IN 46240

Attn: David A. Foster

Telephone: (317) 569-9600

Facsimile: (317) 569-4800

 

Annex A to Loan and Security

Agreement

 

     

     

    

 

SCHEDULE 9.6

 

LITIGATION AND CONTINGENT LIABILITIES

 

None.

 

     

     

    

 

SCHEDULE 9.8

 

SUBSIDIARIES

 

None.

 

     

     

    

 

SCHEDULE 9.16

 

INSURANCE

 

		·	Hazard Insurance (Real and Personal Property) - Special causes of
loss covering all perils except specifically enumerated exceptions in such policy agreed by Bank, in an amount at least equal to
the replacement cost of the Collateral, with no co-insurance requirements.

		·	Liability Insurance - General liability with coverage limits of at
least $1,000,000 per occurrence, including the following coverage:

·   Damage
to Rented Premises - at least $50,000.

·   Medical
Expense (per person) - at least $5,000.

·   Personal
Injury - at least $1,000,000.

		·	Worker’s Compensation Coverage during any period of construction,
in an amount at least equal to the worker’s compensation statutory limit.

		·	Builder’s Risk Insurance during any period of construction.

 

 

     

     

    

 

SCHEDULE 9.21

 

LABOR MATTERS

 

None.

 

     

     

    

 

SCHEDULE 9.29

 

GRANTOR INFORMATION

 

	GRANTOR	STATE
    OF	FEDERAL	CHIEF
    EXECUTIVE OFFICE	ORGANIZATIONAL
	(exact
    legal	ORGANIZATION	EMPLOYER	 	IDENTIFICATION
	name)	 	IDENTIFICAT	 	NUMBER
	 	 	ION
    NUMBER	 	 
	West
    78th	Indiana	N/A	22
    St. Clair Avenue East,	202004071383850
	Street,
    LLC	 	(Passthrough	Suite
    1201	 
	 	 	entity)	Toronto,
    Ontario M4T 2S3	 
	 	 	 	Canada	 

 

     

     

    

 

SCHEDULE 12.1

 

DEBT TO BE REPAID

 

None.

 

     

     

    

 

EXHIBIT A

 

FORM OF

NOTE

 

        
,             

Indianapolis, Indiana

$                         

 

The undersigned, for value received, promises
to pay to the order of CIBC Bank USA (“Lender”) and its registered assigns at its principal office in Chicago,
Illinois the aggregate unpaid amount of all Loans made to the undersigned by Lender pursuant to the Loan and Security Agreement
referred to below (as shown on the schedule attached hereto (and any continuation thereof) or in the records of Lender), such principal
amount to be payable on the dates set forth in the Loan and Security Agreement.

 

The undersigned further promises to pay
interest on the unpaid principal amount of each Loan from the date of such Loan until such Loan is paid in full, payable at the
rate(s) and at the time(s) set forth in the Loan and Security Agreement. Payments of both principal and interest are to be made
in lawful money of the United States of America.

 

This Note evidences indebtedness incurred
under, and is subject to the terms and provisions of, the Loan and Security Agreement, dated as of July 10, 2020 (as amended, restated,
supplemented or otherwise modified from time to time, the “Loan and Security Agreement”; terms not otherwise
defined herein are used herein as defined in the Loan and Security Agreement), between the undersigned and Lender, to which Loan
and Security Agreement reference is hereby made for a statement of the terms and provisions under which this Note may or must be
paid prior to its due date or its due date accelerated.

 

This Note is made under and governed by
the laws of the State of Indiana applicable to contracts made and to be performed entirely within such State.

 

	 	WEST 78TH STREET, LLC
	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 

 

Exhibit A to Loan and Security Agreement

 

     

     

    

 

EXHIBIT B

 

FORM OF NOTICE OF BORROWING

 

To:           CIBC Bank USA, as Lender

 

Please refer to the Loan and Security Agreement
dated as of July 10, 2020 (as amended, restated, supplemented or otherwise modified from time to time, the “Loan and Security
Agreement”) among WEST 78TH STREET, LLC (“Borrower”) and CIBC Bank USA, as Lender. Terms used but
not otherwise defined herein are used herein as defined in the Loan and Security Agreement.

 

The undersigned hereby gives irrevocable
notice, pursuant to Section 2.2.2 of the Loan and Security Agreement, of a request hereby for a borrowing as follows:

 

(i)       The requested
borrowing date for the proposed borrowing (which is a Business Day) is                 
,          .

 

(ii)       The aggregate
amount of the proposed borrowing is $                     .

 

(iii)       The type of Loans
comprising the proposed borrowing are [Base Rate] [LIBOR] Loans.

 

(iv)       The duration
of the Interest Period for each LIBOR Loan made as part of the proposed borrowing, if applicable, is                  
months (which shall be 1, 2 or 3).

 

The undersigned hereby certifies that on
the date hereof and on the date of borrowing set forth above, and immediately after giving effect to the borrowing requested hereby:
(i) there exists and there shall exist no Default or Event of Default under the Loan and Security Agreement; and (ii) each of the
representations and warranties contained in the Loan and Security Agreement and the other Loan Documents is true and correct as
of the date hereof, except to the extent that such representation or warranty expressly relates to another date and except for
changes therein expressly permitted or expressly contemplated by the Loan and Security Agreement.

 

Borrower has caused this Notice of Borrowing
to be executed and delivered by its officer thereunto duly authorized on.            ,              .

 

	 	WEST 78TH STREET LLC
	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 

 

Exhibit B to Loan and Security Agreement

 

     

     

    

 

EXHIBIT C

 

FORM OF NOTICE OF CONVERSION/CONTINUATION

 

To:              CIBC Bank USA, as Lender

 

Please refer to the Loan and Security Agreement
dated as of July 10, 2020 (as amended, restated, supplemented or otherwise modified from time to time, the “Loan and Security
Agreement”) among WEST 78TH STREET, LLC (“Borrower”) and CIBC Bank USA, as Lender. Terms used but
not otherwise defined herein are used herein as defined in the Loan and Security Agreement.

 

The undersigned hereby gives irrevocable
notice, pursuant to Section 2.2.3 of the Loan and Security Agreement, of its request to:

 

(a)       on [       date       ] convert
$[           ] of the aggregate outstanding principal amount of
the [            ] Loan, bearing interest at the [             ]
Rate, into a(n) [            ] Loan [and, in the case of a
LIBOR Loan, having an Interest Period of [            ] month(s)];

 

(b)       on [       date
       ] continue $[            ]of
the aggregate outstanding principal amount of the [            ]
Loan, bearing interest at the LIBO Rate, as a LIBOR Loan having an Interest Period of [             ]
month(s)].

 

The undersigned hereby represents and warrants
that all of the conditions contained in Section 12.2 of the Loan and Security Agreement have been satisfied on and as of
the date hereof, and will continue to be satisfied on and as of the date of the conversion/continuation requested hereby, before
and after giving effect thereto.

 

Borrower has caused this Notice of
Conversion/Continuation to be executed and delivered by its officer thereunto duly authorized on             ,              .

 

	 	WEST 78TH STREET LLC
	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 

 

Exhibit C to Loan and Security Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}]]